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Summary 
 
The purpose of this study was to investigate ROCK2 activation in squamous cell 
carcinogenesis and assess its co-operation with rasHa and fos oncogene activation 
together with loss of PTEN mediated AKT regulation. The analysis of ROCK 
deregulation with these genes in the MAP Kinase and PI3K pathways, two of the 
most commonly deregulated signalling systems, employed a well-characterised, 
transgenic mouse skin model of multi-stage carcinogenesis. A major goal was to 
study co-operation between these genes in the conversion of benign tumours to 
malignancy and investigate subsequent progression to aggressive carcinomas, 
given these are the most significant clinical stages of carcinogenesis from a 
patient’s viewpoint; and also investigated effects of ROCK2 deregulation on the 
processes of normal epidermal differentiation.  
 
ROCK2 is an effector protein of RhoA, which is a member of the ras superfamily 
and ROCK2 activation has been associated with tumour progression via an 
increase in tissue stiffness mediated by changes in actomyosin cytoskeleton 
leading to increased cellular motility. Thus, ROCK2 expression is commonly 
associated with the later events in cancer. Furthermore, there are many studies 
investigating ROCK2 in cancer given that it may be a useful therapeutic target in 
being downstream of oncogenic ras signalling. Yet, relatively few studies have 
explored the possibilities of a definite link that confirms the co-operation status of 
ROCK2 activation with ras/MAPK/fos and /or PTEN/PI3K/AKT pathways in SCC 
aetiology. Thus, questions exist as to exactly when does ROCK2 activation 
become causal; and what are the collaborating genes involved in the mechanism 
that drive the early or late stage events in carcinogenesis.  
 
To begin to answer these questions, inducible ROCK2 activation has been 
introduced into a well-characterised transgenic mouse skin carcinogenesis model 
that expressed a combination of ras and fos activation, driven by a modified 
human keratin 1 vector (HK1). Thus, exclusive epidermal expression of activated 
rasHa and fos oncogenes, in proliferative basal layers, gave hyperplasia and 
papillomatogenesis; but with no evidence of spontaneous malignant conversion. 
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This stability of phenotype is thus ideal to assess roles for multiple transgene co-
operations in the development of benign tumours and their conversion to 
malignancy. Hence, ROCK transgenic mice that expressed a conditionally active, 
4-hydroxytamoxifen (4-HT)-regulated of human ROCK2 transgene were crossed 
with mice expressing activated rasHa and /or fos exclusively in epidermal transit 
amplifying keratinocytes (HK1.ras, HK1.fos). Inducible PTEN tumour suppressor 
gene mutation via exon 5 ablation (K14.Cre/5PTENflx) and thus loss of AKT 
regulation was also incorporated into this model. This was achieved via deletion of 
exon 5 employing the RU486-mediated cre/loxP system, driven by keratin K14 
promoter expression in basal layer keratinocytes. Therefore, to facilitate this 
investigation, a new and unpublished inducible ROCK2 system was employed in 
order to target the identical keratinocytes as PTEN loss. This new transgenic line 
of lsl.ROCKer transgenic mice employed the same 4-HT inducible ROCKer 
transgene but now driven by a generic CAG promoter following cre mediated 
ablation of the stop cassette once treated with RU486.  
 
In bi-genic K14.ROCKer/HK1.ras1205 mice, synergism between ROCK2 activation 
and (wound-promotion) sensitive HK1.ras1205 line showed direct co-operation and 
achieved malignant conversion of benign papillomas to well-differentiated 
squamous cell carcinoma (wdSCCs) histotypes (12 weeks of 4-HT treatment). 
This placed ROCK2 activity as the causal event driving malignant conversion, but 
in the absence of a wound promotion stimulus (loss of ear tag), papillomas did not 
convert. The correct papilloma context was required for ROCK to become causal 
proved to be the case on employing the wound insensitive HK1.ras1276 line. Here, 
K14.ROCKer/HK1.ras1276 mice failed to exhibit any papillomas and required the 
constitutive promotion stimulus from additional fos activation. Interestingly, 
following cessation of 4-HT, two intriguing observations were recorded. Firstly, that 
once bi-genic ROCK/ras1205 achieved malignancy, exogenous ROCKer expression 
appeared to show no involvement once squamous cell carcinomas (SCCs) 
progressed to poorly differentiated squamous cell carcinomas (pdSCCs), given the 
elevated expression of endogenous ROCK upon malignant progression. Secondly, 
the rapid growth of papilloma appeared upon cessation of 4-HT with highly intense 
p21 expression indicated the requirement of exogenous ROCK2 for malignant 
conversion and the possibility of a papilloma inhibition by 4-HT anti-cancer activity.  
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Another major novel finding demonstrated ROCK2 activation could act as an 
initiator in co-operation with fos activation. Direct co-operation between ROCK2 
and fos activation produced benign squamous papillomas yet, whereas ROCK2 
activation alone induced hyperplasia as did fos activation alone at this time point, 
given papilloma formation in HK1.fos mice occur over 4-5 months. However, unlike 
deregulation of MAP Kinase signalling in bi-genic ROCK/ras1205 mice, in bi-genic 
ROCK/fos mice, no malignant conversion was observed due to high levels of 
compensatory p53/p21 expression. Thus, this bi-genic K14.cre/lsl.ROCKer/HK1.fos 
model suggests the requirement of additional mutation event for malignant 
conversion. An unexpected result appeared in bi-genic ROCK/Δ5PTENflx co-
operation experiments where K14.cre/lsl.ROCKer/Δ5PTENflx cohorts exhibited 
epidermal hyperplasia with folded papillomatous appearance to the epidermis, but 
without papillomatogenesis even after seven month of period. This either indicates 
a weak co-operation between ROCK2 and Δ5PTENflx which may be due to the 
unexpected low levels of p-AKT from a compensatory increased p21 expression; 
and additional events needed to fill in the oncogenic gap in this bi-genic 
ROCK/Δ5PTENflx model, or may possibly highlight redundancy in the oncogenic 
hits provided by ROCK and PTEN. This latter suggest similar links exist between 
their normal roles in the epidermis which may be accountable for the alterations 
observed in keratinocyte differentiation. In both in vitro and in vivo experiments, 
K14.cre/lsl.ROCKer/Δ5PTENflx cohorts showed alterations in epidermal 
differentiation via anomalous K1 and low levels of K6 expression. 
 
Interestingly, activated ROCK2 appeared to induce or accelerate differentiation 
activity in K14.cre/lsl.ROCKer keratinocytes via increased K1 (early differentiation 
marker) and reduced K6 (proliferation marker) expression profiles. These results 
were consistent with in vivo data where K6 was expressed in low levels in 
K14.cre/lsl.ROCKer hyperplasia histotypes. In contrast, in 
K14.cre/lsl.ROCKer/Δ5PTENflx keratinocytes, inactivation of PTEN-mediated AKT 
activity may be accountable for restored keratin K6 and anomalous keratin K1 
expression; as keratin K1 was expressed in a similar fashion of normal 
keratinocytes in K14.cre/lsl.ROCKer/fos keratinocytes. 
 
Interestingly, all tri-genic cohorts: K14.cre/lsl.ROCKer/ras1276/fos, 
K14.cre/lsl.ROCKer/fos/Δ5PTENflx and K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx 
synergisms exhibited malignant conversion and /or malignant progression in all 
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animals highlighting a novel role of ROCK2 activation. Further, the stage-specific 
consequences in each model in this study were shown to be influenced by 
p53/p21 status, where typically p53 expression disappeared in late stage 
papillomas yet, p21 expression persisted. This demonstrated the importance of 
compensatory p53/p21 expression in modulating tumour pathogenesis in all these 
models. Given that this study incorporated PTEN mutation, the influence of AKT 
activity was investigated in the SCC progression of tri-genic ROCK/ras1276/PTENflx 
and ROCK/fos/PTENflx cohorts; revealing a crucial antagonism between p21 and 
AKT. However, this study revealed that the malignancy in tri-genic 
ROCK/ras1276/fos cohorts was not influenced by p-AKT expression, and as this tri-
genic model achieved wdSCCs only. This suggests that as the roles of ROCK in 
altering cytoskeletal organisation leading to increase in tissue stiffness are overlaid 
onto both MAP Kinase and AKT deregulation, the outcome is a very aggressive 
pdSCC. Thus, suggesting ROCK signalling to be a potential therapeutic target for 
ras/MAPK/fos pathway in carcinogenesis. Overall, this study showed the 
involvement of ROCK2 activation in the initiation stage for papillomatogenesis with 
fos oncogene, and demonstrated ROCK2 as a converter again and also in 
malignant progression with ras/fos/Δ5PTENflx mutations. This indicates the link of 
ROCK2 signalling with both MAPK and PI3K pathways, thus targeting ROCK2 
would aid in development of cancer therapy.  
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Chapter 1 – Introduction 
 
1.1 General introduction 
 
Cancer is a disease that involves changes in the genetic alterations that transform 
normal cells into malignant derivatives (Hanahan and Weinberg, 2000, 2011). 
Carcinogenesis is not just the result of exposure to environmental carcinogens; it 
requires multiple stages involving many pathways before a tumour develops. 
Various irreversible genetic mutations that co-operate to disrupt normal 
homeostasis at several levels drive the mechanism of carcinogenesis. Initiating 
mutations can lead to pre-neoplastic lesions that can regress, persist or convert to 
malignancy and metastasis. However, the factors that determine whether a pre-
neoplastic lesion converts to malignancy, remains benign or regresses are still 
unclear and will depend on tumour contexts created by each combination of 
specific mutations.  
 
To investigate this complex process, the development of various in vitro and in 
vivo models has been greatly beneficial in cancer studies in allowing investigators 
to explore the underlying mechanisms of molecular carcinogenesis. To examine 
these complex mechanisms in vivo, transgenic mice expressing inducible 
transgenes have proved extremely valuable (Leder et al., 1986, Hanahan, 1988). 
Furthermore, a transgenic mouse skin model that combines the classic mouse 
skin cancer model with genetic engineering offers a useful approach to study 
molecular carcinogenesis. The mouse skin model has been widely utilised to 
explore many cancer theories and its use is beneficial in almost all areas of cancer 
biology and genetics (Brown et al., 1990, Greenhalgh et al., 1993a, Balmain and 
Yuspa, 2014).  
 
It is through the use of such transgenic mouse skin models that the causally 
related mutations that drive stage-specific tumour progression can be tested either 
via gene over-expression or knockdown. Moreover, the mechanism of multistage 
tumourigenesis following the acquisition of subsequent mutations can be explored 
in these models. The development of transgenic mouse models for multistage 
carcinogenesis has been greatly enhanced by using the appropriate regulatory 
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element to target particular genes or genetic pathways in specific tissues in the 
context of the whole organism (Abate-Shen et al., 2008). Typically, transgenic 
mouse skin models employ keratin promoters to target proliferative and stem cell 
keratinocytes and the outcome of tumour phenotypes from transgenic mouse skin 
models enable assessment of particular molecular pathways for each stage of skin 
carcinogenesis: from hyperplasia through benign tumour formation and conversion 
to malignancy (Greenhalgh and Roop, 1994). 
 
Genes that are involved in the formation of cancer fall into many different groups, 
but in brief they act as oncogenes or tumour suppressor genes. Oncogenes are 
cancer-causing and drive progression through each stage. For example: rasHa and 
c-fos are well known oncogenes where direct mutation or overexpression of the 
normal (proto-oncogene) protein has been linked to many cancers and as outlined 
below, their mutations have been shown to mimic the classic two stage mouse 
chemical carcinogenesis model (Greenhalgh et al., 1993a-c, Fernández-Medarde 
and Santos, 2011). On the other hand, tumour suppressor genes are cancer-
preventing. Normally, they may inhibit tumour formation by one or more of 
mechanisms such as inhibiting cell proliferation and growth or accelerating 
differentiation or apoptosis. PTEN, p21 and p53 are classic examples of tumour 
suppressor genes that are most commonly mutated in cancer (Cooper, 2000).  
 
Transgenic mouse skin models that express specific oncogenes or loss of tumour 
suppressor genes in the epidermis have been developed to study multistage 
carcinogenesis, or to investigate epidermal physiology in terms of growth 
regulation and terminal differentiation, failure of which are often associated with 
the signalling pathways and transcriptional events that drive cancer (Greenhalgh 
et al., 1993a-c, Dyke and Jacks, 2002, Yao et al., 2006, 2008, Macdonald et al., 
2014). Therefore, by examining the key genes thought to be responsible for the 
driver mutations that cause tumours at each stage and investigating their co-
operation; the results may be beneficial in identifying the specific stage at which 
mutations become active. These findings may help to design new drugs for 
therapies and provide the most appropriate animal models to stringently test them 
prior to clinical trials. The genes chosen for analysis in this study represent some 
of the most frequently mutated genes in human cancers that are normally 
responsible for regulating cell growth, apoptosis and homeostasis. 
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1.2 ROCK 
 
This study investigates the role of ROCK2 in the multistage carcinogenesis model 
as it transpires that ROCK, an effector of the Rho family proteins RhoA and RhoC, 
plays an essential role in actomyosin contraction driving the elevation of cellular 
tension which affects tissue homeostasis and promotes tumour progression 
(Shimizu et al., 2003, Samuel et al., 2011). ROCK also has important roles in 
proliferation, differentiation, and cellular transformation (Olson, 2008). Moreover, in 
humans it has been shown that ROCK activation is involved in several types of 
cancer including lung, bladder and testicular (Kamai et al., 2003, Rath and Olson, 
2012) and elevated expression of ROCK has most often been implicated in the 
late stages of carcinogenesis including invasion and metastasis. Therefore, 
studies targeting ROCK gene signalling may help to identify those genes involved 
in causing or preventing malignant conversion, as conversion to malignancy is one 
of the most significance clinical events from a clinician’s view point. 
 
1.2.1 ROCK: an overview 
 
Rho-associated kinases (ROCK) are downstream effectors of RhoA and RhoC 
proteins, which are members of the Rho-GTPase family within the Ras 
superfamily, that help propagate signalling from external signals such as ligand-
receptor interactions (Leung et al., 1995, Ishizaki et al., 1996). The three most well 
studied members of the Rho-GTPase family are: RhoA, Rac1, and CDC42; all of 
which play pivotal roles in regulation of the actin cytoskeleton network, cell 
morphology, cell proliferation, apoptosis and many other cellular functions (Rath 
and Olson, 2012, Pan et al., 2013) (figure 1.1). The signalling function of each of 
these Rho GTPases is activated by guanine nucleotide exchange factors (GEFs) 
and deactivated by GTPase-activating proteins (GAPs), thus switching between an 
inactive GDP-bound and an active GTP-bound protein complex (Rossman et al., 
2005). 
 
 
 
Chapter 1  26 
 
 
Figure 1.1 Rho/ROCK signalling pathway regulates cellular functions including actomyosin 
contraction, differentiation, proliferation and apoptosis. (Figure was modified from Rath and Olson, 
2012). 
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ROCK2 was the first ROCK homologue identified as an effector of RhoA, encoding 
a 150-kDa protein (Leung et al., 1995). Following the finding of ROCK2 (also 
known as ROKα) (Leung et al., 1995), ROCK1 was later discovered (also known 
as ROKβ) as a RhoA GTP-binding protein encoding a 160-kDa protein (Ishizaki et 
al., 1996). ROCK1 and ROCK2 are two homologues of Rho effector proteins that 
are well known to have roles in promotion of actin cytoskeleton contractility 
(Amano et al., 1996, Leung et al., 1996, Olson and Sahai, 2009). ROCK (1 and 2) 
generates its actomyosin contraction activity by mediating phosphorylation of 
several downstream targets including LIM kinases (LIMK 1 and 2), myosin light 
chain (MLC) and myosin binding subunit of myosin phosphatase (myosin 
phosphatase targeting protein) (Mypt1). Phosphorylation of LIMK results in 
inactivation of cofilin and this contributes to stabilisation of the actin filament 
(Wickman et al., 2010, Rath and Olson, 2012); whilst phosphorylation of MLC 
promotes actomyosin contraction and through phosphorylation of MYPT1, ROCK 
inhibits the dephosphorylation of MLC. Thus, the net effect of MLC 
phosphorylation is actomyosin contraction (Wickman et al., 2010), which develops 
stress fibers and focal adhesion formation. This in turn leads to increased cellular 
tension that influences cell morphology and cell movement which consequently 
contributes to a wide variety of events in cancer (Samuel et al., 2011) (figure 1.1).  
 
ROCK is also involved in numerous other cellular activities including cell 
proliferation and differentiation (Rath and Olson, 2012); these seemingly 
contrasting observations may depend upon the experimental conditions and /or 
cell type under study. Pirone et al., (2006) have shown that ROCK-mediated 
actomyosin contraction could promote cell proliferation activity in bovine 
pulmonary artery endothelial cells. In epidermal keratinocytes, specific knockdown 
of ROCK2 expression in cultured human keratinocytes led to inhibition of terminal 
differentiation whereas depletion of ROCK1 expression induced terminal 
differentiation (Lock and Hotchin, 2009). Conditional ROCK2 activation in 
keratinocytes induced terminal differentiation and induced expression of 
differentiation markers (McMullan et al., 2003). Taken together, these studies have 
reported important roles for ROCK in regulating keratinocyte differentiation and 
proliferation. Thus, as a consequence, deregulation of ROCK activity which 
contributes to changes in normal keratinocyte physiology may lead to cancer 
formation. The questions these observations raise include: at what stage do these 
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ROCK2 changes become important, and what genes are collaborators or 
inhibitors? 
 
Previous studies indicated the involvement of ROCK activity in cancer formation in 
several ways (Wickman et al., 2010). ROCK activity was reported to be elevated 
during tumour invasion and metastasis, suggesting a role in the later stages of the 
disease consistent with its role in cell migration (Croft et al., 2004, Pan et al., 
2013). Furthermore, studies of ROCK inhibition demonstrated that potent ROCK 
inhibitors were able to suppress K-Ras driven lung tumour growth, suggesting that 
it may be a therapeutic target for Ras-induced cancers (Rath and Olson, 2012) 
which so far have not been successfully treated (Castellano and Downward, 
2011). 
 
1.2.2 The structure of ROCK 
 
ROCK kinases are serine/threonine protein kinases first discovered to act as 
downstream effectors of Rho proteins (Leung et al., 1995, Nakagawa et al., 1996). 
There are two ROCK homologues called ROCK1 (ROCKβ) and ROCK2 (ROCKα) 
(Rath and Olson, 2012). Both share about 90% identities in the kinase domains 
(Amano et al., 2000, Mueller et al., 2005). ROCK is most closely homologous to 
members of the AGC kinase group, such as myotonic dystrophy protein kinase 
(DMPK) (Riento and Ridley, 2003), myotonic dystrophy kinase-related Cdc42-
binding kinase (MRCK) (Wilkinson et al., 2005) and citron kinase (Yamashiro et 
al., 2003). Generally, these kinases share homologous catalytic domains located 
at the amino terminus that phosphorylate several of the same substrates (Mueller 
et al., 2005, Wickman et al., 2010). In both ROCK1 and ROCK2, the amino 
terminus is followed by a coiled-coil region containing the Rho binding domain 
(RBD), and a pleckstrin homology region with an internal cysteine-rich domain 
(CRD) in the carboxyl terminus (Riento and Ridley, 2003, Mueller et al., 2005) 
(figure 1.2). 
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Figure 1.2 Structure of ROCK (1 and 2). ROCK 1 and 2 have approximately 90% identity in kinase 
domain. Both ROCK 1 and 2 have a coiled-coil region containing rho binding domain (RBD) and 
followed by a pleckstrin homology (PH) region with an internal cysteine-rich domain (CRD) in the 
carboxyl terminus (Figure modified from Mueller et al., 2005). 
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Despite the high homology between ROCK1 and ROCK2 protein sequences, there 
is a striking difference in the tissue distribution of each isoform (Nakagawa et al., 
1996, Mueller et al., 2005). ROCK1 is enriched in liver, spleen, kidney and testis; 
while ROCK2 is preferentially expressed in brain and muscle (Nakagawa et al., 
1996). Moreover, previous studies have shown that ROCK2 is localised in the 
cytoplasm and cell membrane, with the majority expressed in the cytoplasmic area 
(Leung et al., 1995, Riento and Ridley, 2003). In terms of the skin, it has been 
demonstrated that ROCK2 rather than ROCK1 plays a significant role in 
keratinocyte differentiation (Lock and Hotchin, 2009); and as shown below, ROCK 
may be integral to the strength of the spinous layer as this is where a broad 
cytoskeletal network of intermediate keratin filaments is constructed (Fuchs, 1990) 
alongside that of the actomyosin cytoskeleton. This would be a logical facet to a 
molecule associated with tensile strength in a tissue associated with a major 
barrier function. 
 
It has been postulated that ROCK is maintained in an inactive state by its carboxyl 
terminus region which forms an auto-inhibitory loop by binding directly to the 
catalytic kinase domain (Mueller et al., 2005). Thus, binding of active GTP-bound 
Rho to the RBD in the coiled-coiled region of ROCK disrupts this auto-inhibitory 
structure and results in increased kinase activity (Pan et al., 2013) (figure 1.3a). In 
addition, some lipids, particularly arachidonic acid, can activate chicken gizzard 
smooth muscle ROCK2 approximately 5-6-fold in vitro, independent of RhoA. This 
finding demonstrates that lipid activation may be an alternative ROCK activator in 
smooth muscle cells (Feng et al., 1999, Miyazaki et al., 2006). 
  
During apoptosis, ROCK can be activated by granzym B (for ROCK2) or by 
caspase 3 (for ROCK1) through cleavage of the carboxyl-terminal region (Riento 
and Ridley, 2003) adding greater complexity to ROCK signalling (figure 1.3b). 
While some GTP-binding proteins act as positive regulators of ROCK as shown for 
RhoA, RhoB and RhoC, other GTP-binding proteins, like RhoE, Gem (in the case 
of ROCK1) and Rad (in the case of ROCK2), inactivate ROCKs by binding to sites 
distinct from the RBD (Olson, 2008, Rath and Olson, 2012).  
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Figure 1.3 Activation of ROCK. The carboxyl terminus of ROCK forms an auto-inhibitory loop to 
maintain ROCK in an inactive state. (a) Upon binding of Rho-GTP to RBD, it disrupts the auto-
inhibitory loop structure and results in the activation of kinase. (b) ROCK can also be activated by 
granzym B (for ROCK2) or caspase 3 (for ROCK1) through cleavage of the carboxyl-terminal 
region. (Figure modified from Julian and Olson, 2014). 
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1.2.3 ROCK and cancer 
 
Extensive research has been conducted into the association between ROCK 
expression and cancer (Horiuchi et al., 2008, Routhier et al., 2010) in relation to 
changes in cell shape and motility. As outlined above, many studies have 
demonstrated the role of ROCK as an essential regulator for actomyosin 
contraction (Riento and Ridley, 2003, Kumper and Marshall, 2011). This ROCK-
mediated increase in actomyosin contraction leading to increased cellular tension 
has been shown to promote tumour progression (Samuel et al., 2011) with ROCK 
expression associated with the later stages of tumour progression to an invasive 
and metastatic phenotype (Croft et al., 2004, Wickman et al., 2010). In addition to 
elevated ROCK expression, it was shown that increased levels of Rho proteins, 
may also be associated with late cancer events (Croft et al., 2004). For example, 
RhoA over-expression could promote cell invasion contributing to cancer 
progression (Yoshioka et al., 1999). Collectively, this suggests that ROCK 
activation acts in later events during tumourigenesis which is consistent with its 
roles associated with the cytoskeleton and cell movement. 
 
Increased cellular tension influences subsequent changes in cellular structure 
including cell-cell adhesion and extracellular matrix (ECM) remodelling leading to 
elevated tissue stiffness (DuFort et al., 2011, Samuel et al., 2011). Stiffness 
contributes to tumour formation via deposition and changes in ECM components 
such as collagen, which can also upregulate signal transduction pathways that 
eventually drive tumour formation and cell proliferation (Kumper and Marshall, 
2011, Samuel et al., 2011). Moreover, increased tissue stiffness has been 
implicated in changes to cell shape (DuFort et al., 2011) which may also trigger 
the activation of pathways including Rho-ROCK signalling that fuel the remodelling 
of the actin cytoskeleton (Samuel et al., 2011, Rath and Olson, 2012). 
 
Inhibition of ROCK proteins has the potential to become an Achilles heel for MAPK 
signalling as it acts as an effector downstream of ras (Castellano and Downward, 
2011). As ras inhibitors have not yet proved successful, inhibition of ROCK is a 
potential alternative therapeutic approach to reduce tumour development (Olson, 
2008, Rath and Olson, 2012, Morgan-Fisher et al., 2013). Previous studies have 
reported successful application of ROCK inhibitors to suppress tumour growth 
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using in vivo and in vitro models (Patel et al., 2012, Zhang et al., 2012), yet there 
is no ROCK inhibitor that has been clinically established for cancer therapy 
(Morgan-Fisher et al., 2013). Furthermore, most studies have indicated important 
roles for ROCK in promoting invasion and metastasis which are involved in the 
later stages of cancer (Croft et al., 2004, Samuel et al., 2011), suggesting that 
inhibiting ROCK at these stages would be the most likely scenario to be of benefit. 
However, whether ROCK can also promote early stages of cancer is still unclear 
(Morgan-Fisher et al., 2013) hence, model studies of ROCK pathway activation 
may highlight new targets in the mechanisms driving carcinogenesis.  
 
In one such study involving ROCK2 transgenic mice (K14.ROCKer), ROCK 
activation significantly influenced tumour formation and progression to invasive 
carcinomas in a two stage chemical carcinogenesis skin cancer model. 
Conversely, application of ROCK inhibitor Y27632 led to reductions in tumour 
growth and conversion (Samuel et al., 2011). However, the two-stage chemical 
carcinogenesis protocol induces many unknown mutations and there is little clear 
indication of which genes directly co-operate with one another. Nevertheless, this 
study implicates an important consequence of ROCK activation in skin tumour 
formation and provides an opportunity to assess ROCK activation in co-operation 
with other genes in classic mouse skin carcinogenesis.  
 
Experiments in this study have included two models that targeting ROCK2 
activation: K14.ROCKer (Samuel et al., 2009a) and lsl.ROCKer transgenic mice. In 
order to assess the stage-specific roles of ROCK2 activation in multistage skin 
carcinogenesis, both transgenic models (K14.ROCKer (Samuel et al., 2009a) and 
lsl.ROCKer) consist of a conditionally-active human ROCK2 kinase domain with 
part of the coiled-coil region fused to the estrogen receptor (ER) hormone binding 
domain at the carboxyl terminus and enhanced green fluorescent protein (GFP) at 
the amino terminus (Croft and Olson, 2006) (figure 1.4). Although this ROCK2er 
fusion protein doesn’t have all the domains at the carboxyl terminus including the 
pleckstrin homology domain which modulates membrane localisation of ROCK, it 
does reflect the consequences of increased actomyosin contraction (per 
communication with Olson). Both ROCK1 and ROCK2 are expressed in 
keratinocytes with ROCK2 being more predominant (McMullan et al., 2003). By 
exchanging RBD in ROCK2 with the ER, the model is conditionally activated by 4-
HT via the K14 promoter, conditionally-active ROCK2 can be selectively 
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expressed in the proliferative basal layers. As shown in a previous study by 
Samuel et al., (2009a), ROCK2er transgene was expressed on the superficial cell 
layer of embriod bodies through GFP staining, consistent with the K14-driven 
specific expression. Activated ROCK2er was also expressed throughout the 
epidermal layers, including hair follicles of K14.ROCKer mouse skin as 
demonstrated by phosphorylated Mypt1 expression, again, consistent to the area 
targeted by K14 promoter (Samuel et al., 2011). The new unpublished lsl.ROCKer 
transgenic model employs the same ROCK transgene but it is now placed 
downstream of a loxP flanked stop codon and is driven by a general CAG-
promoter. This lsl.ROCKer model requires cre recombinase to evict the stop 
cassette located between loxP sites. Thus, mating with K14.creP mice (K14 
promoter) (Berton et al., 2000b) is required to achieve tissue specificity on the 
proliferative basal layers and follicles.  
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Figure 1.4 Schematic diagrams of (a) K14.ROCK
er
 and (b) lsl.ROCK
er
 transgenic mice. (Figure 
modified from Croft and Olson, 2006). 
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1.3 Models of multistage skin carcinogenesis 
 
1.3.1 Epidermal physiology 
 
Prior to exploring the use of transgenic mouse models for skin carcinogenesis, it is 
essential to understand the overall physiology of the epidermis including its 
organisation, structure and cell types as each has the potential to influence cancer 
formation. It is worth remembering that the primary function of the epidermis is to 
act as a barrier, hence it is logical to consider the contribution of ROCK-mediated 
signalling to the tensile strength and integrity of the epidermis which may be a 
latent problem that later contributes to cancer progression via increased tissue 
stiffness. Since the transgenic mouse models employed in this study are primarily 
geared to test the roles of genes in cancer; they are equally valid to investigate an 
interrelationship between keratinocyte proliferation and differentiation during 
normal epidermal functions. By understanding these key aspects of epidermal 
physiology, the changes induced by alteration of the normal proliferation and 
differentiation pathways will facilitate the diagnostic analysis of pre-malignant and 
malignant tumours. 
 
The epidermis forms the outer layer of the skin and mainly consists of 
keratinocytes which are organised into four main layers or compartments: basal 
layer, spinous layer, granular layer and cornified layer (Alonso and Fuchs, 2003, 
Fuchs, 2008) (figure 1.5). It should be noted that in mice, and most animals 
covered in fur, the epidermis is seldom more than one layer thick. The exceptions 
to this are the ear and neonatal epidermis, which is naturally hyperplastic until hair 
follicles form at day 3 to 4, then the epidermis thins out and remains constant 
(Sundberg, 2004) hence, 24 to 48 hour neonates are used to derive keratinocytes 
for culture). The basal layer contains cells which are attached to an epidermal 
basement membrane. This layer consist of occasional interfollicular epidermal 
stem cells but mainly proliferating transit amplifying cells (Alonso and Fuchs, 
2003). Typically these proliferative basal layer keratinocytes express keratins K5 
and K14 (Yuspa et al., 1989, Yuspa, 1994), whilst the majority of pluripotent stem 
cells reside in the hair follicle bulge region and express markers such as K15 and 
K17. The hair follicles also typically express keratin K6, a keratin marker which is 
expressed in wounded or hyperproliferative epidermis (Rothnagel et al., 1999) or 
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at time of stress, such as overexpression of TGFβ in transgenic mouse epidermis 
(Sellheyer et al., 1993, Akhurst and Hata, 2012). As basal cells commit to 
differentiate and move from the basement membrane toward the spinous layer, 
they lose proliferative capability and express early differentiation markers such as 
K1 and K10 (Yuspa et al., 1989, Yuspa, 1994). It is these cells of the spinous layer 
that gain adaptability to mechanical stress that provides the epidermis with its 
tensile strength by strengthening their cytoskeletal filaments and cell-cell 
connections via e.g. adherent junctions, a process influenced by ROCK isoforms 
(Amano et al., 1997, Amano et al., 2000). As differentiation progresses, spinous 
cells migrate into the granular layer and express late stage terminal differentiation 
markers including loricrin, filaggrin and keratinocyte transglutaminase (Yuspa, 
1994) and these differentiation associated genes are regulated by AP1 (DiSepio et 
al., 1995), hence the interest in developing the original fos transgenic mice.  
 
Cells of the granular layer subsequently form the cornified envelope by cross 
linking proteins including filaggrin and loricin mediated by transglutaminase. 
Granular cells also produce lamellar granules containing lipids which attach to 
proteins of the cornified envelope to offer a water-resistant seal for epidermal 
water barrier function (Kalinin et al., 2002, Alonso and Fuchs, 2003, Candi et al., 
2005). Upon progression to the last stages of terminal differentiation, granular cells 
undergo the final processes of cornification producing the outermost layer of 
epidermis called the cornified layer (Alonso and Fuchs, 2003, Candi et al., 2005), 
again a feature regulated by c-fos (Fisher et al., 1991). Of significant importance to 
in vitro studies, this epidermal differentiation programme is regulated in part by an 
epidermal gradient of calcium (Ca2+). This Ca2+ ion concentration gradually 
increases from low concentrations in the basal layer, increases in the spinous 
layer to high concentrations of Ca2+ in the granular layer (Hennings et al., 1980) 
and this can be mimicked in vitro to both grow and induce the terminal 
differentiation of primary keratinocytes and some keratinocyte cell lines (Hennings 
et al., 1980, Greenhalgh et al., 1989). Further resistance to this differentiation 
switch can be employed to test keratinocyte transformation (Greenhalgh et al., 
1989, Morgan et al., 1992).  
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Figure 1.5 Schematic diagram of a typical stratified normal epidermis and typical markers 
associated with terminal differentiation through each layer. Keratin K5 and K14 indicate the 
proliferative compartment; K1 and K10 are early differentiation markers expressed as keratinocytes 
commit to differentiation and leave the basal layer and, loricrin and filaggrin are late stage markers. 
Omitted from this diagram is keratin K6 which is normally expressed in hair follicles and is 
expressed in all layers indicating anomalous pre-neoplastic hyperplasia or epidermal stress. 
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1.3.2 The classic mouse skin model of chemical carcinogenesis 
 
One of the most successful in vivo models used to study molecular carcinogenesis 
over the last 100 years has been the mouse skin model of two-stage chemical 
carcinogenesis (Yuspa et al., 1991). This two-stage chemical carcinogenesis 
protocol was amongst the first to define the stages of initiation, through promotion 
to a benign tumour, and later malignant conversion or progression (figure 1.6). The 
model employs many regimes involving chemicals which possess initiating activity, 
activity associated with promotion or with both initiation and promotion activities 
(Yuspa, 1994). The most common treatment regime typically involves the 
application of a mutagen such as 7, 12-dimethyl-benzanthracene (DMBA), which 
at low level doses provides an initiation step that leads to irreversible DNA 
damage, such as mutation at codon 61 of the rasHa gene (Balmain, 1985, Roop et 
al., 1986) but at this low level dose, tumour formation requires promotion. 
Promotion can happen immediately or up to one year later, thus demonstrating 
that these cells are most likely the cancer stem cell targets (Yuspa, 1998).  
 
The initiated cell populations are expanded by tumour promoters, such as weekly 
application of 12-O-Tetradecanoylphorbol-13-acetate (TPA) and this treatment 
regime can continue for up to 60 weeks. TPA is the classic promoting agent 
typically employed and activates numerous pathways including c-fos signalling in 
the AP-1 complex (Greenhalgh and Yuspa, 1988, Greenhalgh et al., 1990). The 
combined effect of (DMBA) initiation and (TPA) promotion results initially in 
squamous cell papillomas that appear by 8 to 10 weeks and which can persist 
(TPA independent), regress (on cessation of TPA) and approximately 10 to 20% of 
these papillomas progress to carcinomas. Typically the papillomas that appear in 
the first 3 months are most likely to persist and convert (Hennings et al., 1993). 
However, such malignant conversion and papilloma number is also dependent on 
the doses of both initiator and promoter (Hennings et al., 1993, Yuspa, 1994, Abel 
et al., 2011) and their specific strengths to act as initiators or promoters. For 
example sunlight is a strong initiator but is a weak promoter (Brash et al., 1991).  
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Figure 1.6 Classic mouse skin model of chemical carcinogenesis from DMBA initiation to TPA 
promotion leading to formation of benign papilloma that can persist, regress or convert to 
carcinoma. 
 
 
 
Figure 1.7 Operational stages of skin carcinogenesis. The initiated cell remains for the lifespan of 
the animal and thus could be considered a cancer stem cell; the early appearing papillomas are 
more prone to convert (like ras/fos/PTEN) while papillomas appearing later are more likely to be 
TPA dependent and regress on cessation of treatment. This model demonstrates the necessity for 
multiple genetic insults for malignant tumours to occur. 
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Figure 1.7 shows the operational stages of skin carcinogenesis which illustrates 
that multiple events are required for development of most cancers (Yuspa and 
Poirier, 1988, Yuspa, 1994). First, exposure to carcinogen (example: DMBA) 
induces the initiation stage which is irreversible and amongst the many genes that 
are mutated, the rasHa gene is most frequently activated with over 85% of 
papillomas expressing rasHa mutation at codon 61 (Balmain, 1985, Quintanilla et 
al., 1986). The stem cell unit in the bulge region of the hair follicle and in the 
proliferative basal layers are the key targets in this initiation stage (Morris, 2004). 
 
The next stage involves promotion induced by promoters (example: TPA or 
wounding) where initiated cells expand, increase in proliferative activity in the 
basal layers leading to epidermal hyperplasia, observed skin thickening and 
benign tumour formation (Yuspa et al., 1982). These benign squamous papillomas 
may progress to squamous cell carcinoma (SCC) by additional mutation 
(Greenhalgh et al., 1990, Greenhalgh et al., 1993a-c, Yuspa et al., 1994). During 
keratinocytes begin to lose the ability to differentiate in an oderly fashion, alter 
their size and shape and begin to express keratins such as K6. Of note, and 
exploited throughout this study, is the reduction and eventual loss of expression of 
the early differentiation marker keratin K1 which is an indicator of malignant 
conversion and the degree of malignant progression achieved (Greenhalgh et al., 
1993a-c, Slaga et al., 1995). This and other pathological markers such as loss of 
p53 and p21 tumour suppressor genes (TSGs) have been valuable in evaluating 
the tumour development, and appear to be good indicators of tumour progression 
into malignancy (Yao et al., 2006, Yao et al., 2008, Macdonald et al., 2014). 
 
This classic DMBA/TPA two-stage chemical carcinogenesis protocol was 
previously used on ROCK transgenic mice and results showed increased 
malignant progression compared to controls (Samuel et al., 2011). However, while 
it was assumed to co-operate with rasHa activation in this model, many other 
mutations are induced by application of DMBA and single treatment without TPA 
to assess ROCK as a promoter in early stage carcinogenesis were not reported. 
Thus, whether ROCK activation could exert an earlier initiating role or later 
promoting role remained unclear and this has been investigated in this project; as 
the HK1 model was specifically designed to mimic this classic two-stage chemical 
carcinogenesis protocol. Furthermore, these studies directly assess ROCK 
activation together with the co-operating mutations implicated in the chemical 
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carcinogenesis mechanism such as ras and /or fos oncogene activation and then 
progress to assess inactivation of PTEN tumour suppressor gene regulation of 
AKT, and the roles played by p53/p21 in the unfolding mechanism. 
 
1.3.3 The HK1 transgenic mouse model of skin carcinogenesis 
 
The mechanism of carcinogenesis is driven by irreversible genetic mutations that 
cooperate to disrupt normal homeostasis. In skin carcinogenesis, initial mutations 
can lead to pre-neoplastic epidermal hyperplasia and pre-malignant benign 
squamous papillomas which can regress, persist or convert to malignancy and 
(rarely) eventually become metastatic (Balmain et al., 1984, Hennings et al., 
1985). When coupled to the well-characterised mouse skin carcinogenesis 
models, transgenic mice that are designed to investigate particular gene 
expression or knockout, this presents a manageable approach to verify roles in 
each stage of carcinogenesis: initiation, promotion and malignant conversion. At 
the same time, pathways that help inhibit or induce carcinogenesis in responses to 
these specific driving mutations may be discovered through this model.  
 
Here the epidermis is an attractive target tissue where genes are expressed 
through a variety of promoters given the understanding of epidermal 
differentiation. In addition, the use of an inducible system not only gives 
expression in specific tissues, but also at times designated by the investigator; 
such as in adulthood thus avoiding complications during embryogenesis or post-
natal development. These inducible systems also facilitate gene expression at a 
particular stage of the cancer process and cessation of treatment with the inducing 
agent can also provide insight as to causality and oncogene dependence. The 
multistage nature of carcinogenesis in mouse skin presents as a pathology with 
easy accessibility to assist both observations on tumour progression and treatment 
with biological agents. Hence, the transgenic mouse skin model can be used to 
investigate various cancer hypotheses, identify the stage-specific causal factors 
and possibly provide a model system to aid in testing new drugs for the prevention 
and treatment of cancer. 
 
Given that rasHa is the oncogene extensively activated following DMBA treatment 
(Balmain and Pragnell, 1983, Balmain et al., 1984, Roop et al., 1986), previous 
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transgenic mouse studies have mimicked the initiation steps of chemical 
carcinogenesis via the expression of activated proto-oncogene rasHa (HK1.ras). 
Numerous groups have expressed activated ras in the epidermis, by employing 
keratin promoters, to initiate carcinogenesis in transgenic mice and this often 
results in benign squamous papillomas which can lead to a rapid carcinogenesis 
or not depending upon the cell population targeted (Bremner and Balmain, 1990, 
Greenhalgh et al., 1993a-c). As detailed below, to mimic the second, promotion 
stage addition of e.g. v-fos (HK1.fos) oncogene activation Greenhalgh et al., 
1993c), can be employed given it is a major facet of TPA promotion 
(Schlingemann et al., 2003). It has already been shown to co-operate with rasHa 
oncogene activation in the transformation of primary keratinocytes and papilloma 
cell lines (Greenhalgh and Yuspa, 1988, Greenhalgh et al., 1990). In transgenic 
models ras/fos resulted in papillomas that persisted, but without spontaneous 
progression to malignancy (Greenhalgh et al., 1993c). This ras/fos co-operation 
makes it an ideal model to study the mechanism driving conversion of benign 
tumours; such as inactivation of AKT regulation via mutation of PTEN exon5 in tri-
genic HK1.ras/fos/5PTENflx transgenic mice (Macdonald et al., 2014). 
 
This HK1 transgenic mouse model of multistage skin carcinogenesis is 
summarised in figure 1.8 and depicts the classic stages of chemical skin 
carcinogenesis. The data from individual oncogene experiments are reviewed in 
detail below in each section, but in brief, the HK1 mouse skin model employs a 
truncated keratin K1 targeting vector (HK1) modified to specifically target the 
proliferative epidermal keratinocytes with activated rasHa and v-fos expression to 
create HK1.ras and /or HK1.fos transgenic mice (Greenhalgh et al., 1993a-c). This 
model recapitulates each stage of skin carcinogenesis and has a unique feature in 
that progression through each stage requires another genetic event; e.g. co-
expression of rasHa and fos elicited persistent papillomas without spontaneous 
conversion (Greenhalgh et al., 1993a-c), making these models ideal to assess 
conversion. Experiments in this study have included PTEN mutation (Yao et al., 
2006, 2008) and the assessment of stage-specific roles for ROCK2 activation. 
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Figure 1.8 The histotype of typical tumour pathology and expression of tumour markers in 
multistage mouse skin carcinogenesis as typified by HK1.ras/fos/5PTEN
flx
 transgenic mice.  
This progress from (a) normal epidermis, to (b) epidermal hyperplasia, followed by (c) benign 
squamous cell papilloma and subsequent malignant conversion to (d) well-differentiated squamous 
cell carcinoma (wdSCC) then continued with further progression to (e) poorly-differentiated SCC 
(pdSCC). 
IFC analysis of keratin K1 showed strong supra-basal expression from (f,g,h) normal to benign 
papilloma before K1 expression became reduced upon malignancy in (i) wdSCC and disappeared 
in (j) pdSCC. IFC analysis of keratin K6 showed (k) typical expression in hair follicles of normal 
epidermis, and (l-o) persistent expression throughout HK1.ras/fos/5PTEN
flx
 carcinogenesis 
consistent with its association with excessive proliferation. 
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In addition, as detailed below throughout these experiments, keratin K1 an early 
marker of terminal differentiation,  served as an excellent marker of tumour 
progression status (figure 1.8f-j); as during carcinogenesis, supra-basal K1 
expression fades as benign papillomas convert to wdSCC and disappears in 
pdSCC by TPA promotion (figure 1.8f-j). Whilst keratin K6, a keratin that normally 
is expressed in hair follicles and also associated with excessive proliferation or 
epidermal stress, appeared persistently throughout carcinogenesis in these 
HK1.ras/fos/5PTENflx transgenic mice (figure 1.8k-o). Collectively, this model 
supplies the ability to assess ROCK2 activation in both MAPK and PTEN/AKT 
signalling deregulation and to assess co-operation at each stage following the 
mechanism via p53/p21, AKT status and differentiation markers expression. 
 
1.4 Targeting genes to the epidermis: A mimic of classic 
two stage DMBA/TPA mediated chemical 
carcinogenesis 
 
One clear lesson from HK1 transgenic mice was that progression requires more 
than one oncogene; for example: rasHa requires promotion, fos required initiation 
and malignancy required additional events despite co-operation of two powerful 
oncogenes (v-rasHa and v-fos). Given the many studies on ROCK activation in 
carcinogenesis (Sahai and Marshall, 2003, Samuel et al., 2011), the stable 
phenotypes produced in the HK1 model presented an ideal opportunity to examine 
the causal relationship between ROCK signalling deregulation and ras/fos/PTEN 
tumourigenesis giving a valuable approach to understand the events that both 
drive or inhibit tumour formation.  
 
One crucial step is the design of the transgenic mouse model that allows induction 
of a specific gene or expression in specific cell types. To study the mechanism of 
how ROCK2 activation is involved in multistage carcinogenesis, transgenic mice 
expressing tamoxifen-regulated, conditionally active ROCK2-estrogen receptor 
fusion transgene, under control of the keratin K14 promoter have been developed. 
These showed that deregulated ROCK2 expression in the basal layers induced 
keratinocyte hyperplasia, epidermal thickening and elevated collagen deposition 
(Samuel et al., 2009a, 2011, Rath and Olson, 2012). Studies using the classic two-
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stage DMBA/TPA promotion suggested that ROCK2 deregulation was involved in 
the later stages increasing the number of carcinomas. Thus, investigation of 
ROCK activation in this HK1 transgenic mouse model will be used to identify 
partner genes in co-operative studies and examine ROCK2 deregulation in the 
earlier stages of tumour development and progression.  
 
1.4.1 Targeting activated rasHa to the epidermis: A model of 
tumour initiation and papilloma formation 
 
The ras gene family has three members: H-ras, K-ras and N-ras, that form a 
superfamily of membrane bound signalling systems; a molecule turnstile that takes 
external signalling from tyrosine kinase receptors such as epidermal growth factor 
(EGF) and transmits to downstream signalling pathways (Der et al., 1986, Bos, 
1989, Kimmelman, 2015). The biological molecular turnstile activity of ras 
functions by swapping between active GTP-bound and inactive GDP-bound forms 
to switch binding on downstream effectors. Multiple downstream effectors are thus 
being stimulated by Ras-GTP (figure 1.8) and when mutated, it is permanently on 
and this deregulation of signalling contributes to tumourigenesis.  
 
The activation of the ras/MAPK pathway that contributes to cell proliferation and 
sustains cell survival in combination with the activation of PTEN/AKT that 
increases proliferation and gives resistance to apoptosis, show the significant 
potential of both interacting pathways to drive malignant transformation (Chang et 
al., 2003, McCubrey et al., 2007, Macdonald et al., 2014); hence, the interest in 
adding the consequences of ROCK signalling and to assess the effects of cell 
rigidity and tissue stiffness on malignant conversion and invasion (Samuel et al., 
2011, Rath and Olson, 2012). 
 
It has been frequently reported that ras genes play a pivotal role in different types 
of tumours and are a causal factor in tumour development through specific point 
mutations at codons 12, 31 and 61 that activate ras oncogenes (Der et al., 1986, 
Karnoub and Weinberg, 2008). Moreover, ras genes also actively participate in 
carcinogenesis with almost 30% mutated ras being found in all types of human 
tumours (Baines et al., 2011).  Ras genes were identified as critical intermediates 
located between receptor tyrosine kinases and downstream kinases (MAPK) 
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which channel their mitogenic signals to the nucleus leading to malignant 
transformation (Roberts and Der, 2007) (figure 1.9). In human skin cancer studies, 
it has been estimated that up to 50% of SCCs have been demonstrated to have a 
high occurrence of rasHa gene mutation at codon 12 in skin cancer derived from 
UV exposure (Pierceall et al., 1991). This rasHa mutation frequency depends 
mainly on latitude (Bos, 1989, Baines et al., 2011) and the skin type exposed to 
UV-B which acts as both initiator; e.g activating rasHa, inactivating p53 (Brash et 
al., 1991) and over subsequent years acts as a promoter which includes the role of 
UV-induced c-fos expression (Basset-Seguin et al., 1990). 
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Figure 1.9 Schematic diagram of the structure of Ras/MAPK pathway. Tyrosine kinase receptors 
such as epidermal growth factor (EGF) channel external signalling to downstream pathway. Thus, 
GTP binds to Ras and becomes active followed by activation of Raf. Activated Raf leads to 
phosphorylation of MEK which activates MAPK (ERK). Activated MAPK enters the nucleus and 
activates transcription factors. (Figure modified from Roberts and Der, 2007). 
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In the classic DMBA-TPA mouse carcinogenesis models, rasHa gene mutation at 
codon 61 appears as a main target in more than 90% cases (Balmain and 
Pragnell, 1983, Balmain et al., 1984, Roop et al., 1986). This proved to be the 
initiation event as demonstrated by the transfection of primary keratinocytes with 
v-rasHa followed by grafting onto nude mouse skin which resulted in the formation 
of papillomas (Roop et al., 1986). Whilsts ras activation was able to mimic the 
initiating event of chemical carcinogenesis, v-rasHa initiation required a promoting 
agent such as TPA or wounding at the graft site to give rise to benign papillomas 
(Brown et al., 1986). This grafted skin system also offered a co-operation 
approach to identify other genes in multistage skin carcinogenesis, typified by co-
operation with fos when transfected into papilloma cell lines (Greenhalgh and 
Yuspa, 1988). 
 
In order to study the role of rasHa activation, a transgenic mouse model was 
developed where activated v- rasHa was incorporated into a truncated human 
keratin K1 vector (HK1) to generate the HK1.ras transgene (Greenhalgh et al., 
1993a). This truncated form of the keratin K1 gene was based on a 12kb EcoR1 
clone that had lost several 3’ control elements, later shown to be required for 
correct expression in terminal differentiation (Roop et al., 1987, DiSepio et al., 
1995). This allows the HK1 vector to target gene expression exclusively in the 
epidermis from a late stage of embryo development (approximately day 19) and 
fortunately is expressed in 20 to 30% of the proliferative transit amplifying 
keratinocytes of the basal layers and importantly is still expressed following 
malignant conversion. In contrast, the endogenous mouse keratin K1 is lost during 
tumour progression and serves as a very useful marker for the degree of 
transformation achieved (Greenhalgh et al., 1993a-c).  
 
HK1.ras transgenic mice initially presented with a phenotype of neonatal 
hyperplasia which resolved by day 10 and after that the adult mice were the same 
as their normal siblings. Two lines of HK1.ras mice have been maintained over the 
years: HK1.ras1205 and HK1.ras1276 (Greenhalgh et al., 1993a). While both lines 
exhibited identical neonatal phenotypes proving that their epidermis was initiated 
in adults, they presented very different and very useful alternate phenotypes in 
terms of tumour formation. This has been instrumental in the ability to make a 
multistage skin carcinogenesis model. The HK1.ras1205 line formed benign 
squamous papillomas in 100% of animals that received a wound promotion 
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stimulus from ear tagging. This wound promotion stimulus was required and if the 
ear tag fell out, the papilloma regressed in a similar fashion to that observed in the 
two-stage chemical carcinogenesis model that required either continuous TPA 
promotion (Balmain et al., 1984) or the wounding associated with xenografts 
(Strickland et al., 1988) for tumour formation. Hence, these HK1.ras1205 papillomas 
are considered to be regression prone. In contrast, and for reasons unknown, 
HK1.ras1276 mice are not prone to developing papillomas in the absence of an 
additional hit (example: fos activation or PTEN mutation) but again uniquely and 
luckily, once papillomas developed; just as with HK1.ras1205 papillomas, persistent 
tumours arising on a bi-genic 1276 bckground do not undergo spontaneous 
progression (Greenhalgh et al., 1993a,c, Yao et al., 2006).  
 
As shown in figure 1.10(a), HK1.ras1205 transgenic mice produced benign 
squamous papillomas at approximately 10 to 12 weeks of age and typically after 
ear tag wounding. In the absence of the ear tag, these mice only exhibited 
papillomas at sites of excessive scratching or bites. Also despite an initial wrinkly 
phenotype in neonates, adults appeared grossly normal, yet their epidermal 
histopathology was typically hyperplastic (figure 1.10b) without wound promotion. 
Upon promotion by application of TPA, HK1.ras1205 developed rapid onset large 
papillomas, whilst HK1.ras1276 formed smaller sporadic tumours over a longer time 
(Greenhalgh et al., 1996). However, all HK1.ras1205 tumours regressed on the 
removal of TPA promotion (Greenhalgh et al., 1996). Therefore, development of 
rasHa autonomous papillomas required additional events in order to proceed to 
papilloma progression or malignant conversion. 
 
Here, double-labelled immunofluorescence analysis of keratin K1 expression 
showed strong expression in the supra-basal epidermal layers. As demonstrated 
by the red keratin K14 counterstain that highlights the proliferative basal layers 
and follicles, this result was routinely exploited to confirm the benign nature of 
tumours (figure 1.10c). Furthermore, keratin K6 which is typically express in hair 
follicles only or in pathological conditions from wounding or stress (Sellheyer et al., 
1993) showed uniform expression in proliferative epidermal hyperplasia (figure 
1.9d) and was also consistent with this HK1.ras histotype. 
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Figure 1.10 Tumourigenesis in HK1.ras transgenic mice showed (a) histotype of benign squamous 
papilloma by 3 months after wounding in the HK1.ras
1205
 and (b) mild epidermal hyperplasia 
without wounding in the HK1.ras
1276
. (c) IFC analysis of keratin K1 expressed in the supra-basal 
layers of HK1.ras papilloma. (c) Typical keratin K6 marker expression in HK1.ras papilloma, whilst 
(e) in normal epidermal, keratin K6 was only expressed in hair follicles. (Scale: 50-100µm). 
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1.4.2 Targeting v-fos to the epidermis: A model of tumour 
promotion 
 
Fos was first recognised as the transforming gene of Finkel-Biskis-Jinkins murine 
osteosarcoma virus (FBJ-MSV) which was isolated from a spontaneous 
osteosarcoma in CF1 mouse (Finkel et al., 1966). The viral v-fos produced more 
than 90% of the bone tumour in mice and induced transformation of fibroblasts in 
vitro (Ransone and Verma, 1990). Fos in itself cannot form dimers or bind to DNA, 
but heterodimerisation of fos family genes with members of the jun family form the 
activator protein 1 (AP1) complex and these achieve flexibility as transcription 
factors and thus control many physiological processes including cellular 
proliferation, transformation, differentiation and apoptosis which all contribute to 
tumourigenesis (Shaulian and Karin, 2002, Malnou et al., 2007) (figure 1.11). 
 
Previous analysis of the skin of transgenic mice containing a lacZ/fos fusion 
construct showed constitutive expression of fos with β-galactosidase staining in all 
epidermal layers including hair follicle (Smeyne et al., 1992). In normal human 
adult skin, fos is expressed in the proliferative basal layers (Basset-Seguin et al., 
1990) and in the upper keratinocyte layers (Fisher et al., 1991) which suggest its 
role is not restricted to proliferation but that it is also involved in the differentiation 
process and its alteration generates a potential target for tumourigenesis. 
 
The AP1 complex has been shown to be one of the major transcription factor 
targets of RAS/MAPK signalling pathway (Deng and Karin, 1994, Chang et al., 
2003). As outlined above, if activation of ras oncogene is equivalent to the 
initiation event, then, activation of fos oncogene may acts as a promoter to mimic 
the TPA promotion stages of DMBA/TPA chemical carcinogenesis (Schlingemann 
et al., 2003). In support of this idea, analysis of c-fos knockout mice transfected 
with v-rasHa together with TPA application revealed no evidence of tumour 
formation (Saez et al., 1995); whilst tumours formed in c-fos wild type mice with v-
rasHa were successfully converted to malignancy, thus demonstrating that c-fos 
was crucial for late stage of carcinogenesis (Greenhalgh et al., 1990).  
 
In order to study the role of fos activation in the transgenic mouse model, a 
HK1.fos transgene was generated that resulted in constitutive expression of v-fos 
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in the epidermis. This v-fos construct served to amplify the functions of 
endogenous c-fos proto-oncogene in all of its epidermal roles. Initially the HK1.fos 
transgenic mice were indistinguishable from normal mice as effects on proliferation 
were counterbalanced by effects on differentiation; such that the only observation 
was an increased mitotic index. Ultimately, with wound promotion from the ear tag, 
HK1.fos transgenic mice formed hyperplastic and hyperkeratotic phenotypes 
which had a long latency period (> 5 months) before eventually proceeding to form 
highly keratotic papillomas (> 12 months) and although consistent with a 
promotion role, they remained benign (Greenhalgh et al., 1993b). As shown in 
figure 1.12, HK1.fos transgenic mice took a longer time to produce a hyperplastic 
histotype with hyperkeratosis also a prominent feature at approximately 6 to 8 
months of age with wounding. Thus, HK1.fos mice require an additional of 
secondary event for further tumour progression. Yet, upon TPA treatment of 
HK1.fos mice, no changes were recorded until small papillomas appeared after 22 
weeks that all contained an activated rasHa which was the initiating event 
(Greenhalgh et al., 1995). 
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Figure 1.11 Schematic diagram of the heterodimerisation of fos family genes with members of the 
jun family to form the activated AP1 transcriptor factor resulting in various cellular activities 
including differentiation, proliferation and apoptosis. 
 
 
 
 
Figure 1.12 Tumourigenesis in HK1.fos transgenic mice showed (a) mixed histotype of hyperplasia 
and hyperkeratosis that took approximately 6 to 8 months to develop with wounding. (b) IFC 
analysis of keratin K1 expressed in the supra-basal layers of HK1.fos hyperplasia. (c) Typical 
keratin K6 marker expression in HK1.fos epidermal layers indicative of hyperplasia. (Scale: 
100µm). 
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1.4.3 Inactivation of PTEN tumour suppressor gene mediated AKT 
regulation 
 
The phosphatase and tensin homologue deleted at chromosome ten (PTEN) was 
identified in 1997 by mapping of homozygous deletions on chromosome 10q23 
which majorly occurred in breast, brain and prostate cancers (Li et al., 1997, 
Hopkins et al., 2014). PTEN is commonly interrupted in sporadic tumours and is 
also present as a germline mutation associated with the hereditary cancer 
syndrome Cowden disease which is typified by early onset of cutaneous 
hyperkeratosis  suggesting an important role for PTEN in epidermal differentiation 
(Yao et al., 2008, Song et al., 2012). 
 
The ability of PTEN to dephosphorylate protein and lipid substrates means that it 
is known as a dual-specificity phosphatase (Myers et al., 1997, Maehama and 
Dixon, 1998). The phosphatase domain of PTEN is highly important in its tumour 
suppressor role (Myers et al., 1997). PTEN acts as a negative regulator of the 
PI3K/AKT pathway to inhibit cell growth, cell migration and survival by 
dephosphorylating its main substrate, phosphatidylinositol-3,4,5-trisphosphate 
(PIP3) to PIP2 (Stambolic et al., 1998, Hollander et al., 2011) (figure 1.13). As it is 
well documented that PIP3 recruits AKT to the membrane by binding to its plekstrin 
homology (PH) domain, resulting in AKT being phosphorylated at threonine 308 by 
3-phosphoinositide-dependent kinase (PDK1) and at serine 473 by mammalian 
target of rapamycin complex 2 (mTORC2) (Song et al., 2012, Hopkins et al., 
2014). Furthermore, in addition to its function as a negative regulator of the 
PI3K/AKT pathway, a study has shown that PTEN helps restrict MDM2 activity, 
which is a substrate of AKT; via indirectly inhibiting p-MDM2 from entering the 
nucleus to degrade p53 which is essential in the regulation of apoptosis (Mayo and 
Donner, 2002). Therefore, loss of PTEN functions are implicated in AKT activation 
that drives many cellular events such as cell proliferation and cell survival; and 
also contributes to p53 degradation leading to tumourigenesis (Chalhoub and 
Baker, 2009, Song et al., 2012, Hopkins et al., 2014). 
 
There have been many studies investigating the important roles of tumour 
suppressor PTEN in carcinogenesis. In PTEN knockout mice, its loss proved to be 
lethal, (Cristofano et al., 1998, Hollander et al., 2011), therefore chemical 
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carcinogenesis studies employed a heterozygous mouse model (Mao et al., 2004). 
These studies have shown that deletion of one allele of PTEN resulted in tumour 
development (Marsh et al., 1998). However, PTEN-induced tumourigenesis is 
dependent on the type of tissue targeted. Studies demonstrated that homozygous 
PTEN loss in mammary gland (Li et al., 2002) and prostate (Wang et al., 2003) 
resulted in the rapid onset of tumour development. In contrast, there was no 
evidence of tumour formation when PTEN was lost in pancreatic β cells (Stiles et 
al., 2006) or in intestine (Marsh et al., 2008).  
 
Homozygous PTEN loss in transgenic mice resulted in death during 
embryogenesis, whereas heterozygous PTEN loss in mice produced several 
tumours in different tissues, therefore, a conditional knockout of PTEN has been 
developed to study its role in tumourigenesis (Lesche et al., 2002, Freeman et al., 
2006). Exon 5 of PTEN which encodes the phosphatase domain is highly 
associated with mutations in many tumours. Thus, PTEN floxed at exon 5 
transgenic mice have been generated by flanking exon 5 with LoxP sequences 
(Lesche et al., 2002). As shown in figure 1.14a, cre recombinase fused with a 
progesterone ligand binding domain (PLBD) and driven by keratin K14, is 
responsive to RU486 which is an agonist of progesterone and activates the 
recombinase activity (Kellendonk et al., 1996). This Cre-Progesterone fusion 
protein then enters the nucleus to ablate the stop codon in the context of loxP-
stop-loxP (which is applicable to lsl.ROCKer line) or the exon5 flanked by loxP 
(5PTENflx). The result of using this regulator transgene is illustrated in figure 
1.14b, where expression of β-gal appeared in the interfollicular and follicular cells 
of K14.creP/ROSA26 mice at 5 weeks post RU486 treatment, thus proving 
expression in stem cells (Berton et al., 2000b). Also, the hisology of RU486-
treated K14.cre/Δ5PTENflx transgenic mice is shown which developed a mild 
hyperplasia histotype identical to that of Cowden disease (figure 1.14c).  
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Figure 1.13 Schematic diagram of PTEN/PI3K/AKT pathway. PTEN acts as a negative regulator to 
PI3K by inhibiting the phosphorylation of PIP2 to PIP3 that can activate AKT to induce cell 
proliferation and cell survival leading to tumourigenesis. 
 
 
Figure 1.14 Histology analysis of K14.cre/Δ5PTEN
flx 
transgenic mice demonstrated (a) the cre/loxP 
system. Upon introduction of RU486, cre rocombinase became activated and excised the stop 
codon or exon5 flanked by loxP (5PTEN
flx
). (b) Expression of β-gal staining in interfollicular and 
follicular cells of K14.creP/ROSA26 mice after RU486 treatment. (c) Histotype of 
K14.cre/Δ5PTEN
flx 
mice revealed epidermal hyperplasia at 6 to 8 months of age with wounding, but 
no evidence of tumour formation. (Scale: 150µm). 
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Through co-operation of PTEN with other oncogenes or with loss of other tumour 
suppressor genes there is a high probability of cancer formation. As mentioned 
earlier, PI3K is downstream of ras oncogene and ras can activate PI3K signalling 
thus promoting cell proliferation and cell survival (Vivanco and Sawyers, 2002, 
Castellano and Downward, 2010). Previous studies by Yao et al., (2006) showed 
that rasHa activation in co-operation with PTEN loss lead to benign papilloma with 
no sign of conversion, whilst fos activation in co-operation with PTEN loss 
produced keratoacanthomas (KAs) but not carcinomas (Yao et al., 2008). This 
provides an exciting opportunity to include ROCK signalling and to assess the 
interaction of ROCK with ras/fos/PTEN in these epidermal specific mutation 
models; and ask whether it would be redundant or induce conversion. 
 
1.4.4 Analysis of endogenous ROCK expression in the 
ras/fos/PTENflx skin carcinogenesis model 
 
It is well known that certain oncogenes can cooperate with each other to 
accelerate the progression of tumourigenesis (Hunter, 1991, Macdonald et al., 
2014). It is also likely that there is co-operation between particular oncogenes and 
/or loss of tumour suppressor genes in tumour development depending on their 
function, and when they become causal to drive progression to the next stage. It is 
the context created by each mutation that facilitates their co-operation or their 
redundancy. Thus, this subchapter assesses whether changes in ROCK signalling 
in mouse skin carcinogenesis could be observed at each stage involving activation 
of the ras/MAPK pathway to fos/AP1 signalling, together with deregulation of 
PTEN/AKT signalling pathways.  
 
The HK1 model demonstrates ras activation as an initiator whilst fos activation 
acts as a promoter (Greenhalgh et al., 1993a-c, Yao et al., 2008). Alternatively, in 
a separate context, whilst co-operation studies between ras and PTEN loss gave 
papillomas (Yao et al., 2006), conversely, fos activation and PTEN loss drives 
tumour development into highly differentiated keratoacanthomas (KAs) rather than 
to papillomas or carcinomas (Yao et al., 2008). Moreoever, co-operation of ras 
oncogene and loss of PTEN resulted in tumours that still remained benign and 
failed to convert into carcinoma (Yao et al., 2006). Given that ROCK is a member 
of the ras superfamily of small GTPases, it is reasonabe to predict that there will 
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be a link between ROCK and ras signalling deregulation. In addition from these 
previous studies, it is highly probable that there will be co-operation between 
ROCK activation and the epidermal specific fos/Δ5PTENflx mutations as all these 
transgenes interact with many of the same target molecules and signalling 
pathways. The question remains as to whether this linkage is redundant, as both 
are on similar pathways or that the extra changes mediated by ROCK signalling 
with respect to tissue stiffness (Samuel et al., 2011, Rath and Olson, 2012) will be 
additive and at what stage of carcinogenesis do they become causal? 
 
It has already been reported that some Rho GTPases, mainly RhoA and RhoC 
contribute to oncogenic ras transformation (Zohn et al., 1998). Sahai et al., (2011) 
demonstrated a high level of Rho activity in ras-transformed cells and elevated 
Rho suppressed p21 expression leading to cell proliferation, and p21 alongside 
p53 is a critical indicator of tumour progression in the HK1 model (Macdonald et 
al., 2014). However, again demonstrating the importance of mutation timing and 
tumour context, reverse involvement of Rho activity in ras-transformed cells has 
also been reported (Izawa et al., 1998).  
 
Previous studies have demonstrated the interaction between rho kinase and ras 
activation in vitro (Qiu et al., 1995, Olson et al., 1998, Sahai et al., 2001), however 
there remains a relative lack of direct co-operation studies between ROCK2 and 
rasHa activation. Moreover, though the application of DMBA/TPA on ROCK2 
resulted in carcinogenesis (Samuel et al., 2011), yet, there is not enough evidence 
from either DMBA or TPA alone on ROCK2 and at which stage ROCK2 co-
operation with rasHa becomes causal. Thus, this study proves this expectation 
between ROCK2 and rasHa through transgenic mouse models that mimic the 
DMBA/TPA chemical carcinogenesis model. It is well documented that activated 
rasHa can act as a tumour initiator, however, deregulated ROCK expression was 
showed to be elevated in the later stages of events during chemical 
carcinogenesis (Samuel et al., 2011, Ibbetson et al., 2013). Therefore, as a 
baseline, the levels of endogenous ROCK1 and ROCK2 were assessed at each 
stage in the HK1 model of tumourigenesis, which would be augmented by the 
additional expression of exogenous ROCK. 
 
An indication that ROCK signalling is clearly involved in this carcinogenesis model 
is demonstrated in figure 1.15 which analysed multistage tumourigenesis in tri-
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genic ras/fos/ΔPTENflx mice. These results showed expression of both ROCK1 
and 2 in both early epidermal hyperplasia and in benign papillomas and also 
demonstrated that ROCK2 appeared to be more prominent than ROCK1, which 
correlated well in this study. As keratinocyte differentiation follows a relatively 
normal pathway sequence in these early histotypes of epidermal hyperplasia and 
benign papillomas (Greenhalgh et al., 1993a-c, Yao et al., 2006, 2008), there was 
a suggestion that both ROCK 1 and 2 expression appeared predominantly in the 
supra-basal layers of the epidermis (figure 1.15 – arrows). This important finding 
would be consistent with a role for ROCK signalling in maintaining epidermal 
integrity and its role in increasing the tensile strength of tumour tissues (Samuel et 
al., 2011) would be a logical facet in the spinous layer of the epidermis that would 
contribute to the barrier functions of the skin (Byrne et al., 1994, Fuchs, 2007).  
 
This relative lack of basal layer expression would thus provide an ideal opportunity 
to deregulate ROCK in these proliferative layers given expression of the ROCK2er 
transgene from a keratin K14 promoter (Samuel et al., 2009a) where the cancer 
target keratinocytes reside and thus directly assess effects of ROCK2 activation in 
these early phenotypes. Analysis of ROCK protein expression also demonstrated 
that ROCK2 was elevated further in HK1.ras/fos/Δ5PTENflx malignant tumours 
(figure 1.15c,f), and of note, this expression was now found in the basal cell 
compartment. Again, these data were consistent with a later role of ROCK at the 
malignant and invasive stage.  
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Figure 1.15 Immunohistochemical analysis of ROCK1 (a, b, c) and ROCK2 (d, e, f) expression in 
HK1.ras/fos/Δ5PTEN
flx
 tumours. Endogenous ROCK1 (a, b) and ROCK2 (d, e) are expressed in 
the supra-basal layer (arrows) of HK1.ras/fos hyperplasia and benign papillomas whilst both 
ROCK1 (c) and ROCK2 (f) are strongly expressed in all compartments including the basal layer 
following malignant conversion in K14.cre/HK1.ras/fos/PTEN
flx
 SCCs. (Scale: 50-100µm). 
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In addition to potential ROCK and ras co-operation, other studies have reported 
that RhoA/ROCK signalling is associated with PTEN activity in the regulation of 
cell proliferation by downregulating AKT activity (Yang and Kim, 2012), and the 
finding that ROCK is a downstream effector of Rho family signalling to the c-fos 
serum response element  also provides a direct link to fos and regulation of 
transcription by AP1 (Chihara et al., 1997, Perona et al., 1997). 
 
Taken collectively, these findings suggest that the HK1 model would be an ideal 
platform to study and analyse the novel co-operation and molecular mechanism 
which triggers causal roles for ROCK2 and ras/fos activation together with PTEN 
loss and AKT deregulation. Furthermore, the analysis of PTEN loss includes a 
new cre/lox responsive ROCK2 transgenic mouse (lsl.ROCKer) geared to express 
ROCK2 in all tissues from a CAG promoter and is ideal to target ROCK and PTEN 
mutations to the identical lsl.ROCKer/Δ5PTENflx keratinocytes populations and 
observe any malignant conversion events in both carcinogenesis and epidermal 
differentiation.  
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1.5 Hypothesis and Aims of the study 
 
The general aim of this study is to analyse ROCK2 activation in the multistage 
cancer process by employing a transgenic mouse model that has been 
established to express commonly mutated genes in cancer: ras, fos and PTEN 
exclusively in the epidermis. It is hypothesised that ROCK2 can become active in 
the early stage of cancer in co-operation with ras/fos/PTEN. Thus, the selected co-
operative genes permit identification of the cancer stage at which mutations 
become active. 
 
The specific aims of the study were to: 
 
1. Investigate and compare the outcome of two ROCK2 transgenic mouse models: 
K14.ROCKer and K14cre/lsl.ROCKer in carcinogenesis. 
 
2. Examine the synergism of ROCK2 with ras, fos and PTEN in multistage 
carcinogenesis and analyse other oncogenes and /or tumour suppressor genes 
such as p53, p21 and /or p-AKT in this transgenic mouse skin carcinogenesis 
model. At the same time, this study will investigate this synergistic process in vitro 
through low and high calcium changes in transgenic mouse keratinocytes to 
assess effects on proliferation and differentiation activities. 
 
The relevant background and further elaboration of specific aims are discussed in 
further detail within each part of the study.
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Chapter 2 – Materials and Methods 
 
2.1 Materials 
 
2.1.1 PCR materials 
 
2.1.1.1 Reagents and buffers 
 
Taq DNA polymerase, 10X PCR buffer and 50mM Magnesium Chloride (from Life 
Technologies);  
DNTPs (from Roche diagnostics);  
50x PCR running buffer;  
6x DNA loading buffer (0.25% bromophenol blue, 0.25% xylene and 30% 
glycerol);  
Proteinase K (from Sigma); 
DNA extraction buffer (50mM Tris/HCL pH 8.0, 100mM EDTA Ph 8.0, 100mM 
NaCl, 1% SDS and 200µg/ml fresh proteinase K). 
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2.1.2 Immunohistochemistry and immunofluorescence materials 
 
2.1.2.1 Antibodies 
 
Antibody Dilution Company 
Rabbit anti-keratin1 (#PRB-149P) (Greenhalgh et 
al., 1993c) 
1:50 Covance 
Rabbit anti-keratin6 (#PRB-169P) (Greenhalgh et 
al., 1993c) 
1:50 
Guinea pig anti-keratin14 (#20R-CP002) (Yao et 
al., 2006) 
1:500 Fitzgerald 
Rabbit anti-ROCK2 (H-85) (#SC-5561) (Lane et 
al., 2008) 
1:100 Santa Cruz 
Biotechnology 
Rabbit anti-ROCK1 (H-85) (#SC-5560) (Lock and 
Hotchin, 2009) 
1:100 
Rabbit anti-p53 (#SC-6243) (Yao et al., 2008) 1:50 
Rabbit anti-p21 (#SC-397) (Yao et al., 2008) 1:50 
Rabbit anti-phospho-Mypt1 (Thr696) (#ABS45) 
(Samuel et al., 2011) 
1:50 Millipore 
Biotinylated goat anti-guinea pig IgG (#BA-7000) 
(Yao et al., 2008) 
1:200 Vector 
Laboratories 
 Biotinylated goat anti-rabbit IgG (#BA-1000) 
(Steiniger and Barth, 2000) 
1:200 
Strepavidin Texas red (#SA-5006) (Yao et al., 
2006) 
1:400 
Horseradish peroxidase-conjugated anti rabbit 
(#PI-1000) (Yao et al., 2008) 
1:100 
FITC-labelled anti-rabbit (#711-005-152) (Yao et 
al., 2006) 
1:100 Jackson 
Laboratories 
Rabbit anti-Tenascin C (#T2551) (Schauer et al., 
2009) 
1:50 Sigma 
Rat anti-BRDU (#ab6326) (Illa-Bochaca and 
Montuenga, 2006) 
1:50 Abcam 
Rabbit anti-pAKT1 (473) (#ab81283) (Sobinoff et 
al., 2011) 
1:50 
Rabbit anti-GFP living colors A.v. Peptide 
(#632377) (Samuel et al., 2011) 
1:50 Clontech 
Table 2.1 Antibodies used in immunohistochemistry and immunofluorescene procedures. 
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2.1.2.2 Other reagents 
 
Normal goat serum, normal horse serum, and DAB (from Dako);  
1x PBS (from Life Technologies);  
Ethanol (from VWR chemicals); 
Xylene (from Fisher Scientific); 
Citrate buffer and PermaFluor mounting medium (from Thermo Scientific); 
Pertex mounting medium (from Cell Path); 
Paraffin embedding medium (from Ted Pella Inc.); 
Hematoxylin and Eosin (H&E), 3% hydrogen peroxide solution, and 
Bromodeoxyuridine (BrdU) (from Sigma).  
 
2.1.3 Cell culture materials 
 
2.1.3.1 Reagents and buffers 
 
L-Glutamine, sodium pyruvate, penicillin/streptomycin, Dulbecco’s phosphate 
buffered saline (PBS) without Ca2+ and Mg2+, and 2.5% trypsin (all from Life 
Technologies); 
Chelex 100 sodium, ethanol, dimethyl sulfoxide (DMSO), RU486 (mifepristone), 4-
Hydroxytamoxifen (4-HT) (all from Sigma-Aldrich). 
 
2.1.3.2 Media 
 
1. DMEM (Dulbecco’s Modified Eagle Medium) was purchased from Invitrogen. 
2. KGM (Keratinocyte Growth Media 2) and supplement components including: 
Bovine Pituitary Extract, Epidermal Growth Factor, Insulin, Hydrocortisone, 
Epinephrine, Transferrin and CaCl2 were purchased from Promo Cell. 
3. The medium used for primary mouse keratinocyte culture was: 10% KGM, 10% 
chelexed fetal calf serum (FCS), 10% fibroblast conditioned media, 10mM of L-
glutamine, 1mM of pyruvate and penicillin/streptomycin in DMEM supplemented 
with 0.05mM Ca2+.   
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2.1.4 Western blot materials 
 
2.1.4.1 Reagents and Buffers 
 
4-12% Bis-Tris gel and NuPage transfer buffer (from Life Technologies); 
1x MES SDS running buffer, 1x NuPAGE transfer buffer and 1x MOPS buffer 
(from Invitrogen); 
Pageruler Prestained protein ladder (from Thermo Scientific);  
6X loading buffer (1M Tris pH6.8, SDS, glycerol, distilled water and bromophenol 
blue); 
1x TBST buffer pH 7.5 (1M Tris pH8, 5M NaCl, Tween 20 and Milli Q water); 
1x TBST-TM pH 7.5 (1M Tris pH8, 5M NaCl, Tween 20, Marvel and Milli Q water) 
and methanol (from Fisher Scientific). 
 
2.1.4.2 Antibodies 
 
Antibody Dilution Company 
Mouse anti-MRCL3/MRLC2/MYL9 (E-4) (Samuel 
et al., 2011) 
1:1000 Santa Cruz 
Biotechnology 
Alexa fluor 680 donkey anti-rabbit (Samuel et al., 
2011) 
1:5000 Invitrogen 
Goat anti mouse 800 IgG conjugated dylight 1:15000 Jackson 
Rabbit anti-keratin1 (Greenhalgh et al., 1993c) 1:1000 Covance 
Rabbit anti-keratin6 (Greenhalgh et al., 1993c) 1:1000 
Table 2.2 Antibodies used in western analysis. 
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2.2 Methods 
 
2.2.1 Transgenic mouse genotypes and breeding 
 
Two transgenic lines were employed to activate ROCK expression in the 
epidermis. The first transgenic line, K14.ROCKer (Samuel et al., 2009a) consists of 
the human ROCK2 kinase domain fused to mutant 17ß-estradiol-insensitive 
estrogen receptor (ER) hormone binding domain (HBD) (Littlewood et al., 1995) 
and enhanced green fluorescent protein (EGFP). This construct is under the 
control of a keratin K14 gene promoter and knocked into the HPRT locus which 
results in gene expression in all epithelial cells but gene activity is exclusive to 
epidermal cells including interfollicular and follicles due to topical application of 4-
HT. The second transgenic line is the new unpublished model, K14.cre/lsl.ROCKer 
which employs the same ROCKer transgene but it is now inserted downstream of a 
loxP flanked stop cassette and driven by a general CAG-promoter (figure 1.4). 
Thus, to ensure that the transgene is targeting the same proliferative basal layer 
and hair follicles, lsl.ROCKer mice were mated with K14.creP mice 
(K14.cre/lsl.ROCKer). This model achieves tissue specificity in the epidermis as the 
keratin K14 vector is targeting the epidermal basal layer and follicles (Berton et al., 
2000a). The K14.creP is fused to a progesterone ligand binding domain which is 
responsive to RU486, a progesterone agonist, thus, activating the recombinase. 
This cre-fusion protein is translocated to the nucleus to ablate the stop codon 
flanked by loxP sites. RU486 evicts the stop codon and then, topical application of 
4-HT activates the ROCKer transgene as described previously (Samuel et al., 
2009b). This new transgenic line is required to turn on ROCKer protein in the same 
cells and in an identical way to the mechanism of PTEN ablation employed 
previously where loxP-flanked sequences of PTEN exon 5 were removed to 
assess its loss in carcinogenesis (HK1.ras/fos/ΔPTENflx) (Yao et al., 2006, 2008). 
 
In this study, HK1.ras (Greenhalgh et al., 1993a), HK1.fos (Greenhalgh et al., 
1993b) and RU486-inducible K14.creP regulator (Berton et al., 2000a) transgenic 
mice were maintained as heterozygotes on an outbred ICR line, whilst 5PTENflx 
mice were maintained as homozygotes as described previously (Yao et al., 2006, 
2008, Macdonald et al., 2014). For HK1.ras transgenic mice, two different lines 
were used in this study: HK1.ras 1205 (sensitive to wound promotion) and HK1.ras 
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1276 (insensitive to wound promotion). All transgenic lines were bred under 
project licence 60/4318 according to the rules and regulations of the UK Home 
Office. To ablate epidermal PTEN and also the stop cassette, cre recombinase 
was activated by topical treatment with 2µg RU486 in 20µl ethanol per ear for 1 
week. To activate ROCKer transgenes, 15µl of a 10mg/ml solution of 4-
hydroxytamoxifen (4-HT) dissolved in ethanol was topically applied on each ear of 
transgenic mice for 20 weeks with controls received RU486 and ethanol. 
 
2.2.1.1 Tail cutting and DNA isolation 
 
The mice were weaned 21-24 days after birth. To isolate the DNA for genotyping 
by PCR (at 5 weeks), a 4mm of tail tip biopsy was taken under anaesthetic, and 
put into a labelled eppendorf tube. 460µl of DNA extraction buffer was added to 
each tube and the tissue digested overnight at 55ºC with occasional vortexing to 
degrade the tails. Next day, tissue lysate were centrifuged at 13,000 rpm for 15 
minutes to ensure that tail genomic DNA was dissolved in supernatant; whilst 
tissue debris and remnants were pooled as a pellet under the supernatant. 500µl 
of ethanol was added gently to the supernatant to precipitate tail genomic DNA. 
The precipitated DNA was collected by gently rolling onto a clean pipette tip and 
any remaining ethanol allow to evaporate off. The DNA was transferred into a new 
labelled eppendorf tube which contained 280µl dH2O and left to dissolve at 55ºC 
for 1 hour.  
 
2.2.2 Polymerase chain reaction (PCR) 
 
2.5µl of tail DNA was used as a template in a 25µl reaction volume comprising 
2.5mM MgCl2+, 0.5µM reverse and forward primers for each transgene, 0.25mM 
dNTPs and 1 unit Taq DNA polymerase (1U/ µl) set in a 200µl PCR tube (Table 
2.3). PCR was performed for each transgene in a thermal cycler according to the 
programmes listed in Table 2.4. PCR products were maintained at 40C after the 
final step. Electrophoresis was performed on the PCR products by using a 1% 
(K14CreP, Ras, Fos and ROCKer) and 1.5% (PTEN) agarose gels that were 
stained with ethidium bromide to visulise the bands under UV lights and to ensure 
that PCR amplified the DNA from each transgene. 
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Component  Volume Final Concentration 
DNA 2.5µl  
10x PCR buffer 2.5µl 1x 
50mM MgCl2 2.0µl 2.5mM 
Forward primer 0.5µl 0.5µM 
Reverse primer 0.5µl 0.5µM 
dNTP 0.25µl 0.25µM 
Taq polymerase 0.25µl 1 unit 
dH2O To 25µl  
Table 2.3 Master mix solution 
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Name Sequences Programmes 
ROCKer 2F CGACCACTACCAGCAGAACA 
2R GACGAACCAACTGCACTTCA 
Denaturation at 950C (5mins),  
Annealing at 600C (1min),  
Extension at 720C (45secs),  
Final extension at 720C 
(5mins). 
K14CreP 1F CGGTCGATGCAACGAGTGAT 
2R CCACCGTCAGTACGTGAGAT 
Denaturation at 940C (5mins), 
Annealing at 580C (45secs), 
Extension at 720C (45secs),  
Final extension at 720C 
(5mins). 
Ras 1F 
GGATCCGATGACAGAATACAAGC 
2R 
ATCGATCAGGACAGCACACTTGCA 
Denaturation at 950C (5mins), 
Annealing at 560C (1min), 
Extension at 720C (45secs),  
Final extension at 720C 
(10mins). 
Fos 1F 
GGATCCATGATGTTCTCGGGTTTC 
2R CGATTATTGCCACCCTGCCATG 
Denaturation at 950C (2mins), 
Annealing at 620C 
(30seconds), 
Extension at 720C (45secs),  
Final extension at 720C 
(10mins). 
PTEN 1F ACTCAAGGCAGGGATGAGC 
2R GTCATCTTCACTTAGCCATTGG 
3R 
GCTTGATATCGAATTCCTGCAGC 
Denaturation at 950C (2mins), 
Annealing at 620C 
(30seconds), 
Extension at 720C (45secs),  
Final extension at 720C 
(10mins). 
Table 2.4 Primers and programmes used in PCR analysis. 
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2.2.3 Immunohistochemistry and immunofluorescence 
 
2.2.3.1 Preparation of skin biopsy sample 
 
Mice were injected with 125 mg/kg 5-bromo-4-deoxyuridine (BrdU, Sigma) 
(15.625mg of Brdu was dissolved in 1ml of 0.9% sterile NaCl solution, pH 7) 
intraperitoneally and biopsied after 2 hours. Mice were sacrificed and biopsies of 
dorsal skin, tail and ears were taken. Each biopsy was cut in half and one half was 
fixed in 10% buffered formalin for 24 to 48 hours at 4°C before being processed for 
histology and H&E staining in the Beatson Research Institute, while the other half 
was snap frozen in liquid nitrogen and stored at -70°C. 
  
2.2.3.2 Immunohistochemistry analysis 
 
Paraffin sections (5-7µm) were incubated at 65ºC for 30 minutes to soften the wax 
and then immediately placed in xylene for 20 minutes to remove the wax. Sections 
were immersed in absolute ethanol for 1 minute, and then washed in 1x PBS for 
10 minutes to rehydrate the section; followed by antigen retrieval with 1x 
commercial citrate buffer (Thermo Scientific) for 2 minutes in microwave at high 
power. Sections were left to cool at room temperature for 20 minutes before being 
immersed in 3% hydrogen peroxide to block endogenous peroxidase enzyme. 
Sections were washed with 1x PBS then blocked in 10% normal goat serum 
(diluted in 1x PBS) for 10 minutes and then incubated with primary antibodies 
diluted in blocking solution (10% normal goat serum) overnight at 4°C.  
 
After incubation with primary antibody, sections were washed in 1x PBS for 10 
minutes and incubated with secondary horseradish peroxidase-conjugated anti 
rabbit antibody diluted in 20% bovine serum albumin (diluted in 1x PBS), for 1 hour 
at room temperature. Sections were washed in 1x PBS and DAB (3,3’-
diaminobenzidine) substrate solution (Dako) was freshly prepared then added to 
sections for 5 minutes at room temperature. Sections were immediately washed in 
water for 3 minutes and counterstained with Haematoxylin for 20 to 30 seconds. 
Next, sections were washed for 3 times in running tap water and dipped in acid 
alcohol 3 times to remove excessed stain; then, washed again in running tap water 
before immersion in Scott’s water for 1 minute to blue the Haematoxylin stain 
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followed by washing in running tap water 3 times. Sections were immersed in 
absolute ethanol for 3 minutes followed by xylene for 3 minutes, left dried before 
being mounted with Permount solution and covered with a coverslip. Finally, 
sections were visualised by using Carl-Zeiss microscope Axiovision software. 
 
2.2.3.3 Immunofluorescence analysis 
 
For double-labelled immunofluorescence staining, paraffin sections (5-7µm) were 
incubated at 65ºC for 30 minutes and placed in xylene for 20 minutes to remove 
the wax. Next, sections were placed in absolute ethanol for 1 minute to remove 
xylene and then washed in 1x PBS for 10 minutes. Antigen retrieval was 
performed using 1x commercial citrate buffer (boiled for 2 minutes in microwave at 
high power). Sections were allowed to cool at room temperature for 20 minutes 
and washed with 1x PBS for 10 minutes. To prevent non-specific binding, sections 
were blocked in 10% normal horse serum or 10% normal goat serum diluted in 1x 
PBS for 10 minutes. Slides were incubated with primary antibodies diluted in the 
blocking solution overnight at 4°C.  
 
The next day, sections were washed in 1x PBS for 10 minutes before being 
incubated with biotinylated goat anti-species of the primary antibody (usually 
rabbit) diluted in 20% bovine serum albumin (diluted in 1x PBS) for 60 minutes at 
room temperature. Sections were washed with 1x PBS for 10 minutes; and 
incubated with FITC to highlight the selected target protein from primary antibody 
and Texas red avidin to highlight the epidermis and follicles as a background 
(diluted in 20% bovine serum albumin) for 60 minutes at room temperature. 
Sections were washed in 1x PBS for 10 minutes before being mounted with 
Permafluor and then stored at 4°C. 
 
2.2.4 Primary keratinocytes cell culture 
 
Keratinocytes were isolated from normal and transgenic neonatal mice, as 
described by Yuspa et al., (1980) and modified by Greenhalgh et al., (1989). 
Briefly, 24hour old newborn mice were sacrificed through an overdose of 
pentobarbital by intra-peritoneal injection and transported to the lab in 70 % 
ethanol which served as a sterilization step. Individual mice were placed in 60mm 
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dishes and tail biopsies taken for DNA isolation and overnight PCR analysis for 
genotype confirmation. The skin was carefully removed and stretched on the cover 
of each 60mm dish with the dermis face down for approximately 30minutes. Each 
skin was carefully floated onto 5 ml of 0.25% trypsin (diluted in 1x sterile PBS with 
Ca2+ and Mg2+) and incubated overnight at 4°C. Care was taken to avoid the 
edges of the skins curling up.  
 
The next day, with the epidermis side down on petri dish, the epidermis was 
separated from the dermis with sterile forceps. Once genotype was confirmed, 
skins of the same genotype were combined together into a 50ml centrifuge tube 
which contained 40ml of high calcium DMEM media to inhibit the trypsin action. To 
separate keratinocyte cells from the epidermal sheet, the tubes were gently 
inverted for 20minutes and the cornified layer was removed by filtering through 
sterile gauze. The resultant filtrate was centrifuged at 900rpm for 3minutes and the 
pellet resuspended in DMEM medium supplemented with 10% chelexed fetal calf 
serum (FCS), L-glutamine, penicillin/streptomycin and 0.05mM calcium as 
previously described (Hennings et al., 1980). Cells were counted using a 
haemocytometer and typically 1 mouse skin yielded (5-8) x106 cells. Thus, cells 
were plated out in the same number of mouse equivalents (0.5 mouse equivalents 
per each 60mm petri dish) to standardise plating density. After overnight 
incubation to allow the keratinocyte to attach, cells were washed twice with 1x 
sterile PBS (without Ca2+ and Mg2+) to remove unattached and differentiated cells 
and fed with the same low calcium media. To activate ROCKer in vitro, 
K14.cre/lsl.ROCKer keratinocytes were treated with RU486 (10-9M) on day 1; and 
4-HT (10-9M) on day 2 in the low calcium medium for 4 days. The calcium 
concentration was increased to 0.10mM on day 4 for 24 hours to induce 
keratinocyte terminal differentiation, then to 1.5mM calcium on day 5 for 24hours. 
Cells were harvested every 4 to 6 days when cells were 90% confluent or 24 hours 
after the second calcium switch.  
 
2.2.5 Western blot analysis 
 
For analysis of non-soluble keratin proteins (keratin 1 and 6), cells were washed 
with PBS and lysed in buffer with 50mM Tris (pH 6.8), 1% SDS and 2% β-
mercaptoethanol. The cells were gently homogenised using a syringe and then 
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heated at 80 C for 10 minutes. All cells were then transferred to eppendorf tubes, 
centrifuged at 13,000 rpm for 5 minutes and the supernatant was transferred to 
fresh eppendorf tubes. The protein concentration was determined using the BCA 
total protein assay kit as per manufacturer’s instruction (Thermo Scientific). 20µg 
of each lysate was mixed with 6x loading buffer and run out on a NuPAGE Bis-Tris 
mini gel with one lane was loaded in 5µl pageruler prestained protein ladder. Gels 
were run at 200V for 60minutes and transferred to nitrocellulose membrane by 
electro-transfer at 100V for 60minutes. After transfer, the membrane was washed 
in 5% skimmed milk with 1x Tris-buffered saline and Tween20 (TBST) for 15 
minutes to block non-specific binding. Primary antibodies (keratin K1 anti rabbit, 
keratin K6 anti rabbit, and tMLC anti mouse) were diluted in 5% skimmed milk in 
1x TBST buffer, applied to the membrane and incubated overnight at 4°C. The 
next day, the membrane was washed in 1x TBST buffer (3 x 5 minutes) then 
incubated in the dark for 1 hour, with Licor fluorescent-labelled conjugated 
secondary antibody (680 anti-rabbit and 800 anti-mouse) in 5% skimmed milk 
diluted in 1x TBST. The membrane was washed with 1x TBST (3 x 5minutes), 
then washed in distilled water (5minutes) before being stored in water, in the dark 
until scanned by LICOR Odyssey system to capture the image.  
 
2.2.6 BrdU-labelling analysis 
 
All mice received 5-Bromo-4-deoxyuridine (BrdU, 125mg/kg) through 
intraperitoneal injection 2 hours prior biopsy. For BrdU staining, following antigen 
retrieval with 1x commercial citrate buffer, paraffin sections were incubated 
overnight with anti-rat BrdU antibody and anti-guinea pig keratin K14 at 4°C. 
Expression was visualised via Alexa Fluor anti-rat IgG and counterstained with 
biotinylated anti-guinea pig/ Streptavidin-Texas red. Data for BrdU-labelling was 
calculated manually using three sections per tumour (three independent tumours), 
and three independent readings per image, at a 20x magnification. Data were 
presented as the percentage (%) of all nuclei that was immuno-labelled for BrdU 
from total of 100 cells in each area. Statistical analysis of variance test (ANOVA) 
was performed to determine any significant difference between cohorts, with p 
value of <0.05 was considered as significant. 
 
 
Chapter 3 – Results 
 
3.1 PCR analysis and genotyping of transgenic mice 
 
The genotype of each transgenic mouse was confirmed by routine PCR analysis 
of tail or biopsy DNA.  DNA was also isolated from tumour biopsies to confirm their 
identity and RU486-mediated cre activity. As outlined above in the methods, two 
transgenic mouse strains of 4-HT-inducible ROCK2 activation (K14.ROCKer and 
lsl.ROCKer) were employed in this study with both ROCKer transgenes being 
expressed directly or indirectly from a keratinocyte specific K14 promoter (Berton 
et al., 2000b, Samuel et al., 2011). Initial studies involved breeding of HK1.ras, 
HK1.fos, K14.ROCKer and lsl.ROCKer mice. The K14.ROCKer transgene which 
was integrated at the HPRT gene locus, and topical application of 4-HT was 
previously shown induce epidermal hyperplasia fin these mice (Samuel et al., 
2009a, 2011). For experiments involving PTEN mutations, and to ensure ROCK 
activation and inducible PTEN exon 5 loss occurred in the identical epidermal 
cells, later studies employed transgenic mice expressing a K14.creP regulator 
transgene: where a single RU486 treatment activates cre activity in the epidermis; 
and after cre-mediated removal of loxP-flanked stop cassette, the same 4-HT 
inducible ROCK2 transgene was expressed from a generic CAG promoter 
downstream of loxP-flanked stop codons (K14.cre/lsl.ROCKer). Hence, following a 
single RU486 treatment K14 mediated cre activity removes the stop cassette thus 
expressing ROCKer ready to be activated by topical 4-HT treatment.  
 
Using specific primers (Table 2.4) for ROCKer, a 589-bp fragment was observed 
which indicated positive ROCKer transgenic mice (figure 3.1). Similarly, analysis of 
tail DNA for HK1.ras or HK1.fos transgenes employing specific primers gave a 
743-bp and 800-bp bands respectively (figure 3.2). The RU486-inducible K14.creP 
regulator transgene produced a 600-bp band and Δ5PTENflx transgenic mice a 
1.3-kbp band, indicative of the floxed allele, and 1.2-kbp band indicative of the wild 
type allele (figure 3.3). ROCKer mice were created by integrating the transgene in 
the HPRT locus on the X-chromosome. Thus in this study, most ROCKer 
transgenic mice maintained on treatment procedures were males due to potential  
X-linked chromosome inactivation in ROCKer female mice. Similarly, all HK1.ras, 
Chapter 3  77 
 
HK1.fos and K14.creP transgenic mice were maintained as heterozygous lines on 
a background of outbred ICR mice.  
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Figure 3.1 PCR analysis of ROCK
er
 genotypes. PCR product represents ROCK
er
 transgenic line. 
ROCK
er
 positive progenies were identified from genomic tail DNA derived from K14.ROCK
er 
mice 
(lane 1 to 3) and lsl.ROCK
er
 mice (lane 4 to 6). 589-bp fragment represents ROCK
er
 positive 
transgenic mice (lane 1 to 6) and is absent in the three negative controls from non transgenic ICR 
mice (lane 7 to 9). (DNA ladder is Biolabs 1kb). 
 
 
Figure 3.2 PCR analysis of HK1.ras and HK1.fos genotypes. (a) 743-bp band represents HK1.ras 
positive transgenic lines (lane 1 to 6) and is absent in the three negative controls from non 
transgenic ICR mice (lane 7 to 9). (b) 800-bp band represents HK1.fos positive transgenic lines 
(lane 1 to 6) and is absent in the three negative controls from non transgenic ICR mice (lane 7 to 
9). (DNA ladder is Biolabs 1kb). 
 
 
 
 
 
 
a 
b 
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3.1.1 Confirmation of gene switch activation 
 
This study incorporates an inducible cre/loxP gene switch system so that PTEN 
loss or ROCKer activation can be limited to specific sites on the mouse skin and 
once the mouse has fully developed. The cre recombinase is fused to the 
progesterone ligand binding domain which is induced to dimerise and translocate 
to the nucleus by topical application of RU486. This acts to evict a stop cassette in 
the ROCKer transgene or exon 5 of PTEN. This regulator transgene is driven by a 
keratin K14 promoter (Berton et al., 2000b). Thus the transgene is exclusively 
expressed in epidermal basal layers, including hair follicles and stem cells. These 
mice have been successfully used to ablate lox-P flanked PTEN exon 5 (Δ5PTEN) 
and eliminate the inhibition of AKT (Wu et al., 2003) along with ras and fos 
activation (Yao et al., 2006, Macdonald et al., 2014).  
 
To produce bi-genic K14.cre/Δ5PTENflx mice, two matings of heterozygous 
K14.cre were set with floxed PTEN homozygous (Δ5PTENflx) to firstly generate bi-
genic mice heterozygous for the Δ5PTEN allele (K14.cre/Δ5PTENwt/flx) and in the 
second round the desired floxed PTEN homozygous K14.cre/Δ5PTENflx genotype 
was produced by mating between Δ5PTENflx and K14.cre/Δ5PTENwt/flx mice. This 
allowed the assessment of the effects of PTEN heterozygousity and was 
occasionally essential when a floxed homozygous Δ5PTENflx background gave a 
phenotype too severe for the Home Office UK regulations, for example in the 
HK1.ras 1205 transgenic line when crossed with homozygous K14.cre/Δ5PTENflx 
genotypes. 
 
For PTEN analysis, as shown in figure 3.3, using primer sequences positioned in 
exon 4 (PTEN1F) and in exon 5 (PTEN2R) specific PTEN products, 1.3-kbp 
(floxed), 1.2-kbp (wild type) and 1.3/1.2-kbp (heterozygous), were produced. To 
verify the functional RU486 cre activity and elimination of exon 5 after topical 
RU486 treatment, bi-genic K14.cre/Δ5PTENflx or K14.cre/Δ5PTENwt/flx mice 
produced a 500-bp band when primer sequences positioned in exon 4 (PTEN1F) 
and in exon 6 (PTEN3R) were used (figure 3.4). This band was absent in wild type 
mice, K14.creP-negative Δ5PTENflx siblings or RU486-untreated bi-genic 
K14.cre/Δ5PTENflx mice.  
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A similar analysis was performed to identify K14.cre/lsl.ROCKer mice in which cre 
acted to ablate the stop cassette in the lsl.ROCKer transgene construct. The CAG 
expressed form of lsl.ROCKer was detected using ROCK3F (forward) and 
ROCK4R (reverse). Results (figure 3.4) confirmed that RU486-mediated stop 
codon ablation occurred in RU486-treated K14.cre/lsl.ROCKer mice by the 
presence of a 500-bp band, but not in either RU486-untreated mice or mice 
without K14.creP transgene. Collectively, these data consistently indicated a 
thriving cre/lox system in RU486-treated homozygous PTEN, heterozygous PTEN, 
and lsl.ROCKer. These conditions were applied to confirm the identity of routine 
tumour biopsy DNA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3  81 
 
 
 
Figure 3.3 PCR analysis of K14.creP and Δ5PTEN
flx 
genotypes. (a) 600-bp band represents 
K14.creP positive transgenic mice (lane 1 to 6) and is absent in the three negative controls (lane 7 
to 9). (b) 1.3-kbp band represents floxed PTEN (lane 1 to 6), 1.3/1.2-kbp band represents 
heterozygous PTEN (lane 4 to 6) and 1.2-kbp band wild-type PTEN (lane 7 to 9) transgenic mice. 
(DNA ladder is Biolabs 1kb). 
 
 
 
Figure 3.4 PCR analysis of Δ5PTEN
flx
 and ROCK
er
 expression in RU486-treated 
K14.cre/Δ5PTEN
flx
 and K14.cre/lsl.ROCK
er
 ear-tagged biopsies. (a) RU486-treated heterozygous 
PTEN (lane 1 to 3), homozygous PTEN (lane 4 to 6), wild type PTEN (lane 7) and RU486-
untreated K14.cre/Δ5PTEN
flx
 mice (lane 8 to 9). (b) RU486-untreated K14.cre/lsl.ROCK
er
 (lane 1 to 
3) and RU486-treated K14.cre/lsl.ROCK
er
 mice (lane 4 to 9). (DNA ladder is Biolabs 1kb). 
b 
a 
a 
b 
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3.2 ROCK2 activation in transgenic mouse skin 
carcinogenesis 
 
As mentioned in the introduction, ROCK plays a major role in actomyosin 
contraction leading to increased cellular tension which contributes to tumour 
progression (Rath and Olson, 2012). Therefore, the first phase of this study 
focused on ROCKer activation alone in carcinogenesis. Previously, Samuel et al. 
(2011) reported that 4-HT inducible ROCKer activation resulted in epidermal 
hyperplasia using a K14.ROCKer transgenic mouse model. In this section, 
experiments focused on assessment of ROCK activation alone not only to repeat 
the earlier studies again this time in the background of outbred ICR mice, but also 
by employing a new cre/lox responsive ROCK system: K14.cre/lsl.ROCKer . These 
transgenic mice were put on procedure to confirm similar results in the epidermis. 
This new ROCK model was necessary to activate the ROCKer transgene in the 
same keratinocytes in the K14.cre/PTENflx strains and in ras/fos/Δ5PTENflx in the 
next co-operative study. 
 
3.2.1 ROCKer transgenic mouse skin induces hyperplasia 
 
All ROCKer transgenic mice were first analysed for ROCKer transgene expression 
exploiting the green fluorescent protein (gfp) tag. This would confirm the presence 
and location within the epidermis of ROCKer (EGFP- ROCKer). Unfortunately, the 
GFP fluorescene was not detectable, thus, analysis of GFP expression was 
confirmed by immunohistochemical (IHC) techniques. As shown in figure 3.5, 
RU486/4-HT-treated K14.cre/lsl.ROCKer (figure 3.5a) and 4-HT-treated 
K14.ROCKer epidermis (figure 3.5b), together with RU486-treated/4-HT-untreated 
K14.cre/lsl.ROCKer mouse skin (figure 3.5c) exhibited the expected EGFP- 
ROCKer expression profile in all epidermal layers compared to control 4-HT-treated 
non-transgenic ICR mouse skin (figure 3.5d).  
 
ROCKer is activated upon application of 4-HT due to the estrogen receptor (er) 
fusion protein and activated ROCK phosphorylates its substrates, Mypt1. Thus, to 
determine that ROCKer was activated by 4-HT treatment, K14.cre/lsl.ROCKer and 
K14.ROCKer skin biopsies were analysed for phosphorylation of the myosin 
Chapter 3  83 
 
phosphatase targeting subunit (p-Mypt1) (Samuel et al., 2009a). Consistent with 
prior findings (Samuel et al., 2009a, 2011), RU486-/4-HT-treated 
K14.cre/lsl.ROCKer and 4-HT-treated K14.ROCKer mice (figure 3.5 e,f) showed 
strong Mypt1 phosphorylation throughout the follicular and interfollicular layers, 
thus confirming their expression from a K14 promoter. In contrast, little trace of p-
Mypt1 was observed in RU486-treated/4-HT-untreated K14.cre/lsl.ROCKer mice 
(figure 3.5g) whilst p-Mypt1 was undetectable in non-transgenic normal skin (figure 
3.5h). Therefore, these experiments confirmed expression of the ROCKer protein 
and its activation upon 4-HT application, in all epidermal layers including hair 
follicles in K14.ROCKer and K14.cre/lsl.ROCKer mice.  
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Figure 3.5 IHC analysis of GFP-tagged ROCK
er
 transgene [a-d] and p-Mypt1 of ROCK substrate 
[e-h]. (a) Strong expression (brown) of exogenous ROCK (EGFP- ROCK
er
) throughout epidermal 
layers of RU486-/4-HT-treated K14.cre/lsl.ROCK
er
 and (b) 4-HT-treated K14.ROCK
er
 hyperplasia 
histotypes. (c) GFP expression was manifested in normal epidermis of RU486-treated/4-HT-
untreated K14.cre/lsl.ROCK
er
. (d) GFP was not expressed in normal epidermal layer of 4-HT-
treated control ICR.  
Elevated p-Mypt1 expression appears in all epidermal layers and follicles of (e) RU486/4-HT-
treated K14.cre/lsl.ROCK
er
 skin and (f) 4-HT induced K14.ROCK
er
 hyperplasia. (g) Little trace of p-
mypt1 was detected in normal histotype of RU486-treated/4-HT-untreated K14.cre/lsl.ROCK
er 
and 
(h) p-Mypt1 was undetectable in 4-HT-treated control epidermis. (Scale bar: 100µm).  
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In order to compare the K14.ROCKer and K14.cre/lsl.ROCKer models to see if they 
gave the same outcomes as in previous experiments, 4-5 weeks old K14.ROCKer 
adult mice were first bred onto the HK1 ICR background (4 rounds of breeding) 
and a cohort of 10 male heterozygous mice were put on procedure. Topical 
treatment with a volume of 15µl of a 10mg/ml solution of 4-hydroxytamoxifen (4-
HT) dissolved in ethanol on both tagged and untagged ears was performed three 
times per week to activate ROCKer in the epidermis. Transgenic mice controls (n= 
6 per cohort) received ethanol alone and ICR controls (n= 6 per cohort) received 
4-HT. K14.cre/lsl.ROCKer mice received identical treatment but the adult mice 
were also pre-treated with RU486 (2µg RU486 in 20 µl ethanol per ear) for one 
week.  
 
After 20 weeks of treatment, mice were assessed for phenotypes and biopsied to 
investigate the histotypes of ROCK activation. All 4HT-treated ROCKer mice 
showed a very mild, extremely subtle phenotype of a slightly thickened ear, while 
no phenotypes were obtained in 4-HT-untreated ROCKer mice or control normal 
ICR mice treated with 4-HT (figure 3.6a-f). Histological analysis revealed that both 
4HT-treated K14.ROCKer (figure 3.6g) and K14.cre/lsl.ROCKer mice (figure 3.6h) 
had induced epidermal hyperplasia. Control RU486-treated/4-HT-untreated 
K14.cre/lsl.ROCKer mice and 4-HT-treated non-transgenic ICR mice remained 
normal (figure 3.6i,j).  
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Figure 3.6 (a) 4-HT-untreated K14.ROCK
er
, (b) RU486-treated/4-HT-untreated K14.cre/lsl.ROCK
er
 
transgenic mice and (c) 4-HT-untreated non-transgenic ICR control mice; together with (d) 4-HT-
treated K14.ROCK
er
, (e) RU486/4-HT-treated K14.cre/lsl.ROCK
er
 transgenic mice and (f) 4-HT-
treated non-transgenic ICR control mice at 20 weeks showed no differences in phenotypes.  
However, from histology analysis; (g) 4-HT-treated K14.ROCK
er
 and (h) RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
 epidermis showed thickened layers and hyperplasia histotypes. (i) RU486-
treated/4-HT-untreated K14.cre/lsl.ROCK
er
 and (j) 4-HT-treated non-transgenic ICR epidermis 
showed a similar typical normal histotype. (Scale bar: 100µm). 
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3.2.2 Expression of differentiation markers in ROCK hyperplasia 
 
Keratin K1 was analysed by double-labelled immunofluorescence and its 
expression examined to assess any changes in early keratinocyte differentiation. 
Keratin K1 is expressed in all supra-basal layers of the epidermis as they commit 
to differentiate. Keratin K1 expression is not only an important marker for early 
epidermal differentiation, but it is also an important indicator of the differentiation 
state and has been successfully employed as a marker of tumour progression as 
decreased expression of K1 marker appears as tumours convert to carcinomas 
(Greenhalgh et al., 1993a-c, Yao et al., 2006, 2008, Macdonald et al., 2014). 
Analysis of keratin K1 expression in hyperplastic K14.cre/lsl.ROCKer epidermis 
showed a normal, relatively ordered expression in the supra-basal epidermal 
layers. Keratin K1 expression appears scattered unevenly in non-transgenic ICR 
normal epidermis due to the supra-basal layer being only one cell thick (figure 
3.7a,b).  
 
Skin biopsies were also analysed for the expression of keratin K6 by double-
labelled immunofluorescence. Typically, keratin K6 shows no expression in normal 
interfollicular epidermis, but expression appears in the upper part of the hair 
follicles. In addition, in wounded or stressed, interfollicular epidermis keratin K6 
expression is always very strong and often associated with wounding or 
keratinocyte hyperproliferation (Rothnagel et al., 1999). As shown in figure 3.7c, 
keratin K6 expression was correctly limited to the hair follicles of normal non-
transgenic ICR epidermis. Interestingly, K6 expression is patchy in hyperplastic 
K14.cre/lsl.ROCKer epidermis (figure 3.7d). Consistent with a study by Rothnagel 
et al. (1999), K6 which is a marker of proliferation was expressed in all epidermal 
layers of HK1.ras and HK1.fos hyperplasia (figure 3.7e,f). Both keratin K1 and K6 
were counterstained with keratin K14 (red) which represents the keratinocytes. In 
ROCK hyperplasia K14 was expressed throughout the epidermis and hair follicles 
(figure 3.7a-f).  
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Figure 3.7 Immunofluorescence analysis of keratin K1 and K6 markers in RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
 hyperplasia. (a) Normal non-transgenic ICR epidermis shows K1 expression in 
one cell thick layer. (b) Hyperplastic K14.cre/lsl.ROCK
er
 epidermis exhibits strong K1 expression in 
the supra-basal layers. (c) Normal non-transgenic ICR epidermis displays limited K6 expression 
only in the hair follicles. (d) Patchy K6 expression in hyperplastic K14.cre/lsl.ROCK
er 
epidermis. (e) 
Typical K6 expression in all epidermal layers of HK1.ras and (f) HK1.fos hyperplasia (Scale bar: 
100µm). 
 
 
 
 
 
 
 
 
Chapter 3  89 
 
3.2.3 Summary 
 
Collectively, this study indicated that ROCK2 activation in this latest cre/lox 
ROCK2 model (K14.cre/lsl.ROCKer) gave identical results to the previous outcome 
of ROCK2 activation in K14.ROCKer transgenic mice (Samuel et al., 2009a). 
These data show that even though there were very mild phenotypes in both 
K14.ROCKer and K14.cre/lsl.ROCKer mice that were almost undistinguishable from 
control ICR mice, from histology analysis, ROCK2 activation resulted in an 
epidermal hyperplastic histotype which was distinguishable from the normal 
control ICR mice. Thus, as anticipated, there appears to be little or no difference 
between K14.ROCKer and K14.cre/lsl.ROCKer mice in terms of both gross 
phenotype and histotype. Furthermore, although it is well known for keratin K6 to 
become highly expressed during keratinocyte proliferation in vivo and in vitro 
(Rothnagel et al., 1999), or under hyperproliferative conditions mediated by 
oncogene expression (Greenhalgh et al., 1993a-c); expression of K6 also 
indicates a stressed epidermal state an example of which is when TGFβ1 
overexpression was targeted to the epidermis using the HK1 vector (Sellheyer et 
al., 1993), this led to inhibition of epidermal proliferation although IFC analysis 
revealed high levels of K6 expression. In this study, K6 expression suggested that 
ROCK activation induced differentiation activity which associated with hyperplasia. 
Lock and Hotchin, (2009) have shown that knockdown of ROCK2 in HaCat cells 
resulted in reduced differentiation. Therefore, in this study, differentiation is 
expected to increase with ROCK2 activation but the end result is epidermal 
hyperplasia. However, the lack of keratin K6 proliferation marker displayed by odd 
and patchy expression suggests that the differentiation part is still listening to the 
role of ROCK2 in differentiation. This unique expression of K6 is also seen in 
Δ5PTENflx cohorts that give similar odd differentiation responses (chapter 3.5). 
There was no sign of tumour formation with ROCK2 activation for up to 5 months 
of continuous treatment in this study. Therefore, this result suggests that additional 
mutations are required in co-operation with ROCK2 activation for tumour 
formation. Accordingly, the next approach in this study investigated the co-
operation between ROCK and an activated ras oncogene to examine their 
potential co-operation in skin carcinogenesis and determine at which stage their 
co-operation drives progression. 
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3.3 Co-operation of ROCK2 and HK1.ras activation in 
transgenic mouse skin carcinogenesis 
 
Previous studies have shown that activation of the rasHa oncogene either by 
DMBA initiation (Brown et al., 1990, Balmain and Yuspa, 2014), viral infection 
(Roop et al., 1986) or grafting models of multistage carcinogenesis (Greenhalgh 
and Yuspa, 1988, Strickland et al., 1988) confirmed an early role leading to 
formation of papillomas. Of the numerous transgenic mouse studies, Greenhalgh 
et al., (1993a) demonstrated that exclusive epidermal expression of activated rasHa 
driven by truncated human keratin K1 promoter (HK1.ras) produced an initiated 
epidermis (HK1.ras1276) and wound dependent regressing squamous papillomas 
(HK1.ras1205); but no conversion to carcinoma. These mice were therefore ideal to 
study the mechanism of papillomatogenesis (Greenhalgh et al., 1993c, 1995, 
1996) or malignant conversion (Macdonald et al., 2014).  
 
Earlier data showed that ROCK activation in transgenic mouse skin resulted in 
epidermal hyperplasia without tumour formation, and two-stage chemical 
carcinogenesis (DMBA/TPA) on these ROCK mice revealed an increased 
carcinoma conversion rate (Samuel et al., 2011) that suggested the need for 
additional, possibly earlier events. Even though this chemical carcinogenesis study 
suggested the indirect link between ROCK and rasHa activation, yet there is still no 
definite evidence of ROCK2 and ras synergism in the skin carcinogenesis models. 
However, links already exist and can be contradictory.  
 
Studies have demonstrated that the interrelationship between RhoA (which act as 
an upstream regulator of ROCK) and ras in increasing cell proliferation in Swiss-
3T3 cells occurs by inhibiting p21 expression (Olson et al., 1998, Sahai et al., 
2001); and these data have implications for the p21 findings in this current model 
(below). Conversely, studies have also shown that inhibition of ROCK activities 
have little effect on ras-dependent-proliferation and showed no changes in p21 
levels after treatment of fibroblast cell lines with the ROCK inhibitor, Y-27632 
(Sahai et al., 2001). Given the complexity and feedback loops in these inter-
related signalling pathways it appeared that ERK/MAPK signalling from ras-
transformed cells bypassed this inhibition via the downregulation of ROCK (1 and 
2) expression (Sahai et al., 2001).  
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In the chemical carcinogenesis experiments, there is no clear indication as to 
whether ROCK2 co-operated with rasHa as in the absence of TPA promotion, a 
single dose of DMBA on ROCK alone, which supposedly activated endogenous c-
rasHa (Strickland et al., 1988, Greenhalgh et al., 1995) failed to elicit tumours; in a 
similar fashion to ROCK activation alone (Olson, unpublished data). Thus the 
questions remains as to what stage of carcinogenesis did this potential 
ROCK2/rasHa synergism become active and what was the underlying 
mechanism?. Therefore, to investigate any co-operation in multistage tumour 
formation between ras oncogene and ROCK, ROCKer mice were crossed with 
both lines of HK1.ras mice and the phenotypes produced by these bi-genic 
ROCK/ras progeny were analysed.  
 
3.3.1 Confirmation of ROCKer transgene in bi-genic ROCK/ras1205 
mouse and expression of downstream targets 
 
K14.ROCKer/HK1.ras1205 mice were first analysed for expression of the ROCKer 
fusion protein-tagged with the green fluorescent protein (EGFP) by IHC analysis. 
Unfortunately the GFP was not detectable by fluorescence microscopy thus the 
ROCKer transgene was confirmed in 4-HT-treated K14.ROCKer/HK1.ras1205 
epidermal layers (figure 3.8a). IHC analysis of p-Mypt1, a downstream substrate of 
ROCK was performed on the K14.ROCKer/HK1.ras1205 mouse skin to further 
confirm that exogenous ROCKer was activated by induction with 4-HT (figure 3.8b). 
These results showed that p-Mypt1 was expressed throughout the epidermal 
layers of K14.ROCKer/HK1.ras1205 mice.  
 
Analysis of GFP and p-Mypt1 expression was performed on 4-HT-treated 
HK1.ras1205 (figure 3.8c,d) and 4-HT-untreated K14.ROCKer/HK1.ras1205 (figure 
3.8e,f) mice. Conversely, GFP was not expressed in 4-HT-treated HK1.ras1205 
epidermis (figure 3.8c) as compared to 4-HT-untreated K14.ROCKer/HK1.ras1205 
epidermis (figure 3.8e) where GFP was expressed. However, both mice showed 
low p-Mypt1 expression (figure 3.8d,f) as exogenous ROCK was not activated 
compared to 4-HT-treated K14.ROCKer/HK1.ras1205 mouse skin (figure 3.8b). 
These findings confirmed ROCKer transgene expression and activation by 4-HT, 
again repeating the earlier result in the ROCK activation alone cohorts; and this 
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finding also indicated that effects of ROCK2 synergism in the bi-genic 
ROCK/ras1205 cohorts is mediated in part via phosphorylation of Mypt1.  
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Figure 3.8 IHC analysis of GFP and p-MYPT1 expression in K14.ROCK
er
/HK1.ras
1205
 tumours. (a) 
4-HT-treated K14.ROCK
er
/HK1.ras
1205
 wdSCC histotype exhibited high expression of GFP and (b) 
pMypt1 in all epidermal layers. (c) 4-HT-treated HK1.ras
1205
 papilloma showed no expression of 
GFP and (d) faint expression of p-Mypt1. (e) GFP expression was detected in 4-HT-untreated 
K14.ROCK
er
/HK1.ras
1205
 papilloma but (f) only low levels of p-Mypt1 were displayed due to a lack 
of exogenous ROCK activity. (Scale bar: 100µm). 
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3.3.2 ROCK2 co-operates with rasHa to elicit benign tumours (at 8 
weeks) 
 
As cited in the introduction, two lines of HK1.ras mice were employed in these 
studies. The first series of experiments used the 1205 line resulting in wound 
sensitive papillomas in 100% of animals. Later cohorts employed the HK1.ras line 
1276, a less potent oncogenic insult, but its initiation was vital to the success of 
establishing viable, bi-genic and tri-genic genotypes for later experiments. 
 
In repeated experiments, cohorts of K14.ROCKer/HK1.ras1205 (n= 12) and 
HK1.ras1205 (n= 6) age-matched siblings (6-7 week old) were treated with 15µl of 
10mg/ml 4-hydroxytamoxifen (4-HT) per dorsal surface of both tagged and 
untagged ears, initially for up to 12 weeks with K14.ROCKer/HK1.ras1205 and 
HK1.ras1205 (n= 5 each) controls receiving ethanol alone. At 8 weeks, both 
K14.ROCKer/HK1.ras1205 and HK1.ras1205 mice had developed tumours with little 
difference when compared to controls either with or without 4-HT treatment (figure 
3.9); although there was a suggestion that control HK1.ras1205 mice receiving 4-HT 
resulted in slightly smaller tumours compared to previous studies. 
 
Histological analysis of 4-HT-treated K14.ROCKer/HK1.ras1205 tumours (figure 
3.10a) showed a typical benign papilloma histotype, with a relatively well-ordered 
keratinocyte differentiation pattern despite an expansion of each epidermal layer 
due to the proliferation and subsequent differentiation. This histotype was similar 
to 4-HT-treated HK1.ras1205 papillomas (figure 3.10b). For the HK1.ras1205 cohorts, 
these results are consistent with all previous studies as HK1.ras1205 mice produce 
benign papillomas on the tagged ear due to the wounding which exerts a 
promotion stimulus (Greenhalgh et al., 1993a, Yao et al., 2006).  
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Figure 3.9 Phenotypes of K14.ROCK
er
/HK1.ras
1205
 mice at 8 weeks. (a) 4-HT-treated 
K14.ROCK
er
/HK1.ras
1205
 and (b) HK1.ras
1205
 mice; together with (c) 4-HT-untreated 
K14.ROCK
er
/HK1.ras
1205
 and (d) HK1.ras
1205
 mice display papillomas in similar size. 
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Figure 3.10 H&E staining of K14.ROCK
er
/HK1.ras
1205
 papillomas at 8 weeks. (a) 4-HT-treated 
K14.ROCK
er
/HK1.ras
1205
 and (b) HK1.ras
1205
 epidermis; together with (c) 4-HT-untreated 
K14.ROCK
er
/HK1.ras
1205
 and (d) HK1.ras
1205
 epidermis remain benign papillomas with no evidence 
of conversion at this stage. (Scale: 100µm). 
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Given this lack of overt co-operation, skin biopsies were analysed for the 
expression of keratins K1 and K6 by a double-labelled immunofluorescene. As 
shown in figure 3.11(a,b), both 4-HT-treated K14.ROCKer/HK1.ras1205 and 
HK1.ras1205 epidermis displayed strong K1 expression (green) in the benign 
papillomas in a typical, supra-basal expression profile. All biopsies were 
counterstained with keratin K14 (red) to highlight the epidermis and hair follicles. 
However, in some K14.ROCKer/HK1.ras1205 papillomas (H&E benign), areas of K1 
expression showed a more yellow colour as shown by the arrow in figure 3.11(a). 
This suggested a decreased expression of K1 (green) in that area, which has been 
suggestive of malignant conversion in all previous HK1.ras model studies (Yao et 
al., 2006, Macdonald et al., 2014) and this prompted a repeat experiment and 
analysis at later time periods. Both 4-HT-treated K14.ROCKer/HK1.ras1205 and 
HK1.ras1205 papillomas demonstrated uniform and intense K6 expression 
throughout the epidermal layers (figure 3.11c,d), a finding previously associated 
with both keratinocyte proliferation and situations of epidermal stress.  
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Figure 3.11 Immunofluorescence analysis of K1/K14 and K6/K14 expression at 8 weeks in 4-HT-
treated K14.ROCK
er
/HK1.ras
1205
 and HK1.ras
1205 
tumours. (a) K14.ROCK
er
/HK1.ras
1205
 and (b) 
HK1.ras
1205
 epidermis exhibit strong K1 expression in the supra-basal layers confirming that the 
papillomas remain benign. (c) K14.ROCK
er
/HK1.ras
1205
 and (d) HK1.ras
1205
 papillomas show K6 
expression throughout epidermal layers. (Scale bar: 100µm). 
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3.3.3 ROCK2 co-operates with rasHa to elicit malignant conversion 
(at 12 weeks) 
 
Experiments were repeated with cohorts of K14.ROCKer/HK1.ras1205 (n= 12) and 
HK1.ras1205 (n= 6) mice due to unique finding of K1 expression in the bi-genic 
ROCK/ras1205 benign tumours at 8 weeks. Therefore, all mice were kept on 
procedure for 12 weeks to test whether the co-operation between ROCK and 
ras1205 would produce any malignant tumours. At 12 weeks, again there was little 
difference in tumour size or appearance between 4-HT-treated 
K14.ROCKer/HK1.ras1205 and HK1.ras1205 transgenic mice (figure 3.12). However, 
at this time point, their histotypes were quite different. 
 
At this time point, the previous suggestion of papilloma progression to a later stage 
as determined by K1 expression proved to be correct. Histological analysis of 4-
HT-treated K14.ROCKer/HK1.ras1205 demonstrated a mixed histotype with areas of 
malignant transformation, predominantly to wdSCC (figure 3.13a); whilst 4-HT-
treated HK1.ras1205 papillomas remained benign at 12 weeks (figure 3.13b). The 
composite K14.ROCKer/HK1.ras1205 tumour histology highlights a junction between 
papilloma and carcinoma (figure 3.13a - arrows), while the HK1.ras1205 tumour 
showed a thickened folded papillomatous epidermis (figure 3.13b) which is a 
typical characteristic of benign tumours. At higher magnification, the area of 
malignant conversion showed a mainly well-differentiated squamous cell 
carcinoma (wdSCC) histotype with disorganisation in the epidermal basal layers 
and exhibited invasive keratinocytes which penetrated through the basal layer into 
the dermis together with an appearance of mitotic body (figure 3.13c - arrow). It 
should be noted that at this 12 week time point, K14.ROCKer/HK1.ras1205 tumours 
displayed mainly wdSCC histotype as determined by K1 expression below.  
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Figure 3.12 Phenotypes of K14.ROCK
er
/HK1.ras
1205
 and HK1.ras
1205
 mice at 12 weeks. (a) 4-HT-
treated K14.ROCK
er
/HK1.ras
1205
 and (b) HK1.ras
1205
 mice; together with (c) 4-HT-untreated 
K14.ROCK
er
/HK1.ras
1205
 and (d) HK1.ras
1205
 mice showed similar-sized papillomas and tumour 
clusters. 
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Figure 3.13 H&E staining of 4-HT-treated K14.ROCK
er
/HK1.ras
1205
 and HK1.ras
1205
 tumours at 12 
weeks. (a) Composite micrograph of K14.ROCK
er
/HK1.ras
1205
 epidermis demonstrating a mixed 
histotype from benign papilloma (right arrow) to malignant conversion (left arrow) to wdSCC and 
progression to some SCCs. (b) Conversely, composite micrograph of HK1.ras
1205
 epidermis shows 
a typical benign papilloma histotype. (c) Higher magnification of K14.ROCK
er
/HK1.ras
1205
 SCC area 
shows disorganisation of epidermal architecture especially in basal layers together with the 
appearance of mitotic figures (arrow). (d) In contrast, higher magnification of HK1.ras
1205
 papilloma 
exhibit well-organised basal layers. (Scale bar: 100µm in a,b; 50µm in c,d). 
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Given that decreased K1 expression is a useful marker of tumour progression from 
benign to carcinoma stages, K14.ROCKer/HK1.ras1205 tumours (at 12 weeks) were 
analysed for the expression of K1 to confirm malignant conversion. As shown in 
figure 3.14a, K1 expression became reduced and the micrograph appeared yellow 
due to the background of uniform K14 expression (red); thus this indicated a 
wdSCC histotype (Yao et al., 2006, Macdonald et al., 2014). Interestingly, in light 
of the findings in alternate models, K6 expression in K14.ROCKer/HK1.ras1205 
wdSCC appeared in the typical fashion observed previously, with strong uniform 
expression in all epidermal layers (figure 3.14c). This contrasted with K6 
expression in activated ROCKer hyperplasia (above) and also bi-genic 
ROCK/Δ5PTENflx (below). In all control genotypes, both K1 and K6 expression 
after 12 weeks (e.g. 4-HT-treated HK1.ras1205 benign histotypes - figure 3.14b,d) 
remained identical to K1 and K6 expression in HK1.ras1205 histotypes at 8 weeks 
(figure 3.11b,d). 
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Figure 3.14 Immunofluorescence analysis of K1/K14 and K6/K14 expression at 12 weeks in 4-HT-
treated K14.ROCK
er
/HK1.ras
1205 
and HK1.ras
1205
 tumours. (a) K14.ROCK
er
/HK1.ras
1205
 epidermis 
displays reduced K1 expression and indicative of a carcinoma histotype.(b) HK1.ras
1205
 papilloma 
exhibits strong K1 expression in the supra-basal layers and remained benign. (c) Keratin K6 
expression in K14.ROCK
er
/HK1.ras
1205
 wdSCC and (d) in HK1.ras
1205
 benign papilloma appeared 
uniform in all epidermal layers which is similar to a typical K6 expression in response to 
hyperproliferation. (Scale bar: 100µm). 
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3.3.4 Expression of p53 and p21 in bi-genic ROCK/ras1205 tumours 
 
Tumour suppressor genes p53 and p21 have an essential role in suppression of 
tumour development in all cancers and are particularly important in skin 
carcinogenesis (Topley et al., 1999, Wang et al., 2000, Macdonald et al., 2014). 
Therefore their status was analysed in K14.ROCKer/HK1.ras1205 papillomas and 
carcinomas. Given these previous studies, and the fact that bi-genic ROCK/ras1205 
papillomas had converted to carcinoma after 12 weeks, it was anticipated that at 
least p53 expression would be altered at this conversion stage. As shown in figure 
3.15a, this proved to be correct as an early 8 weeks K14.ROCKer/HK1.ras1205 
papilloma expressed relatively high p53 levels in both the nuclei and cytoplasm of 
basal layer keratinocytes. Following a malignant conversion after 12 weeks 
treatment, p53 expression in K14.ROCKer/HK1.ras1205 wdSCC area became 
supra-basal and was gradually lost from the basal layer (figure 3.15b), and 
showed complete loss in SCC area (figure 3.15c). This p53 loss is paralleled with 
the reduction in K1 expression. In contrast, p53 expression in control HK1.ras1205 
papillomas remained high and persisted throughout the epidermal layers (figure 
3.15d). 
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Figure 3.15 IHC analysis of p53 expression in 4-HT-treated K14.ROCK
er
/HK1.ras
1205 
and 
HK1.ras
1205 
tumours. (a) Early K14.ROCK
er
/HK1.ras
1205
 benign papilloma histotype (at 8 weeks) 
shows high p53 expression in all epidermal layers. (b) Following malignant conversion (at 12 
weeks), p53 shows a reduction in expression that became supra-basal in K14.ROCK
er
/HK1.ras
1205
 
wdSCC area.  (c) Whilst p53 expression shows complete loss upon progression in 
K14.ROCK
er
/HK1.ras
1205
 SCC area. (d) HK1.ras
1205
 benign papillomas exhibit strong and uniform 
p53 expression throughout the epidermal compartment. (Scale bar: 100µm in a,d; 50µm in b,c). 
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Whilst p53 expression became reduced as K14.ROCKer/HK1.ras1205 papillomas 
converted to carcinomas, surprisingly p21 a primary effector of p53 and often lost 
in tandem (el-Deiry et al., 1993), was still retained in bi-genic ROCK/ras1205 
carcinomas. In K14.ROCKer/HK1.ras1205 benign papillomas (figure 3.16a), p21 was 
high and was shown to be somewhat supra-basal, a result perhaps consistent with 
its role in the induction of keratinocyte differentiation (Topley et al., 1999) and this 
subtle feature was also similar to its expression in HK1.ras1205 benign papilloma 
(figure 3.16b). Thus, surprisingly, instead of an anticipated p21 loss in conjunction 
with p53, this study found that reduced p53 expression resulted in elevated p21 
expression. As shown in figure 3.16(c,d), p21 expression still remained persist in 
the K14.ROCKer/HK1.ras1205 wdSCC (figure 3.15c) but gradually faded and 
became supra-basal in the SCC area (figure 3.15d) which was the reverse of the 
p53 expression profile. Moreover, in wdSCC, p21 expression was confined to 
basal layer before disappearing in SCC, similar to K14.ROCKer/HK1.ras1205 
tumours at 16 weeks (a control for cessation of 4-HT) where p21 expression faded 
upon progression to pdSCC (below).These novel findings suggest that p53 loss 
was sensed and a feedback system induced p21 expression to act as a backup 
support for the loss of the anti-tumour effects of p53.  
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Figure 3.16 IHC analysis of p21 expression in 4-HT-treated K14.ROCK
er
/HK1.ras
1205 
and 
HK1.ras
1205 
tumours. (a) Early K14.ROCK
er
/HK1.ras
1205
 benign papilloma histotype (at 8 weeks) 
shows strong and uniform p21 expression in all epidermal layers. (b) HK1.ras
1205
 benign papilloma 
histotype also display p21 expression throughout the epidermal layers.  (c) Following malignant 
conversion at 12 weeks, p21 expression remained confined to K14.ROCK
er
/HK1.ras
1205
 wdSCC 
area. (d) However, p21 expression was lost in the basal layer of K14.ROCK
er
/HK1.ras
1205
 SCC 
area and appeared supra-basal upon tumour progression, while p53 expression had completely 
gone at this stage. (Scale bar: 100µm in a,b; 50µm in c,d). 
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3.3.5 BrdU-labelling of bi-genic ROCK/ras1205 tumours 
 
5-bromo-2-deoxyuridine (BrdU) labelling is a typical test to measure cell 
proliferation (Crane and Bhattacharya, 2013). The purpose of this study was to 
examine cell proliferation rates in K14.ROCKer/HK1.ras1205 papillomas and 
carcinomas, and HK1.ras1205 benign papillomas as an increase in the epidermal 
proliferation activity is indicative of tumour progression. As shown in figure 3.17, 
BrdU-labelling revealed that 4-HT-treated K14.ROCKer/HK1.ras1205 carcinomas 
have the highest high proliferation activity (65.1%) followed closely by 4-HT-
treated K14.ROCKer/HK1.ras1205 benign tumours (45.4%). In contrast, cell 
proliferation rates were lower and almost similar in almost all control groups that 
produced papillomas (4-HT-untreated K14.ROCKer/HK1.ras1205 17.7%; 4-HT-
treated and 4-HT-untreated HK1.ras1205 papillomas: 18% and 16.1%).  
 
These results indicate that cell proliferation rates increased as bi-genic 
ROCK/ras1205 tumours converted from benign to the malignant stage. However, 
the proliferation rates in bi-genic ROCK/ras1205 papilloma (+ 4-HT) were much 
higher than control HK1.ras1205 papillomas. This result may be due to the bi-genic 
ROCK/ras1205 papillomas (+ 4-HT) that have already begun to show signs of 
malignant conversion (unique K1 expression) at 8 weeks compared to ras1205 
papillomas that were persistently benign. Moreover, the higher proliferation rate in 
K14.ROCKer/HK1.ras1205 carcinomas coincided with the loss of p53 expression 
(figure 3.15). However, this mitotic index was lower than that observed in previous. 
HK1.ras1276/Δ5PTENflx cohorts promoted with TPA (Yao et al., 2006). This may 
indicate the persistence of p21 expression in these tumours, as observed in 
previous tri-genic ras/fos/Δ5PTENflx mice (Macdonald et al., 2014); a result also 
consistent with the further increased cellular proliferation observed in tri-genic 
ROCK/ras1276/Δ5PTENflx cohorts that had lost p21 expression and exhibited high 
levels of activated AKT (below). 
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Figure 3.17 BrdU-labelling of bi-genic ROCK/ras
1205
 carcinogenesis. Graph displays serial 
increases in cell proliferation rate upon conversion to carcinomas in 4-HT-treated 
K14.ROCK
er
/HK1.ras
1205
 mice. (a,b,c,d,e,f : significantly difference between 
K14.ROCK
er
/HK1.ras
1205
 carcinoma (+ 4-HT) and each cohort (p<0.05), but not with 
K14.ROCK
er
/HK1.ras
1205
 papilloma (+ 4-HT) (p>0.05)). 
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3.3.6 Tenascin C expression in bi-genic ROCK/ras1205 tumours 
 
Given that ROCK molecules are closely involved in tissue integrity and stiffness, 
experiments progressed to a preliminary analysis of tenascin C. This is another 
molecule commonly associated with malignant progression and was an attractive 
target for investigation in this model given its role in the organisation of the ECM 
and thus may be influenced by ROCK-mediated change in tissue stiffness or cell 
migration. Tenascin C, a large ECM molecule is expressed at low levels in normal 
tissues (Midwood and Orend, 2009), yet shows high expression in many cancers 
and its expression is increases with tumour progression (Dang et al., 2006). In this 
study expression of tenascin C was examined in the multistage cancer event of 
K14.ROCKer/HK1.ras1205 by IHC analysis.  
 
As shown in figure 3.18(a,b), tenascin C was sparsely expressed in both 
HK1.ras1205 and K14.ROCKer/HK1.ras1205 papillomas. However, upon conversion 
of bi-genic ROCK/ras1205 papilloma to wdSCC (at 12 weeks), tenascin C 
expression was elevated in both epidermal and dermal areas (figure 3.18c,d). 
Conversely, tenascin C expression was undetectable in ROCK2 hyperplasia 
histotype (figure 3.18e) and absent in normal epidermis (figure 3.18f). Therefore, 
data shows that the elevated presence of tenascin C is associated with tumour 
progression in the multistage carcinogenesis of K14.ROCKer/HK1.ras1205 
histotypes. 
 
Chapter 3  111 
 
 
 
Figure 3.18 IHC analysis of tenascin C in 4-HT-treated K14.ROCK
er
/HK1.ras
1205
 tumours. (a) 
Tenascin C was expressed at low levels in both 4-HT-treated HK1.ras
1205
 and (b) 
K14.ROCK
er
/HK1.ras
1205
 papillomas. (c) The highest level of tenascin C was displayed upon 
K14.ROCK
er
/HK1.ras
1205
 papilloma conversion to wdSCC and (d) showed expression in both 
epidermal and dermal areas. (e) Tenascin C was undetectable in K14.cre/lsl.ROCK
er
 hyperplasia 
and (f) absent in normal epidermis. (Scale bar: 100µm in a-d,f; 50µm in e). 
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3.3.7 Cessation of 4-HT treatment in bi-genic ROCK/ras1205 
tumours 
 
One advantage of using this 4-HT inducible form of the transgenic model is the 
ability to assess oncogene dependence via cessation of treatment. 4-HT treatment 
was stopped in a cohort of six K14.ROCKer/HK1.ras1205 mice that had been 
topically treated with 4-HT for approximately 14 weeks; and animals were biopsied 
two to three weeks later. This determined whether bi-genic ROCK/ras1205 
malignant tumours remained dependent on activated ROCKer to either reduce 
SCC size and show that ROCK2 no longer drives the tumour progression, or 
whether activated ROCKer had become redundant and progression continued. In 
these experiments, this smaller cohort of mice were closely examined on a daily 
basis; as beyond 16 weeks the size of these K14.ROCKer/HK1.ras1205 tumours 
began to give concern to the Home Office Inspector. Hence, a separate procedure 
was included on the Licence prior to these experiments commencing.  
 
K14.ROCKer/HK1.ras1205 mice demonstrated larger size of tumours by 14 weeks of 
4-HT treatment, which were more obviously SCCs when compared to papillomas 
of control cohorts (figure 3.19a,b). However, most interestingly, at 16 weeks, two 
weeks post cessation of 4-HT compared to their size at 14 weeks, all 
K14.ROCKer/HK1.ras1205 tumours became larger (figure 3.19d,e). This result 
suggested that ROCK2 was no longer involved, but this assumption also proved to 
be incorrect on detailed analysis (below). The cessation of 4-HT-tumours showed 
an increased size, but overall they remained pale and had a weakly vascularised 
appearance at biopsy as compared to aggressive carcinomas produced in e.g. 
ras1276/Δ5PTENflx cohorts treated with TPA which appears less keratotic and a 
highly vascularised red colour (Yao et al., 2006). In contrast, control HK1.ras1205 
mice post two weeks without 4-HT showed little to no difference in tumour size and 
remained classical ras papillomas (figure 3.19c,f).  
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Figure 3.19 Phenotypes of K14.ROCK
er
/HK1.ras
1205
 mice after termination of 4-HT for 2 weeks. (a, 
b)  K14.ROCK
er
/HK1.ras
1205
 and (c) HK1.ras
1205
 mice exhibit large tumours at 14 weeks of 4-HT 
treatment. (d, e) K14.ROCK
er
/HK1.ras
1205
 mice display larger tumours with a pale and less 
vascularised appearance after 2 weeks cessation of 4-HT; whilst (f) HK1.ras
1205
 tumour shows no 
changes in size or phenotypes at 16 weeks. 
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Typically, older K14.ROCKer/HK1.ras1205 tumours possessed a mixed histotype of 
wdSCC, plus areas of K1/p53 negative-p21 positive SCC (figure 3.20a - small box, 
figure 3.20d,f,h,j) alongside occasional areas of highly invasive pdSCC 
(K1/p53/p21 negative) (figure 3.20a - larger box, figure 3.20e,g,I,k). Whereas 
control littermate HK1.ras1205 tumours remained as papillomas (figure 3.20b), with 
strong K1 expression (figure 3.20c). However, following cessation of 4HT, 
K14.ROCKer/HK1.ras1205 wdSCCs exhibited a disturbed architecture (figure 3.20d). 
Here, [p53-negative] basal layer keratinocytes became disarranged and appeared 
to terminally differentiate (as apoptosis is not a preferred option for a tissue 
involved in barrier maintenance) consistent with the appearance of elevated K1 
expression [increased green overtones in wdSCC areas: figure 3.20f); and 
elevated p21 (figure 3.20j) also consistent with roles in epidermal differentiation 
(Devgan et al. 2006).  
 
These data suggest that at this wdSCC stage exogenous ROCKer activation was 
still required to maintain malignancy. Indeed following cessation of 4-HT treatment, 
remarkably (and repeatedly) it appeared that at the sites of wdSCC, p21 levels 
actually increased and this would be consistent with the retention of K1 at such 
wdSCC sites given the role of p21 in keratinocyte differentiation (Topley et al., 
1999, Yao et al., 2008, Macdonald et al., 2014). This persistence appeared in 
many wdSCCs (below, such as tri-genic ROCK/ras1276/fos) and a recurrent theme 
was antagonism with AKT; but here these data suggest that the loss of activated 
ROCK2 facilitated an anti-progression response involving terminal differentiation 
(figure 3.20d,f,j). In contrast, in pdSCC histotypes (figure 3.20a – larger box, figure 
3.20e), this was not the case. In these more invasive pdSCCs (figure 3.20a – 
larger box, figure 3.20e), the opposite profile appeared, as K1/p53/p21 expression 
disappeared completely (figure 3.20g,i,k) and this K1 result, together with analysis 
of p53/p21 suggest that once K14.ROCKer/HK1.ras1205 carcinomas had 
progressed from wdSCC to pdSCC the presence of exogenous ROCKer 
expression was redundant.  
 
Analysis of GFP in K14.ROCKer/HK1.ras1205 wdSCC and pdSCC showed 
expression in all epidermal layers (figure 3.20l,m).  However, following cessation 
of 4-HT, p-Mypt1 analysis in both wdSCCs and pdSCC histotypes showed 
reduced expression that appeared more supra-basal (figure 3.20n,o) compared to 
previous analysis of uniform and strong p-Mypt1 expression in all epidermal layers 
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of K14.ROCKer/HK1.ras1205 wdSCC at 12 weeks (figure 3.17b). Thus, this may 
indicate that the cessation of 4-HT has turned off the ROCK2er system. 
Moreoever, these findings suggested that whilst K14.ROCKer/HK1.ras1205 tumours 
remained wdSCC, they relied on exogenous ROCKer to maintain malignancy. 
However, this 4-HT cessation study suggests that exogenous ROCKer activation is 
no longer a rate limiting factor once wdSCC has progressed to pdSCCs. 
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Figure 3.20 Histotype of K14.ROCK
er
/HK1.ras
1205
 biopsies at 16 weeks, after 2 weeks termination 
of 4-HT. (a) A low magnification composite K14.ROCK
er
/HK1.ras
1205
 tumour exhibits a mixed 
histotype of papilloma, wdscc (small box) and invasive pdscc (large box). (b) In contrast, at this 
time point control HK1.ras
1205
 tumours still remain as benign papilloma histotype and (c) display a 
supra-basal keratin K1 expression typical of their benign nature.  
(d) At higher magnification, K14.ROCK
er
/HK1.ras
1205
 wdSCC areas display a disorganised basal 
layer, whilst (e) K14.ROCK
er
/HK1.ras
1205
 pdSCC areas display finger like projections of highly 
invasive cells into the dermis. 
(f) K14.ROCK
er
/HK1.ras
1205
 wdscc areas demonstrate expression of retained K1, whilst (g) in 
K14.ROCK
er
/HK1.ras
1205
 pdSCC areas, K1 expression is completely lost.  
(h) p53 expression is already totally lost in K14.ROCK
er
/HK1.ras
1205
 wdSCC and (i) again in pdSCC 
histotypes.  
(j) p21 expression persists in K14.ROCK
er
/HK1.ras
1205
 wdSCC areas and is elevated, but  in (k) 
K14.ROCK
er
/HK1.ras
1205
 pdSCC areas, p21 expression is disappearing.  
(l) K14.ROCK
er
/HK1.ras
1205
 wdSCC and (m) pdSCC histotypes exhibit gfp expression in all 
epidermal layers.  
(n) Following cessation of 4-HT, both K14.ROCK
er
/HK1.ras
1205
 wdSCC and (o) pdSCC histotypes 
display p-Mypt1 expression that seems to appear more in the supra-basal layer. 
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On further investigation, the increase in tumour size was not all it seemed. All 
K14.ROCKer/HK1.ras1205 tumours became larger after cessation of 4-HT, yet it 
appeared that in the areas of wdSCC, the tissue architecture appeared disrupted; 
several portions of these tumours were examined more stringently. In all mice, the 
tumour forming the majority of the additional growth was biopsied to determine the 
histotype and expression profiles (figure 3.21a). As displayed in figure 3.21b, the 
histological analysis showed an aggressive late papilloma histotype, not wdSCC or 
pdSCC; and this was supported by strong expression of K1 and an ordered 
differentiation pattern as exhibited by K14 (red) expression typical of standard 
papillomas (figure 3.21c).  
 
The reduced levels of p53 expression in emerging K14.ROCKer/HK1.ras1205 
tumours were consistent with a late-stage, aggressive papilloma (Macdonald et al., 
2014) and this expression faded in several areas (figure 3.21d); this was 
counteracted by the huge intensity of p21 expression in basal and differentiated 
layers which was both nuclear and cytoplasmic (figure 3.21e,f). This level of p21 
has not been seen in any other tumour analysis in the HK1 model, and this result 
was repeated in all emerging K14.ROCKer/HK1.ras1205 papillomas analysed to 
date; regardless of technical issues e.g. new p21 antibodies or DAB reagents.  
 
These results suggest several conclusions. It may be that malignant conversion 
and progression are totally dependent on ROCK2 activation and thus, loss of 
exogenous ROCK2 activity suddenly induced papillomatogenesis; where perhaps 
p53 and certainly p21 expression prevented conversion. No tumour aetiology 
suggests that these were once wdSCC/SCCs that regressed to papilloma. These 
appeared to be novel tumours. A second hypothesis may be that these are 
additional papilloma subtypes which arise simply due to cessation of 4-HT. This 
further suggests that certain papilloma subtypes (Glick et al., 1991, Hennings et al., 
1993, Yao et al., 2006) may be sensitive to the nature of 4-HT anti-cancer 
activities; and consequently another earlier facet of K14.ROCKer/HK1.ras1205 co-
operation is that it may give rise to a set of papillomas that are destined to become 
malignant; unlike e.g. HK1.ras1276/fos papillomas. Although why ear-tag tumours 
arose in 4-HT-treated HK1.ras1205 mice is unclear (yet, these do not become 
malignant (Greenhalgh et al., 1993a)) and this may centre on the wound 
promotion stimulus, as in all these K14.ROCKer/HK1.ras1205 cohorts, if the ear tag 
had been lost tumours rarely appeared and this was investigated further (below). 
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The analysis to investigate wound (or fos-mediated) promotion demonstrated that 
it was vital to attain the papilloma context where ROCK2 activation induced 
malignant conversion.  
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Figure 3.21 Histotype of K14.ROCK
er
/HK1.ras
1205
 tumour from the additional papilloma growth at 
16 weeks, after 2 weeks termination of 4-HT. (a) K14.ROCK
er
/HK1.ras
1205
 mouse shows the area 
of additional tumour growth (line). (b) Histology analysis shows a late stage papilloma histotype 
and confirmed by (c) strong K1 expression which is weak in some areas. (d) Pre-malignant tumour 
shows faded p53 expression and (e,f) intense p21 expression in all epidermal layers in both the 
nuclei and cytoplasm. 
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3.3.7 Wound promotion for development of appropriate late-stage 
papilloma prior to ROCKer causality. 
 
As shown in results above, bi-genic ROCK/ras1205 tumours converted from benign 
papillomas to malignant tumours at approximately 12 weeks continuous 4-HT 
activation compared to HK1.ras1205 cohorts that still remained benign papillomas. 
However, if the ear tag falls out prior to overt papillomas forming at approximately 
6 weeks of 4-HT treatment; it was noted that despite continued 4-HT treatment, 
these mice did not develop tumours. Neither did the control ras1205 cohorts which 
also lost an ear tag.  
 
Next, the study proceed to address the possibilities that bi-genic ROCK/ras1205 
tumours required a wound promotion stimulus to establish the appropriate late-
stage papilloma context prior to and essential for malignant conversion by ROCKer 
papilomatogenesis in bi-genic ROCK/ras1205 mice with and without ear tagging or 
accidental loss. ROCK associated papillomatogensis in HK1.ras line 1205 
papillomas which are normally prone to regression once the ear tag (wound 
promoter) was lost, were compared to papillomatogenesis in the HK1.ras1276; a 
background insensitive to wound promotion and later employed in most tri-genic 
experiments as HK1.ras1205 mice compromise compound transgenic mouse 
viability. 
 
As shown in figure 3.22a, K14.ROCKer/HK1.ras1205 mice (n= 6) developed tumours 
at 8 weeks, but there was no sign of tumourigenesis following loss of ear tag 
(K14.ROCKer/HK1.ras1205 mouse – right (n= 6)) prior to tumours forming around 5 
to 6 weeks. At 12 weeks, bi-genic ROCK/ras1205 mice with intact ear tags 
possessed typical papillomas on their way to conversion. These appeared bigger 
and, if papillomas developed but the tags were lost at 7-8 weeks there was no 
conversion, instead the tumours were smaller which indicated a lack of growth 
following 4-HT treatment (figure 3.22b).  
 
On loss of ear tag promotion, the histopathology analysis revealed that this 
K14.ROCKer/HK1.ras1205 papilloma (figure 3.22c) had also failed to achieve 
malignant conversion confirmed by strong K1 (green) expression (figure 3.22d). 
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This supports the requirement (some form of) for promotion in this model 
consistent with the fos models (below). This was further supported by results from 
line 1276 where in the absence of additional genetic events such as v-fos co-
operation (below), K14.ROCKer/HK1.ras1276 mice (n= 6) showed a complete lack of 
tumourigenesis with or without ear tag; even after 16 weeks of 4-HT treatment 
(figure 3.22e). Here, histology analysis revealed only mild hyperplasia in 
K14.ROCKer/HK1.ras1276 ear epidermis (figure 3.22f) similar to the mild 
hyperplasia histotype from ROCKer activation alone. 
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Figure 3.22 Phenotype and histopathology of 4-HT-treated K14.ROCK
er
/HK1.ras lines 1205 and 
1276. (a) K14.ROCK
er
/HK1.ras
1205
 mice at 8 weeks display tumourigenesis on ear tag (left) and 
exhibit lack of tumour formation on loss of ear tag (right). (b) K14.ROCK
er
/HK1.ras
1205
 tumours at 
12 weeks appear bigger on ear tag (left) and show regression on loss of ear tag (right). (c) Bi-genic 
ROCK/ras
1205
 tumours on loss of tag ear show benign papilloma histotype and (d) express strong 
K1 in supra-basal layer. (e) K14.ROCK
er
/HK1.ras
1276 
mice display no sign of tumourigenesis on ear 
tag (left) and on loss of ear tag (right). (f) Histology of K14.ROCK
er
/HK1.ras
1276 
skin on loss of ear 
tag show hyperplasia histotype. 
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3.3.8 Summary 
 
Taken together, results in this study indicated that ROCK co-operates with rasHa to 
induce conversion of benign papillomas to wdSCC (at 12 weeks) supported by 
loss of keratin K1, p53 and elevated expression of tenascin C. p21 expression 
persisted in the bi-genic ROCK/ras1205 wdSCC which suggests it limits further 
malignant progression. This is consistent with a previous study by Macdonald et 
al., (2014) that reported on persistent p21 expression in wdSCC histotype of tri-
genic ras1276/fos/Δ5PTENflx mice and suggested that loss of p21 (upon loss of p53) 
is implicated in advanced carcinoma progression. Data also demonstrated that 
wound promotion is crucial for the appropriate development of a late-stage 
papilloma phenotype prior to ROCK causality in ROCK/ras1205 malignant 
conversion as loss of the ear tag before the papilloma became mature resulted in 
tumour regression which remained benign. Results from the cessation of 4-HT 
experiments suggest that upon conversion to malignancy and progression to 
aggressive carcinomas, exogenous ROCKer is dispensable. Whereas findings 
indicate that in earlier stages of malignancy, K14.ROCKer/HK1.ras1205 wdSCCs are 
still dependent on ROCKer expression for continuing progression to aggressive 
SCCs. Excitingly, after cessation of 4-HT, the appearance of late stage benign 
papillomas suggested either dependence on ROCK2 activation for conversion or 
that a subtype of K14.ROCKer/HK1.ras1205 papilloma histotype is sensitive to 4-HT 
induction. Either way these emerging papillomas had intense p21 expression 
possibly deriving from the cessation of ROCKer activities. Overall, these data 
propose that ROCK has an important role in early malignant conversion events in 
co-operation with rasHa but only once the appropriate papilloma context had been 
achieved. 
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3.4 Co-operation of ROCK2 and HK1.fos in transgenic 
mouse skin carcinogenesis 
 
The transcription factor fos has been shown to be a major regulator of keratinocyte 
proliferation and differentiation, and its deregulation can potentially contribute to 
tumourigenesis (Basset-Seguin et al., 1990). Since fos acts as a nuclear 
transcription factor and is an eventual downstream target of ras/MAPK pathway 
(Greenhalgh et al., 1993c, Macdonald et al., 2014), there is a possibility of 
interaction with Rho/ROCK signalling since data have shown the direct co-
operation between ROCK and rasHa in malignant conversion with ROCK2 being a 
downstream effector of ras family. Intriguingly, there is still lack of in vivo research 
on co-operation between ROCK and fos. In addition, the bi-genic ROCK/ras 
experiments clearly demonstrated a need for promotion (wounding) and in several 
experiments, fos oncogene was associated with the multistage chemical 
carcinogenesis model as a major effector of chemical promotion by TPA 
(Schlingemann et al., 2003). But of greater relevance to these studies, in the HK1 
model, activated v-fos was involved in promoting papillomatogenesis leading to 
autonomous papilloma formation through co-operation with v-rasHa (Greenhalgh et 
al., 1993c). Interestingly, fos activation alone elicits a hyperplasia histotype 
(Greenhalgh et al., 1993b) after a long latency and is dependent on a wound 
promotion stimulus. Indeed a HK1.fos mouse appears identical to normal mouse 
except that is has a doubled mitotic index as determine by BrdU labelling. Thus an 
accelerated differentiation must compensate for this increased proliferation giving 
a normal histotype (Greenhalgh et al., 1993b). This would be consistent with roles 
assigned to the fos transcription factor via AP1 which acts as a switch to turn 
pathways on or off such as in the change from proliferation to differentiation 
(Curran et al., 1984) or granular cells commitment to become cornified (Fisher et 
al., 1991); hence, often keratins possess several AP1 sites (DiSepio et al., 1995). 
In stress conditions such as ear tag wounding, v-fos interferes with the c-fos roles 
in both proliferation and differentiation in the healing processes, resulting in 
keratotic hyperplasia by 4 to 6 months and keratotic papillomas around 9 to 12 
months (Greenhalgh et al., 1993b). A previous study demonstrated the role of fos 
in the later events of cancer formation. In the HK1 model, v-fos provided a 
constitutive promotion role for HK1.ras giving papillomas (Greenhalgh et al., 
1993c) and by using a knockout c-fos mouse infected with v-rasHa no tumours 
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were produced; again demonstrating the importance of fos to papilloma formation 
(Saez et al., 1995). No evidence of tumour formation was recorded in K14.ROCKer 
mice following TPA application (Olson, - unpublished data). Hence, co-operation 
studies of ROCK and fos in a transgenic mouse model would be useful to examine 
the potential effects of such a combination in tumour formation and keratinocytes 
differentiation. To investigate co-operation in tumourigenesis between fos and 
ROCK, K14.cre/lsl.ROCKer mice were crossed with HK1.fos mice to produce bi-
genic ROCK/fos cohorts. 
 
3.4.1 ROCK2 co-operates with activated fos to elicit benign 
tumours 
 
In these experiments, given that future tri-genic co-operation studies would exploit 
the new lsl.ROCKer genotype, these mice were also used in this bi-genic study and 
thus phenotypes from bi-genic K14.cre/lsl.ROCKer/HK1.fos mice also became 
useful comparison controls. These mice also employed the K14.creP regulator 
(Berton et al., 2000b) to express lsl.ROCKer following topical treatment with 
RU486. Initially, 10 individual adult K14.cre/lsl.ROCKer/HK1.fos mice and HK1.fos 
age-matched littermates were treated with RU486 at 5/6 weeks of age. This 
activated cre recombinase to remove the transcriptional stop cassette in the 
lsl.ROCKer transgene and CAG-expressed ROCKer activity was activated by 4-HT 
(3 times per week) for 12 weeks and biopsies taken. This time point was chosen 
as bi-genic ROCK/ras mice had begun to co-operate and sporadic malignant 
conversion was observed. Control groups (n= 6 each) included RU486 treatment 
of K14.cre/lsl.ROCKer/HK1.fos mice without 4-HT, and HK1.fos mice received 
treatment of both RU486 and 4-HT. A second experiment involved treated mice (3 
times per week) for 20 weeks. 
 
Following 12 weeks treatment with 4HT, both K14.cre/lsl.ROCKer/HK1.fos and 
HK1.fos mice showed little difference in phenotypes, but there was a suggestion 
that K14.cre/lsl.ROCKer/HK1.fos mice had a more developed ear thickening and 
possibly the beginning of tumour formation. At this time point, all control mice had 
developed scaly and thickened ears particularly on the tagged ear, but with no 
sign of tumour formation (figure 3.23). This control cohort finding was identical to 
that reported for HK1.fos mice (Greenhalgh et al., 1993b). However, histological 
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analysis of K14.cre/lsl.ROCKer/HK1.fos mice revealed an increased hyperplasia 
(figure 3.24a) with elevated areas of acanthosis (expansion of the spinous layer) in 
particular (figure 3.24b). This observation indicates the potential of ROCK activities 
in supra-basal keratinocytes that may contribute to epidermal strength and the 
roles assigned to fos in the commitment to differentiation (Fisher et al., 1991, 
Greenhalgh et al., 1993b). This acanthosis again suggests a possible co-operation 
between ROCK and fos and provides a first direct link to a potential co-operation 
in proliferation and terminal differentiation (figure 3.24b). In comparison, 4-HT-
treated HK1.fos and 4-HT-untreated K14.cre/lsl.ROCKer/HK1.fos control cohorts 
showed epidermal hyperplasia (figure 3.24c,d) consistent with all previous HK1.fos 
reports (Greenhalgh et al., 1993b,c). At the same time, all bi-genic ROCK/fos mice 
were analysed for expression of ROCKer fusion protein-tagged with GFP (EGFP-
ROCKer). IHC analysis of GFP showed that ROCKer transgene was confirmed in 
RU486-/4-HT-treated K14.cre/lsl.ROCKer/HK1.fos epidermis, but GFP was not 
expressed in 4-HT-treated HK1.fos hyperplasia (figure 3.24e,f). IHC analysis of p-
Mypt1 was performed to confirm that exogenous ROCKer transgene was activated 
upon application of 4-HT. As shown in figure 3.24(g), p-Mypt1 was expressed 
throughout epidermal layers of RU486-/4-HT-treated K14.cre/lsl.ROCKer/HK1.fos 
cohort. Whilst lack of p-Mypt1 expression was demonstrated in 4-HT-treated 
HK1.fos cohort (figure 3.24h). Histologically, K14.cre/lsl.ROCKer/HK1.fos appeared 
to be progressing to papilloma hence, the repeat experiment was extended to 20 
weeks. 
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Figure 3.23 Phenotypes of K14.cre/lsl.ROCK
er
/HK1.fos and HK1.fos mice at 12 weeks. (a) RU486-
/4-HT-treated K14.cre/lsl.ROCK
er
/HK1.fos mouse exhibits a thickened ear compare to (b) 4-HT-
treated HK1.fos and (c) RU486-treated/4-HT-untreated K14.cre/lsl.ROCK
er
/HK1.fos mice. 
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Figure 3.24 Histotype of K14.cre/lsl.ROCK
er
/HK1.fos and HK1.fos mice at 12 weeks. (a) RU486-/4-
HT-treated K14.cre/lsl.ROCK
er
/HK1.fos epidermis shows hyperplasia with expanded epidermal 
compartments. (b) At higher magnification, RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/HK1.fos 
epidermis shows area of acanthosis (arrow) and much thicker hyperplasia compared to (c) 4-HT-
treated HK1.fos or (d) RU486-treated/4-HT-untreated K14.cre/lsl.ROCK
er
/HK1.fos hyperplastic 
histotypes. (e) IHC analysis of GFP marker exhibits expression throughout epidermal layers in 
RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/HK1.fos cohort, but (f) 4-HT-treated HK1.fos cohort GFP 
is undetected. (g) RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/HK1.fos epidermis exhibits strong p-
Mypt1 expression but (h) 4-HT-treated HK1.fos cohort displays a little trace of p-Mypt1 expression. 
(Scale bar: b,c,d,f,h: 50 µm,  a,e,g: 100µm). 
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The genotypes allowed exploration of the possible co-operation between ROCK 
and fos deregulation in keratinocyte differentiation given the observation of 
acanthosis. Skin biopsies were further analysed for the expression of keratin K1 
and K6 by double-labelled immunofluorescence (figure 3.25). These results 
showed strong K1 expression in both K14.cre/lsl.ROCKer/HK1.fos and HK1.fos 
hyperplasia in a normal supra-basal fashion (figure 3.25a,b); however, 
occasionally in areas of multiple basal layers, at the basal/supra-basal junction, a 
faint possibility of premature K1 expression could be seen in the upper expanded 
basal layer of K14.cre/lsl.ROCKer/HK1.fos hyperplasia(figure 3.25a – arrows). 
Analysis of K6 however found a typical uniform high level of K6 expression in both 
bi-genic ROCK/fos and fos mice in all epidermal layers (figure 3.25c,d) that was 
classically matched with K6 expression in previous hyperproliferative HK1-
transgenic epidermis (Greenhalgh et al., 1993a-c). This was quite different to K6 
expression in ROCKer alone but typical of fos (or rasHa) expression (Greenhalgh et 
al., 1993a-c) and suggests that fos signalling restores this K6 expression and over 
rides that of ROCK2; a result that is also observed in vitro (below). 
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Figure 3.25 Immunofluorescence analysis of K1/K14 and K6/K14 expression in RU486-/4-HT-
treated K14.cre/lsl.ROCK
er
/HK1.fos mice at 12 weeks. (a) K14.cre/lsl.ROCK
er
/HK1.fos and (b) 
HK1.fos hyperplasia exhibit K1 expression in supra-basal layers. (c) K14.cre/lsl.ROCK
er
/HK1.fos 
and (d) HK1.fos hyperplasia express K6 throughout epidermal layers. (Scale bar: 100µm). 
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Due to lack of differences in phenotype between bi-genic ROCK/fos and fos mice, 
in the repeat experiment, a second cohort of mice were kept on procedure for 20 
weeks to test whether bi-genic ROCK/fos would produce any tumours. Typically 
this line of HK1.fos mice (Greenhalgh et al., 1993b) failed to develop overt 
tumours until around 6 to 8 months and these appeared on the tagged ear. In this 
experiment, at 20 weeks treatment, significant differences in phenotypes were 
displayed between K14.cre/lsl.ROCKer/HK1.fos and HK1.fos mice as shown in 
figure 3.26. Here, during this extra time, K14.cre/lsl.ROCKer/HK1.fos mice 
developed protruding, highly keratotic tumours whilst control untreated mice or 
HK1.fos alone mice presented only increased ear thickening (figure 3.26). On 
histological analysis, K14.cre/lsl.ROCKer/HK1.fos mice displayed highly keratotic 
papillomas together with a significant number of keratin pearls encircled by classic 
papilloma histotypes (figure 3.27), again suggestive of roles in keratinocyte 
terminal differentiation as well as hyperproliferation and papillomatogenesis. In 
contrast, HK1.fos mice exhibited classic hyperplasia, similar to previous results 
with ROCKer activation alone. However, at this time point, there was no indication 
of further progression to aggressive papillomas or conversion to malignancy in any 
K14.cre/lsl.ROCKer/HK1.fos mice in these bi-genic experiments. 
 
The lack of malignant conversion is also in stark contrast to that found in 
K14.ROCKer/HK1.ras1205 mice; thus perhaps the context of tumours in 
K14.cre/lsl.ROCKer/HK1.fos mice appears to be distinctly different to the results 
from the earlier K14.ROCKer/HK1.ras1205 study where papillomas had converted to 
well-differentiated SCC histotypes at approximately 12 weeks. Nonetheless, these 
exciting data prove for the first time that ROCK2 deregulation co-operates with 
oncogenic fos in carcinogenesis and moreover, this may be the first example of 
ROCK being involved in the early stages prior to malignancy; by driving the 
formation of benign papillomas. This co-operation with fos appears to be a novel 
finding for ROCK activities and may be consistent with the roles for ROCK2 
downstream of ras activation, and possible co-operation in terminal differentiation. 
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Figure 3.26 Phenotypes of K14.cre/lsl.ROCK
er
/HK1.fos and HK1.fos mice at 20 weeks. (a) RU486-
/4-HT-treated K14.cre/lsl.ROCK
er
/HK1.fos mouse exhibits a protruding keratotic tumour. (b) 4-HT-
treated HK1.fos and (c) RU486-treated/4-HT-untreated K14.cre/lsl.ROCK
er
/HK1.fos mice display 
scaly and thickened ears. 
 
 
Figure 3.27 Histotype of K14.cre/lsl.ROCK
er
/HK1.fos and HK1.fos epidermis at 20 weeks of 4-HT 
treatment. (a) Composite micrograph of K14.cre/lsl.ROCK
er
/HK1.fos epidermis displays a papilloma 
histotype with keratin encircled cyst appearing between epidermal layers. (b) Higher magnification 
of K14.cre/lsl.ROCK
er
/HK1.fos tumour shows a papilloma histotype with the appearance of 
acanthosis and some odd differentiation in each compartment, but no signs of malignancy as 
confirmed by K1, p53 and p21 expression (below). (c) RU486-treated/4-HT-untreated 
K14.cre/lsl.ROCK
er
/HK1.fos epidermis and (d) 4-HT-treated HK1.fos shows hyperplasia with 
papillomatous epidermal layers and a very prominent granular layer associated with HK1.fos 
expression. (Scale bar: a: 100µm, b-d: 50µm) 
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Expression of keratin K1 confirmed that the tumours produced in 
K14.cre/lsl.ROCKer/HK1.fos mice were benign, whereas bi-genic ROCK/ras1205 
tumours lost K1 expression by this time following conversion to wdSCC and 
progression to SCC. Further, as shown in figure 3.28, intense K1 expression 
appeared in the supra-basal layers of bi-genic ROCK/fos mice. This finding again 
supports the idea that ROCKer may accelerate an early differentiation response 
along with, or amplified by, HK1.fos activation particularly with the appearance of 
keratin pearls and the massive overt keratosis exhibited by these bi-genic 
ROCK/fos papillomas. K6 expression in K14.cre/lsl.ROCKer/HK1.fos and HK1.fos 
cohorts showed a distribution more typical of HK1.fos phenotypes with expression 
occurring in a uniform fashion throughout epidermal layers, a result that was 
typically linked to the active proliferation events that drive tumour promotion. 
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Figure 3.28 Immunofluorescence analysis of K1/K14 and K6/K14 expression in 
K14.cre/lsl.ROCK
er
/HK1.fos and HK1.fos mice at 20 weeks of 4-HT treatment. (a) 
K14.cre/lsl.ROCK
er
/HK1.fos keratotic papilloma and (b) HK1.fos hyperplasia exhibit K1 expression 
in the supra-basal layers. (c) K14.cre/lsl.ROCK
er
/HK1.fos benign papilloma and (d) HK1.fos 
hyperplasia display K6 expression in all epidermal layers consistent with a typical K6 expression in 
response to hyperproliferation. (Scale bar: 100µm). 
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3.4.2 Expression of p53 and p21 in bi-genic ROCK/fos mice 
 
Given the lack of malignant progression and the dominant keratosis in the 
papillomas, the expression profiles of p53 and p21 were determined by IHC 
analysis of K14.cre/lsl.ROCKer/HK1.fos tumour histoypes. Both p53 and p21 are 
known for their tumour growth inhibitory function, and were shown to be 
fundamental in preventing conversion of both bi-genic ras1276/Δ5PTENflx and 
fos/Δ5PTENflx tumours (Yao et al., 2006, 2008, Macdonald et al., 2014) . 
Therefore, it was expected that both p53 and p21 would be strongly expressed at 
this benign stage.  
 
As shown in figure 3.29, K14.cre/lsl.ROCKer/HK1.fos papillomas expressed high 
p53 levels with intense distribution in all epidermal compartments including the 
proliferative basal layer keratinocytes (figure 3.29a,b), similar to its expression in 
HK1.fos epidermis (figure 3.29e). Moreover, both K14.cre/lsl.ROCKer/HK1.fos 
(figure 3.29c,d) and HK1.fos (figure 3.29f) exhibited elevated and uniform 
expression of p21 throughout the epidermal layers. This finding was similar to the 
p53/p21 expression profiles observed in bi-genic ROCK/ras1205 during formation of 
benign papillomas. However, in this context and unlike the previous model where 
first p53 then followed by p21 expression became faded, persistent p53/p21 
expression became elevated and resulted in a stable papilloma not prone to 
conversion, despite ROCK2 activation. Hence, both p53 and p21 act as pivotal 
targets to suppress malignant conversion in K14.cre/lsl.ROCKer/HK1.fos benign 
tumours. 
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Figure 3.29 IHC analysis of p53 and p21 in RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/HK1.fos and 
HK1.fos cohorts. (a) p53 is highly expressed throughout epidermal layers including (b) basal layers 
of K14.cre/lsl.ROCK
er
/HK1.fos benign papilloma histotypes. (c, d) Uniform expression of p21 in all 
epidermal layers of K14.cre/lsl.ROCK
er
/HK1.fos papilloma histotypes. (e) HK1.fos hyperplasia 
histotypes also exhibit strong expression of p53 and (f) p21 in all epidermal layers.  
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3.4.3 BrdU-labelling of bi-genic ROCK/fos mice 
 
Skin biopsies were analysed for BrdU-labelling expression to assess proliferating 
cells in K14.cre/lsl.ROCKer/HK1.fos mice. As expected, BrdU-positive cells (figure 
3.30) showed more distribution in RU486-/4-HT-treated 
K14.cre/lsl.ROCKer/HK1.fos benign tumours which indicated higher cell 
proliferation activity (22.1%) than fos hyperplasia (4-HT-treated and 4-HT-
untreated HK1.fos hyperplasia: 15.2% and 14.8%; RU486-treated/4-HT-untreated 
K14.cre/lsl.ROCKer/HK1.fos 14.5%). These findings indicate that cell proliferation 
rates increase as ROCK co-operates with fos in benign papilloma formation as 
compared to fos or ROCK/fos in the hyperplasia stage. 
 
Higher levels of BrdU-labelling were displayed in bi-genic ROCK/fos benign 
papillomas. However, this proliferation rate was considerably lower in comparison 
to mitotic activity during bi-genic ROCK/ras1205 papillomatogenesis which was 
almost three times higher and consistent with p53 loss that led to a papilloma 
prone to conversion. This lower level of proliferative activity also supports the idea 
that increased expression of p53 and p21 is instrumental in preventing conversion 
in bi-genic ROCK/fos papillomas. 
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Figure 3.30 BrdU-labelling of bi-genic ROCK/fos carcinogenesis. Graph displays serial increases 
in cell proliferation activity upon conversion of hyperplasia to benign papilloma phenotypes in 
K14.cre/lsl.ROCKer/HK1.fos mice. (No significant difference between each cohort; p>0.05). 
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3.4.4 Summary 
 
Collectively, this study has shown for the first time that ROCK2 can act as an 
initiator in co-operation with fos oncogene activation and together their activation 
produce benign squamous papilloma histotypes. Since ROCK is well-known for its 
role during the late stage of cancer (Croft et al., 2004, Samuel et al., 2011), this 
finding is also a novel indicator of early co-operation between ROCK2 and fos 
activation in benign tumour formation. Moreover, in comparison to co-operation 
between activated ROCK and rasHa, bi-genic ROCK/fos mice did not achieve the 
context where papillomas are prone to convert to malignancy. The resistance in 
K14.cre/lsl.ROCKer/HK1.fos benign papillomas was associated with an increased, 
possibly premature expression of keratin K1, and compensatory p53 and p21 that 
supported formation of stable benign squamous papillomas, and limited further 
progression.  
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3.5 Co-operation of ROCK2 and K14.cre/Δ5PTENflx in 
transgenic mouse skin carcinogenesis 
 
 
PTEN is one of the major tumour suppressor genes targets in cancer, thus its loss 
may be one of the key elements in tumourigenesis (Yao et al., 2006, 2008). It has 
been shown that inactivation of PTEN, particularly on exon 5 which encodes the 
phosphatase active site, is implicated in tumour formation (Suzuki et al., 2003, 
Freeman et al., 2006). Since PTEN negatively regulates the PI3K/AKT pathway, 
apparent differentiation activity may be induced to compensate for loss of PTEN 
as AKT is essential in proliferation (Suzuki et al., 2003). A long term goal of this 
study has been to model the effect of deregulated ROCK signalling alongside the 
PTEN/AKT pathway (Yao et al., 2006) as mediated by loss of PTEN regulation of 
AKT (Macdonald et al., 2014). As ROCK kinase is well-known for its role in 
actomyosin contraction which affects cellular tension and cytoskeletal organisation 
(Samuel et al., 2011, Rath and Olson, 2012); and PTEN has been associated with 
regulation of cytoskeleton proteins and adherens junctions (Subauste et al., 2005) 
prior to its more popular roles in interacting with p53 expression (Yao et al., 2006, 
2008, Macdonald et al., 2014) . This made the study of the roles of ROCK 
activation with PTEN loss in carcinogenesis and epidermal differentiation a logical 
step. 
 
In the past, in vivo models were unable to address these questions, yet evidence 
of a relationship between the Rho/ROCK signalling pathway and PTEN in the 
regulation of p-AKT levels was suggested by a single in vitro study (Li et al., 2005). 
However, this past study was performed on human embryonic kidney cells and did 
not specify whether it was ROCK1 or ROCK2. Furthermore, there is still a lack of 
evidence about the relationship between ROCK and PTEN through in vivo, thus, a 
co-operation study between ROCK2 activation and inactivation of PTEN activity 
was directly examined in this transgenic mouse model.  
 
It is documented that PTEN shares a homology with tensin which is a cytoskeleton 
component (Li et al., 1997, Di Cristofano et al., 1998) and it is known that ROCK 
plays an essential role in the regulation of actin cytoskeleton. However, the 
implication of direct co-operation between ROCK2 activation and inactivation of 
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PTEN activity in multistage skin carcinogenesis remains unclear. Yao et al., (2006) 
demonstrated that inactivation of PTEN alone in the absence of chemical 
treatment or additional oncogenes resulted in mild epidermal hyperplasia and 
hyperkeratosis associated with Cowden disease, a familial cancer syndrome 
(Suzuki et al., 2003, Mao et al., 2004). Interestingly, co-operation between PTEN 
loss (Δ5PTENflx) and rasHa activation produced benign squamous papillomas 
without conversion (Yao et al., 2006), whilst co-operation between PTEN loss 
(Δ5PTENflx) and fos oncogene activation showed an alternative tumour formation 
which developed to a progressive keratoacanthoma (KA) (Yao et al., 2008). 
Therefore, the mechanistic consequences of co-operation between ROCK2 and 
PTEN loss (Δ5PTENflx) in early tumour formation will be examined and later, 
studies will progress to ROCK2 activation in bi-genic ras/Δ5PTENflx and 
fos/Δ5PTENflx.  
 
3.5.1 Confirmation of lsl.ROCKer expression in bi-genic 
ROCK/Δ5PTENflx mice 
 
As mentioned earlier, the new lsl.ROCKer model was used in this study to ensure 
the same genes: ROCKer and 5PTENflx were targeted by the K14.CreP vector in 
the epidermis and hair follicles following induction by RU486 treatment (Berton et 
al., 2000b). K14.cre/lsl.ROCKer/Δ5PTENflx mice were first analysed to verify the 
expression of the gfp-tag which is indicative of ROCKer transgene expression 
(EGFP). As shown in figure 3.31a, K14.cre/lsl.ROCKer/Δ5PTENflx skin 
demonstrated gfp expression in all epidermal layers including follicular areas as 
compared to no expression in K14.cre/Δ5PTENflx mice (figure 3.31b). Therefore, 
this study confirmed ROCKer transgene expression in 
K14.cre/lsl.ROCKer/Δ5PTENflx mice.  
 
To confirm that the K14.cre/lsl.ROCKer/Δ5PTENflx phenotype was due to activation 
of 4-HT treatment, analysis of p-Mypt1 which is a downstream substrate for ROCK 
was performed on the skin biopsies. As shown in figure 3.31c, p-Mypt1 was 
expressed throughout the epidermal layers of RU486-/4-HT-treated 
K14.cre/lsl.ROCKer/Δ5PTENflx mouse skin including the proliferative basal layer 
and hair follicles, consistent with the K14.CreP expression profile (Berton et al., 
2000b). In contrast, p-Mypt1 expression appeared at very low levels in the mildly 
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hyperplastic RU486-/4-HT-treated K14.cre/Δ5PTENflx control epidermis (figure 
3.31d). These findings showed that not only was the ROCKer transgene expressed 
in all epidermal layers including hair follicles of the new lsl.ROCKer model, but also 
confirmed the 4-HT activation of K14.cre/lsl.ROCKer/Δ5PTENflx cohorts. 
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Figure 3.31 IHC analysis for the GFP-tagged ROCK
er
 transgene and p-Mypt1 of ROCK substrate. 
(a) Strong basal expression of exogenous ROCK
er
 in the keratinocyte cytoplasm of all epidermal 
layers including follicular areas of RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/Δ5PTEN
flx
 
papillomatous hyperplasia. (b) No gfp expression in RU486-/4-HT-treated K14.cre/Δ5PTEN
flx 
line. 
(c) Elevated expression of Mypt1 phosphorylation in RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
/Δ5PTEN
flx
 papillomatous hyperplasia including hair follicles compared to (d) 
weak p-Mypt1 expression in RU486-/4-HT-treated K14.cre/Δ5PTEN
flx 
hyperplasia. 
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3.5.2 ROCK2 co-operates with 5PTENflx to elicit hyperplasia with 
papillomatous appearance 
 
Transgenic mice expressing the new ROCK2 transgenic genotype, lsl.ROCKer 
mice were crossed with K14.cre/Δ5PTENflx lines to make sure that the same 
epidermal cells were being targeted as in the PTEN floxed model which requires 
the K14.creP regulator (Berton et al., 2000b). Cohorts (n=10) of new 
K14.cre/lsl.ROCKer/Δ5PTENflx and age-matched K14.cre/Δ5PTENflx siblings were 
topically treated with RU486 on both ears to activate the cre and thus ablate the 
exon5 of PTEN and the transcriptional stop cassette for lsl.ROCKer transgene 
expression. Subsequently, mice were treated with 4-HT 3 times per week to 
activate the ROCKer function in the epidermis, for an eventual 7 months. Each bi-
genic control genotype (n=5) received identical RU486/4-HT treatment for up to 27 
weeks; with a cohort (n=5) of K14.cre/lsl.ROCKer/Δ5PTENflx controls receiving 
RU486 but ethanol alone.  
 
Both RU486-/4-HT-treated K14.cre/lsl.ROCKer/Δ5PTENflx and K14.cre/Δ5PTENflx 
transgenic mice had skin thickening with mild keratosis as early as 10 to 12 weeks 
but these remained relatively unchanged on week 27th (figure 3.32a,b). However, 
no tumours appeared at any time unlike bi-genic ROCK/ras1205 and ROCK/fos 
mice where tumours appeared by 12–18 weeks. All control cohorts, 4-HT-
untreated K14.cre/lsl.ROCKer/Δ5PTENflx or K14.cre/Δ5PTENflx exhibited similar 
phenotypes with no tumours produced up to 7 months (figure 3.32c,d), a result 
consistent with the K14.ROCKer genotypes and earlier K14.cre/Δ5PTENflx studies 
(Yao et al., 2006, 2008). 
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Figure 3.32 Phenotypes of K14.cre/lsl.ROCK
er
/Δ5PTEN
flx 
and K14.cre/Δ5PTEN
flx
 mice at 27 weeks 
treatment. (a) RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/Δ5PTEN
flx 
exhibit thickened ear with small 
protrusion. (b) RU486-/4-HT-treated K14.cre/Δ5PTEN
flx
 together with (c) RU486-treated/4-HT-
untreated K14.cre/lsl.ROCK
er
/Δ5PTEN
flx 
and (d) RU486-treated/4-HT-untreated K14.cre/Δ5PTEN
flx
 
mice display scaly and slightly thickened ears.  
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Following initial RU486 treatments in week 1, and 27 weeks of 4-HT treatment, 
K14.cre/lsl.ROCKer/Δ5PTENflx ear skin biopsies were shown histologically to have 
a more extensive epidermal hyperplasia, hyperkeratosis and papillomatous 
features with many folds (figure 3.33a) as compared to RU486-/4-HT-treated 
K14.cre/Δ5PTENflx cohorts; which showed a mild epidermal hyperplasia with a 
slightly folded appearance and mild keratosis as observed previously (figure 
3.33b), and as observed in control RU486-treated/4HT-untreated 
K14.cre/lsl.ROCKer/Δ5PTENflx and K14.cre/Δ5PTENflx cohorts (figure 3.33c,d). 
This finding suggests that at this stage, in the absence of rasHa-associated 
initiation or fos associated promotion, there appears to be little co-operation 
between ROCK and PTEN to drive papillomatogenesis in 
K14.cre/lsl.ROCKer/Δ5PTENflx cohorts. However, there appears to be a synergism 
between these pathways in terms of increased proliferation and altered 
differentiation when compared to their single transgene littermates. This unique 
and unexpected finding from RU486-/4-HT-treated K14.cre/lsl.ROCKer/Δ5PTENflx 
mice showed a distinctive opposite outcome when compared to the result from bi-
genic ROCK/ras1205 and ROCK/fos mice which resulted in tumour formation 
around 8-12 weeks. Moreover, K14.cre/lsl.ROCKer/Δ5PTENflx histotypes showed 
little difference to the mild hyperplasia histotypes from ROCK activation alone and 
K14.cre/Δ5PTENflx mice.  
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Figure 3.33 Histotype of K14.cre/lsl.ROCK
er
/Δ5PTEN
flx and K14.cre/Δ5PTEN
flx
 mice at 27 weeks. 
(a) RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/Δ5PTEN
flx epidermis show hyperplasia with expanded 
epidermal compartments. (b) RU486-/4-HT-treated K14.cre/Δ5PTEN
flx
 mice; together with (c) 
RU486-treated/4-HT-untreated K14.cre/lsl.ROCK
er
/Δ5PTEN
flx and (d) RU486-treated/4-HT-
untreated K14.cre/Δ5PTEN
flx
 mice exhibit identical hyperplasia. (Scale bar: 100µm). 
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3.5.3 Expression of differentiation markers in bi-genic 
ROCK/Δ5PTENflx 
 
Skin biopsies were analysed for the expression of the early differentiation markers 
keratin K1 and K6 to examine the effects of bi-genic ROCK/Δ5PTENflx in 
keratinocytes differentiation as no tumours resulted from this co-operation. K1, 
which is expressed in the supra-basal layer, is one of the earliest markers of 
differentiation whereas K6 is not expressed in the normal epidermis, except for the 
hair follicle, and its expression in the epidermis is associated with 
hyperproliferation or stress.  Both K1 and K6 markers are counterstained with 
keratin K14 which represents the keratinocytes. 
 
RU486-/4-HT-treated K14.cre/lsl.ROCKer/Δ5PTENflx and K14.cre/Δ5PTENflx 
cohorts exhibited K1 expression in the supra-basal layers (figure 3.34a,b), 
however K1 expression in the K14.cre/lsl.ROCKer/Δ5PTENflx epidermis appears to 
be stronger than typical K1 expression in hyperplasia (e.g. HK1.fos hyperplasia), 
due to thick basal layer (arrows) which suggests a high rate of proliferation (figure 
3.34a), consistent with an increased mitotic index (below). In 
K14.cre/lsl.ROCKer/Δ5PTENflx cohorts, K6 expression seems to appear in an 
atypical fashion with patchy expression in the thick hyperplastic layers (figure 
3.34c) whereas no K6 expression was seen in the mild epidermal hyperplasia of 
K14.cre/Δ5PTENflx cohorts, and only appeared in the follicles (figure 3.34d). These 
findings suggest that co-operation between ROCKer activation and PTEN loss 
(Δ5PTENflx) can lead to changes in proliferation and differentiation activities 
leading to a greater degree of both hyperplasia and hyperkeratosis instead of 
papilloma formation. 
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Figure 3.34 Immunofluorescence analysis of K1/K14 and K6/K14 expression at 27 weeks of 4-HT 
treatment. (a) RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/Δ5PTEN
flx
 epidermal hyperplasia shows a 
supra-basal K1 expression in folded papillomatous epidermal layers and appears delayed (arrows) 
due to thick proliferative basal layers. (b) RU486-/4-HT-treated K14.cre/Δ5PTEN
flx
 mild hyperplasia 
exhibits uneven green K1 expression in the supra-basal layer. (c) RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
/Δ5PTEN
flx
 papillomatous hyperplasia shows patchy expression of K6. (d) 
RU486-/4-HT-treated K14.cre/Δ5PTEN
flx
 mild hyperplasia exhibits a usual lack of K6 expression 
except in the follicle areas. (Scale bar: 100µm). 
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3.5.4 Expression of p53, p21 and p-AKT1 in bi-genic 
ROCK/Δ5PTENflx mice 
 
It is well documented that PTEN acts as negative regulator of AKT inhibiting 
phosphorylation of AKT (p-AKT) and this inactivation leads to apoptosis and cell 
death (Vasudevan et al., 2007). In addition, loss of PTEN regulation also has an 
impact on p53/p21 expression given that p-AKT activation typically leads to down-
regulation of p53 by increasing MDM2, which is induced by p-AKT (Freeman et al., 
2003, Suzuki et al., 2003), and thus facilitates tumourigenesis. As previously 
shown both p53 and p21 are compromised during multistage carcinogenesis 
studies with loss of p53 expression observed upon malignant conversion, followed 
by p21 loss when tumours progressed to aggressive carcinomas (Macdonald et 
al., 2014), and p53/p21 profiles in bi-genic ROCK/ras1205 carcinomas concurred 
with this (above). In addition, both p53 and p21 are also known to prevent further 
tumour progression and this compensatory function has been demonstrated in all 
early bi-genic ROCK/ras1205 papillomas; and as shown in bi-genic ROCK/fos 
tumours can prevent malignant conversion as these papillomas remain benign. 
These results were consistent with findings in previous studies involving PTEN 
mutation (Yao et al., 2006, 2008, Macdonald et al., 2014).  
 
In this study, expression profiles of p53, p21 and p-AKT1 in 
K14.cre/lsl.ROCKer/Δ5PTENflx hyperplastic histotypes were determined by IHC 
and IFC analysis. As hyperplastic K14.cre/lsl.ROCKer/Δ5PTENflx cohorts resulted 
in changes in epidermal differentiation instead of tumour formation, it was 
anticipated that expression of p53 and p21 may be up regulated as previously 
observed in bi-genic ROCK/fos and ROCK/ras1205 epidermis. For activated AKT, 
expression of p-AKT1 protein was chosen for analysis which is detectable and 
specific to skin instead of p-AKT2 protein which has not been detected in skin 
(below).  
 
As shown in figure 3.35, surprisingly RU486-/4-HT-treated 
K14.cre/lsl.ROCKer/Δ5PTENflx cohorts demonstrated patchy expression of p53 
(figure 3.35a, b) and anomalous expression of p21 (figure 3.35d, e). Similarly, 
mildly hyperplastic K14.cre/Δ5PTENflx epidermis also displayed uneven and weak 
expression of both p53 and p21 (figure 3.35c, f) at this stage. This anomalous 
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expression of both p53 and p21 in K14.cre/lsl.ROCKer/Δ5PTENflx and 
K14.cre/Δ5PTENflx epidermis was unexpected and appeared to be in contrast to 
the uniform and elevated p53/p21 expression in benign tumour formation observed 
in bi-genic ROCK/ras1205 and ROCK/fos benign papillomas (above). However, as 
shown in figure 3.35(d - box,e), there seem to be an elevated expression of p21 
and this may suggest the limited expression of p-AKT1 in the same area of 
K14.cre/lsl.ROCKer/Δ5PTENflx hyperplasia (figure 3.36a – box). Only low levels of 
p-AKT1 expression appeared in the proliferative basal layer of RU486-/4-HT-
treated K14.cre/lsl.ROCKer/Δ5PTENflx epidermis (figure 3.36a) and this also 
compared to a surprising lack of p-AKT1 expression in RU486-/4-HT-treated 
K14.cre/Δ5PTENflx hyperplasia (figure 3.34b). These interesting findings indicate 
that at this early stage, neither p53 nor p21 appear to be induced in 
K14.cre/lsl.ROCKer/Δ5PTENflx and K14.cre/Δ5PTENflx epidermal hyperplasia. At 
this hyperplastic stage active proliferation and altered differentiation have been 
shown occurr (K6 analysis - above), which perhaps implies limited expression of p-
AKT1 and thus, a lack of oncogenic activity in the context of this mild hyperplasia 
insufficient to induce high levels of p53/p21 expression. Nonetheless, often the 
p21 expression profile increase with time and this may have contributed to the lack 
of papillomas; however, the conclusion remains that the oncogenic hits supplied 
by ROCK and PTEN are either redundant or need to be linked by deregulation of 
the MAPK pathway in terms of ras initiation, fos promotion or both. 
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Figure 3.35 IHC analyses of p53 and p21. (a, b) RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
/Δ5PTEN
flx
 papillomatous hyperplasia histotypes show uneven expression and 
sparse distribution of p53 in the epidermal layers. (c) Low level of p53 expression in the mildly 
hyperplastic RU486-treated/4-HT-treated K14.cre/Δ5PTEN
flx
 epidermis. (d) RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
/Δ5PTEN
flx
 hyperplasia histotypes display anomalous expression of p21 in the 
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epidermal layer, though p21 expression appeared to be elevated in some areas (box). (e) Elevated 
p21 expression in RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/Δ5PTEN
flx
 hyperplasia may be the 
reason for the lack of p-AKT1 expression in the same area (figure 3.36a-box). (f) Higher 
magnification of RU486-treated/4-HT-treated K14.cre/Δ5PTEN
flx 
hyperplasia shows lack of p21 
expression. 
 
 
Figure 3.36 Immunofluorescence analysis of p-AKT1. (a) RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
/Δ5PTEN
flx
 folded hyperplasia exhibits little expression of p-AKT1 which is 
limited to the proliferative basal layer. However, in the box area (elevated p21) shows no 
expression of p-AKT1, suggesting suppression by p21. (b)  RU486-treated/4-HT-treated 
K14.cre/Δ5PTEN
flx 
display supra-basal expression of p-AKT1 in the epidermal hyperplasia 
histotypes. (c) RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/Δ5PTEN
flx 
and (d) RU486-treated/4-HT-
treated K14.cre/Δ5PTEN
flx 
exhibit no expression of p-AKT2 which is not specific to skin unlike p-
AKT1. 
 
 
 
 
Chapter 3  155 
 
3.5.5 BrdU-labelling of bi-genic ROCK/Δ5PTENflx mice 
 
Analysis of BrdU-labelling was performed on K14.cre/lsl.ROCKer/Δ5PTENflx 
epidermis as a measure of cell proliferation activity. As shown in figure 3.37, BrdU-
labelling of papillomatous hyperplasia from RU486-/4-HT-treated 
K14.cre/lsl.ROCKer/Δ5PTENflx epidermis showed three times more proliferating 
cells (64.2%) than in mildly hyperplastic K14.cre/Δ5PTENflx epidermis (RU486-/4-
HT-treated and RU486-treated/4-HT-untreated K14.cre/Δ5PTENflx cohorts: 18.2% 
and 20%; RU486-treated/4-HT-untreated K14.cre/lsl.ROCKer/Δ5PTENflx 18.6%). 
Moreover, IFC analysis demonstrated groups of BrdU-labelled cells scattered in 
the proliferative basal layers of the K14.cre/lsl.ROCKer/Δ5PTENflx epidermis (figure 
3.37a) as compared to that of BrdU-labelled cells in control K14.cre/Δ5PTENflx 
epidermis (figure 3.37b). This finding indicates that although an elevated level of 
p21 expression (figure 3.35d-box, e) that downregulates p-AKT1 (figure 3.36a – 
box), and the lack of p53 expression (figure 3.35a) together with some p-AKT1 
expression in the basal layer (figure 3.36a) may induce the significant increase in 
proliferative acitivity in K14.cre/lsl.ROCKer/Δ5PTENflx papillomatous hyperplasia. 
This too may cause feedback loops that inhibited papilloma formation. 
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Figure 3.37 BrdU-labelling of bi-genic ROCK/Δ5PTEN
flx 
carcinogenesis. The graph displays cell 
proliferation activity in RU486-/4-HT-treated bi-genic ROCK/Δ5PTEN
flx
 mice that is significant and 
three times higher than that from Δ5PTEN
flx
 mice (with or without 4-HT-treatment). (a,b,c,d : 
significant difference between K14.cre/lsl.ROCK
er
/Δ5PTEN
flx
 (+ 4-HT) and each cohort; p<0.05).  
(a) RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/Δ5PTEN
flx 
epidermis exhibits a high number of BrdU-
labelled keratinocytes in proliferative basal layers compared to (b) low numbers of BrdU-labelled 
cells in mildly hyperplastic epidermis of RU486-/4-HT-treated K14.cre/Δ5PTEN
flx
. (Scale: 100µm). 
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3.5.6 Summary 
 
Bi-genic ROCK/Δ5PTENflx synergism showed little appearance of tumour 
formation even with continuous treatment for 7 months. Instead, alteration in both 
epidermal proliferation and differentiation appeared as shown by a delay in K1 
expression due to increased thickness in the proliferative basal layers together 
with anomalous expression of K6. Nonetheless, in this study, the K6 expression in 
K14.cre/lsl.ROCKer/Δ5PTENflx cohorts was elevated as compared to lack of K6 
expression in Δ5PTENflx hyperplasia, matched by the folded hyperplasia and much 
thicker appearance in bi-genic ROCK/Δ5PTENflx. This finding is consistent with the 
high proliferation rates from BrdU data. 
 
In addition, low and patchy expression of p53 and p21 in bi-genic 
ROCK/Δ5PTENflx compared to a strong and uniform p53/p21 expression profile in 
bi-genic ROCK/fos papillomas indicate that p53 and p21 are not responsible for 
the lack of tumour formation. On the other hand, phosphorylated AKT which could 
contribute to tumourigenesis by its cell growth and cell survival functions may be 
accountable for the lack of tumour formation as it exhibited little expression. 
However, the areas of patchy p-AKT1 expression in RU486-/4-HT-treated 
K14.cre/lsl.ROCKer/Δ5PTENflx folded hyperplasia were accompanied by an 
increased p21 expression which may suppress the p-AKT1 oncogenic functions; 
as observed in tri-genic ras/fos/Δ5PTENflx models (Greenhalgh, - manuscript in 
preparation, per communication with Greenhalgh). Furthermore, deregulation of 
PTEN has been associated with hyperkeratosis such as in Cowden’s disease and 
is implicated in premature keratinocyte differentiation (Yao et al., 2008), which 
suggests that ROCK2 acts as a weak partner in co-operation with Δ5PTENflx 
compared to its novel early co-operation with the fos oncogene in the initiation of 
papillomatogenesis.  
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3.6 Analysis of ROCK2 activation in vitro: effects on 
differentiation not carcinogenesis. 
 
Earlier results successfully demonstrated co-operation between ROCK and each 
of the ras/fos/Δ5PTENflx transgenes in vivo. Several interesting features came to 
light, one of which was the surprising lack of co-operation with Δ5PTENflx and the 
unusual expression of various differentiation markers, such as keratin K6. In 
addition, the ROCK family has been demonstrated to effect and regulate 
keratinocytes differentiation (McMullan et al., 2003, Lock and Hotchin, 2009) and 
some of the first IHC staining experiments suggested that both ROCK1 and 2 were 
predominantly expressed in differentiated supra-basal cells; a finding consistent 
with roles in epidermal integrity and barrier functions. Therefore, this study now 
aimed to establish primary transgenic mouse keratinocyte cultures to mimic the in 
vivo model in order to understand further the role of ROCK2 in epidermal 
differentiation and proliferation.  
 
Keratinocytes undergo different stages of growth in the formation of an epidermis 
and keratinocytes differentiation can be modelled in vitro by altering the calcium 
concentration in the medium. Through in vitro analysis, expression of keratin 
markers related to keratinocytes proliferation and differentiation can be analysed 
such as keratin K14 in the proliferative keratinocytes, keratin K1 expressed in the 
early stages of terminal differentiation as keratinocytes fully commit to the 
differentiation process following exposure to increased calcium, and keratin K6 
which is often associated with hyperproliferation and wounding in vivo (Schermer 
et al., 1989, Rothnagel et al., 1999) and also with a highly stressed epidermis such 
as transgenic expression of TGFβ1 (Sellheyer et al., 1993) which inhibited 
neonatal keratinocyte proliferation but induced dermal fibroblast proliferation.  
 
Employing standard protocols (Hennings et al., 1980, Yuspa et al., 1980) modified 
to prevent spontaneous transformation (Greenhalgh et al., 1989), primary 
keratinocytes were isolated from transgenic neonatal mouse skin and both 
differentiation and proliferation activities were monitored by switching to different 
calcium concentrations in the culture medium  (Hennings et al., 1980). Calcium 
(Ca2+) concentrations are a critical factor in primary keratinocytes culture, low 
calcium medium (0.05 mM) maintains a proliferative basal cell population whereas 
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switching to higher calcium concentration (> 0.10 mM) was classically employed to 
induce keratinocyte differentiation (Hennings et al., 1980, Yuspa et al., 1980); and 
later a staggered switch to 0.10 mM from 24 hours then to 0.15 mM was found to 
enhance expression of early differentiation markers such as K1 (Greenhalgh et al., 
1989, Rothnagel et al., 1993). 
 
3.6.1 Establishment of primary transgenic mouse keratinocyte 
culture 
 
In order to investigate differentiation and proliferation activities, primary 
keratinocytes isolated from transgenic neonatal mouse skin were grown in DMEM 
medium containing 10% commercial keratinocyte growth medium (KGM), 10% 
chelexed fetal calf serum (FCS) and 10% fibroblast conditioned media with a 
calcium concentration of 0.05 mM (low Ca2+ medium) and plated out at 5 x 106 
primary keratinocytes per 60mm dish in 5ml medium. As demonstrated in figure 
3.38, at 48 hours in low Ca2+ medium (0.05 mM), primary keratinocytes isolated 
from K14.cre/lsl.ROCKer transgenic mice grew uniformly and had a typical 
cobblestone appearance. There was little difference in the cell growth profiles 
between K14.cre/lsl.ROCKer cells supplemented with 4-HT (10-9M) (figure 3.38a) 
and RU486-treated/4-HT-untreated (10-9M) K14.cre/lsl.ROCKer cells (figure 3.38b).  
 
Terminal differentiation was induced by additing medium containing first 0.10 mM 
for 24 hours and then 0.15 mM Ca2+ for 48 hours. K14.cre/lsl.ROCKer keratinocytes 
with or without 4-HT in 0.10 mM Ca2+ demonstrated the typical signs of 
stratification and spaces between cells became apparent after 24 hour incubation 
(figure 3.38 c,d). Significant changes in cells appearance were noted and many 
cells sloughed off during the differentiation to form squames or cornified envelopes 
displayed in the cells supplemented with 0.15 mM Ca2+ after 48 hours (figure 3.38 
e,f). However, again there were no obvious changes in the cell morphology to 
suggest an effect of additional ROCK2 activation in these K14.cre/lsl.ROCKer cells. 
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Figure 3.38 Morphology of primary K14.cre/lsl.ROCK
er 
keratinocytes in medium containing different 
calcium concentrations. (a, b) Primary keratinocytes 2 days after plating in 0.05 mM, low calcium 
media: (a) supplemented with (RU486-) 4-HT and (b) without 4-HT/with RU486. Cells were 
switched to 0.10 mM Ca
2+
 (c) with (RU486-) 4-HT and (d) without 4-HT/with RU486, which became 
less bright and lost the cobblestone appearance; continued to second switch 0.15 mM Ca
2+
 (e) with 
(RU486-) 4-HT and (f) without 4-HT/with RU486 where keratinocytes displayed the typical 
stratification and sloughing of cells into the medium. 
 
a b 
c d 
e f 
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In the next experiment, primary keratinocytes isolated from newborn 
K14.cre/lsl.ROCKer/HK1.fos and K14.cre/lsl.ROCKer/Δ5PTENflx mice were plated in 
medium supplemented with different calcium concentrations to investigate their 
differentiation and potential transformation due to resistance to Ca2+-induced 
terminal differentiation in vitro (Strickland et al., 1988, Greenhalgh et al., 1989, 
Morgan et al., 1992). Here, both bi-genic ROCK/fos (figure 3.39) and 
ROCK/Δ5PTENflx (figure 3.40) keratinocytes rapidly reached confluency in low 
Ca2+ media (0.05mM) compared to K14.cre/lsl.ROCKer alone or non-transgenic 
normal ICR cultures. Although no formal growth curves were performed, in these 
bi-genic cultures, many individual rounded cells were seen floating in low Ca2+ 
medium due to this confluency and limited space for cells to grow. Following the 
staggered switch to 0.15mM Ca2+, these bi-genic keratinocytes rapidly changed 
morphology and differentiation to form several distinct layers (figure 3.39 b,d,f and 
figure 3.40 b,d,f). However, this may be due to the low Ca2+ medium observations 
that suggested an increased plating efficiency, may lead to a more rapid or intense 
response to the Ca2+ challenge. Few other differences were observable between 
treated bi-genic versus non-transgenic or untreated controls keratinocytes. Neither 
K14.cre/lsl.ROCKer, HK1.fos nor K14.cre/lsl.ROCKer/fos expression elicit classical 
keratinocyte transformation, as determined by resistance to Ca2+ induced terminal 
differentiation following extensive culture over a 6 weeks period (Strickland et al., 
1988, Greenhalgh et al., 1989, Morgan et al., 1992). This in vitro result would be 
consistent with the earlier in vivo findings given that neither fos nor ROCK2 
activation gave rise to malignant tumours in the absence of ras activation and that 
bi-genic ROCK/Δ5PTENflx seemed to be redundant perhaps representing a similar 
oncogenic ‘hit’ as with Δ5PTENflx which just altered the keratinocyte differentiation 
programme. Hence, to confirm these observations, western analysis (below) was 
performed. 
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Figure 3.39 Morphology of K14.cre/lsl.ROCK
er
/HK1.fos mouse keratinocytes in medium containing 
different calcium concentrations. Cells were maintained in low Ca
2+
 medium (0.05mM) (left) for 3 
days and switched to high Ca
2+
 medium (0.15mM) (right) for 24 to 48 hours. 
 [(a, b) RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/HK1.fos cells; (c, d) 4-HT-untreated/RU486-
treated K14.cre/lsl.ROCK
er
/HK1.fos cells; (e, f) 4-HT-treated HK1.fos cells ]. 
 
 
a b 
c d 
e f 
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Figure 3.40 Morphology of K14.cre/lsl.ROCK
er
/Δ5PTEN
flx mouse keratinocytes in medium 
containing different calcium concentrations. Cells were maintained in low Ca
2+
 medium (0.05mM) 
(left) for 3 days and switched to high Ca
2+
 medium (0.15mM) (right) for 24 to 48 hours. [(a, b) 
RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/Δ5PTEN
flx
 cells; (c, d) 4-HT-untreated/RU486-treated 
K14.cre/lsl.ROCK
er
/Δ5PTEN
flx cells; (e, f) RU486-/4-HT-treated K14.cre/Δ5PTEN
flx cells]. 
d 
a b 
c 
e f 
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One unfortunate observation was that neither primary bi-genic 
K14.cre/lsl.ROCKer/HK1.ras1276 nor HK1.ras (line 1276 and 1205) alone 
keratinocytes could be maintained in culture; even after multiple attempts. 
Typically within 24 hours of plating, the majority of cells had either failed to attach 
or had attached but remained rounded. The cells quickly become senescent as 
early as day 3, before the induction of high calcium concentration (figure 3.41). 
This finding suggests that due to the hyperplastic nature of a rasHa epidermis, cells 
detached in this early growth by trypsinisation died and /or could not be cultured 
due to the oncogenic ras induction of cellular senescence (Yaswen and Campisi, 
2007). 
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Figure 3.41 Morphology of primary K14.cre/lsl.ROCK
er
/HK1.ras
1276
 mouse keratinocytes. (a) 
Several primary K14.cre/lsl.ROCK
er
/HK1.ras
1276
 keratinocytes failed to attach after 24 hour of 
plating. (b) RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/HK1.ras
1276
, (c) 4-HT-treated HK1.ras
1276
 and 
(d) RU486-treated/4-HT-untreated K14.cre/lsl.ROCK
er
/HK1.ras
1276
 cells became senescent on day 
3 in low Ca
2+
 medium. 
 
 
 
 
 
 
 
 
 
 
 
 
c d 
a b 
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3.6.2 Expression of keratinocyte differentiation markers in vitro 
 
As outlined above, in vivo both K14.cre/lsl.ROCKer and /or Δ5PTENflx expression 
appeared to alter keratinocyte differentiation in terms of atypical keratin K6 
expression and, for Δ5PTENflx early anomalous keratin K1 expression in the basal 
layer. This led to speculation that these two insults may exert a similar effect as 
surprisingly, relatively little co-operation was observed in the bi-genic 
ROCK/Δ5PTENflx cohorts. Furthermore, a previous report demonstrated that 
ROCK2 knockdown inhibited terminal differentiation in the HaCat human 
keratinocyte cell line (Lock and Hotchin, 2009) and again this led to speculation 
that the odd keratin K6 result may also reflect a response to anomalous ROCK2 
activation that instigated the differentiation pathways rather than proliferation 
signals; or it may be that given the extra or increased intra-cellular tension 
provided by ROCK2 activation via MLC, that stress response keratin such as K6 or 
early differentiation keratins such as K1 were altered. 
 
In this in vitro study, keratinocytes from the K14.cre/lsl.ROCKer model were used to 
compare results on the differentiation changes in vivo due to co-operation of bi-
genic ROCK/fos and ROCK/Δ5PTENflx. As shown in figure 3.42, western analysis 
demonstrated that K14.cre/lsl.ROCKer (n= 3) is activated and expressed more 
upon induction by RU486/4-HT treatment in both low and high calcium conditions. 
From western analysis, RU486-/4-HT-treated K14.cre/lsl.ROCKer primary 
keratinocytes showed increased MLC phosphorylation (ROCK substrate) 
particularly in the RU486-/4-HT-treated K14.cre/lsl.ROCKer  cells in low Ca2+ 
medium (figure 3.42: L+ versus L). Whilst in high Ca2+ medium, the high levels of 
endogenous MLC phosphorylation produced on induction of differentiation were 
increased again in 4-HT-treated cells (figure 3.42: H+ versus H). These data are 
consistent with previous findings from Samuel et al., (2009, 2011) with the 
increased MLC phosphorylation in RU486-/4-HT-treated K14.cre/lsl.ROCKer cells 
comparable to the levels in high calcium medium and consistent with ROCK2 roles 
in differentiation. To assess this possibility, further western analysis was 
performed to assess keratin K1 and K6 expression in cultured K14.cre/lsl.ROCKer 
primary keratinocytes. 
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Figure 3.42 K14.cre/lsl.ROCK
er 
is activated after RU486-/4-HT treatment. Western blot shows 
endogenous ROCK, ROCK
er
 transgene, phosphorylated MLC and total MLC in K14.cre/lsl.ROCK
er 
primary keratinocytes. Similar levels of ROCK
er
 expression were determined after treatment with 4-
HT as compared to 4-HT-untreated. Increased expression of phosphorylated MLC in both low and 
high Ca
2+
 medium treated with 4-HT was also observed. (L: low calcium; L+: low calcium with 4-
HT; H: high calcium; H+: high calcium with 4-HT).  
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Next, western analysis was performed to assess K1 and K6 expression in cultured 
K14.cre/lsl.ROCKer primary keratinocytes. Confluent dishes of transgenic and 
normal keratinocytes were cultured in low Ca2+ for 3 days with or without RU486/4-
HT treatment and a cohort switched for 24 hours into 0.10mM Ca2+ and then 0.15 
mM Ca2+ for a second 48 hours. Normal keratinocytes proliferate in low Ca2+ 
conditions expressing typical markers such as K14 and K5, together with the 
hyperproliferative keratin K6. Upon induction of high Ca2+ (0.15 mM), these keratin 
markers persist due to their stability and are joined by early markers of 
differentiation such as keratin K1 and K10, and their expression increases 
maximally if pre-incubation at an intermediate Ca2+ concentration of 0.10 mM for 
24 hours is applied when primary keratinocytes adopt a spinous cell morphology 
(above). 
 
As shown in figure 3.43(a), western analysis of normal ICR keratinocytes exhibit 
this K1/K6 profile in the presence or absence of 4-HT. K1 is often detected in low 
Ca2+ keratinocytes as they naturally differentiate and this level varies from batch to 
batch. In this primary culture, there was a higher degree of K1 expression but this 
increased in high Ca2+ appeared as routinely observed. K6 expression is also high 
in these low cells Ca2+ as expected and is detectable in high Ca2+ due to the 
general stability of keratin proteins. Interestingly, primary keratinocytes isolated 
from K14.cre/lsl.ROCKer did not show this standard K1/K6 profile (figure 3.43b). 
Instead, keratin K1 expression was increased in low Ca2+ medium after treatment 
with 4-HT (figure 3.43b – box) as compared to untreated group (a result that 
parallels to the MLC phosphorylation – above). This result was repeated several 
times and was consistent with the overall observation that there appeared to be an 
increased stratification of K14.cre/lsl.ROCKer cultured in high calcium with more 
squames and floating cornified envelope cells in the media; all indicative of an 
elevated level of differentiation.  
 
This increased keratin K1 expression may indicate a role for ROCK2 in 
keratinocyte differentiation in primary cultures concurs with a previous study that 
reported reduced differentiation following ROCK2 knockdown in the human 
keratinocyte cell line, HaCat (Lock and Hotchin, 2009). Further supporting this 
idea, K14.cre/lsl.ROCKer cells exhibited very low levels of the hyperproliferative, 
wound/stress-associated keratin K6 (figure 3.43b – box), again consistent with an 
increased shift towards differentiation rather than proliferation in vitro. These 
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results are consistent with that observed in vivo, as IFC analysis also found patchy 
K6 expression in hyperplastic K14.cre/lsl.ROCKer histotypes. Therefore, these 
data support the idea that alterations in keratinocyte differentiation are mediated 
by ROCK2 signalling activation, suggesting important roles for ROCK family 
members in maintenance of epidermal homeostasis.  
 
When the same analysis was performed on primary K14.cre/lsl.ROCKer/Δ5PTENflx 
and K14.cre/lsl.ROCKer/fos keratinocytes, several differences became more 
apparent. In these bi-genic keratinocytes, both expression of additional HK1.fos or 
Δ5PTENflx in activated K14.cre/lsl.ROCKer keratinocytes rescued their K6 
expression profiles (figure 3.43c,e (box) – middle and lower panels). For 
K14.cre/lsl.ROCKer/fos keratinocytes, this result was consistent with the uniform 
keratin K6 expression data observed in vivo; whilst keratin K6 expression in 
K14.cre/lsl.ROCKer/Δ5PTENflx hyperplasia remained only patchy and this may be 
due to the complex situation found in mutated PTEN keratinocytes and 
subsequent AKT deregulation. 
 
Whilst K14.cre/lsl.ROCKer/HK1.fos and HK1.fos appeared to restore the normally 
low levels of in vitro keratin K1 expression in low Ca2+ medium, this increased on a 
staggered switch to high Ca2+ medium; the same was not observed in 
K14.cre/lsl.ROCKer/Δ5PTENflx and K14.cre/Δ5PTENflx keratinocytes. Here, keratin 
K1 expression occurred in exactly the opposite pattern to what would be expected. 
A unique and novel K1 expression was noticed in both 
K14.cre/lsl.ROCKer/Δ5PTENflx and K14.cre/Δ5PTENflx keratinocytes which showed 
little K1 expression in high Ca2+ medium but high levels in low Ca2+ medium (figure 
3.43c,d – middle panel). Further, it appears that activated ROCK2 expression 
again contributed to this mainly Δ5PTENflx associated result, via increased keratin 
K1 expression in 4-HT-treated low Ca2+ medium, but it is also noted that K1 levels 
are lesser in K14.cre/lsl.ROCKer/Δ5PTENflx versus K14.cre/Δ5PTENflx 
keratinocytes independent of 4-HT treatment; and this keratin K1 observation is 
unclear. Nonetheless, this finding of reduced keratin K1 expression in vitro 
correlates with earlier immunofluorescence data where a delay in supra-basal K1 
expression appeared in K14.cre/lsl.ROCKer/Δ5PTENflx papillomatous hyperplasia 
consistent with the increases in the proliferative basal layer compartment. 
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However, this finding may also be due to the difference in p-AKT function in vivo 
versus in vitro. The idea in brief, being that one major AKT function in the 
epidermis is its supra-basal expression to prevent p53-mediated induction of 
widespread apoptosis, a counter-productive feature in a tissue evolved for barrier 
maintenance (Calautti et al., 2005, Macdonald et al., 2014). This provides times for 
keratinocytes to commit to the terminal differentiation programme. As outlined 
elsewhere, basal p53/p21 expression appears as a ready response to prevent 
anomalous AKT expression in the basal layers and basal p21 expression is known 
to accelerate commitment to differentiation in basal cells (Devgan et al., 2006);  
hence anomalous basal layer keratin K1 expression appears in K14.cre/Δ5PTENflx 
hyperplasia (Greenhalgh, – manuscript in preparation). But conversely, p21 
actually inhibits differentiation in the later stages of terminal differentiation of the 
supra-basal/granular layers (Devgan et al., 2006). Thus, collectively, this K1 oddity 
in K14.cre/lsl.ROCKer/Δ5PTENflx and K14.cre/Δ5PTENflx keratinocytes may derive 
in part from the fact that in low calcium medium, anomalous expression of AKT 
may paradoxically induced a feedback that express markers of early stage 
differentiation programme; leading to anomalous expression of a keratin 
associated with the keratinocyte commitment to differentiate (e.g. keratin K1). 
Whilst in high calcium, p-AKT expression returns to its oncogenic role and inhibits 
differentiation at a stage where now a p21 response also inhibits differentiation. 
This is still unclear, but what is clear is that this phenotype is mediated by PTEN 
not ROCK2 and the latter still exerts a slight increase in K1 expression in 4-HT-
treated K14.cre/lsl.ROCKer/Δ5PTENflx keratinocytes cultured in low calcium. 
Furthermore, as keratin K1 is significantly reduced in high calcium medium and 
expression of ROCK2 in this K14.cre/lsl.ROCKer/Δ5PTENflx was insufficient to 
rescue the K1 expression profile, yet it appeared to increase K1 in low calcium, 
again suggests that these two molecules have close links in the regulation of 
keratinocyte terminal differentiation. 
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Figure 3.43 Western analysis of K1 and K6 differentiation marker expression in primary 
keratinocytes. 
Top panel: (a) (left) Keratin K1 expression in normal ICR keratinocytes showed typical elevated 
expression when switched from culture in low (L, L+) to high calcium medium (H, H+). Keratin K6 
expression is high in low calcium proliferative conditions and is stable, thus it also appears in high 
calcium too.  
(b) (Right): ROCK2 activation induces more K1 expression in low calcium medium with 4-HT (box) 
(L+ versus L); and K1 appears increased further when switched to high calcium medium (H, H+). 
Interestingly, anomalous low levels of K6 expression appear upon ROCK2 activation in low calcium 
medium (box) (L+ versus L) consistent with in vivo observations of roles of ROCK2 activation in 
alteration of differentiation markers. 
Middle panel: (K1) Keratin K1 expression was altered being low in the high calcium medium of 
both (c) K14.cre/lsl.ROCK
er
/Δ5PTEN
flx
 and (d) K14.cre/Δ5PTEN
flx 
keratinocytes. This may suggest 
that due to inactivation of PTEN activity leading to more activated AKT. This mediated more 
oncogenic proliferation, which counteract the calcium-induced differentiation.  
(K6) However, in vitro combination of Δ5PTEN
flx
 deregulation to activated ROCK2 has rescued 
keratin K6 expression (box); and this too was observed in vivo.  
Bottom panel: In both (e) K14.cre/lsl.ROCKer/HK1.fos and (f) HK1.fos keratinocytes expression of 
fos restore the correct normal expression profile of keratin K1 in both low and high calcium medium 
and bi-genic ROCK/fos keratinocytes also restored typical K6 expression (box), similar to typical 
K1/K6 expression profiles as in normal non-transgenic ICR keratinocytes.  
Total MLC served as a loading control. (L: low calcium; L+: low calcium with 4-HT; H: high calcium; 
H+: high calcium with 4-HT). 
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3.6.3 Summary 
 
This study has demonstrated both changes in morphology in vitro and atypical 
expression of standard proliferation and differentiation markers when 
K14.cre/lsl.ROCKer, K14.cre/lsl.ROCKer/Δ5PTENflx and K14.cre/lsl.ROCKer/fos 
primary keratinocytes were cultured in low calcium conditions and challenged to 
differentiate by increasing calcium. However, both K14.cre/lsl.ROCKer/ras1276 and 
HK1.ras1276 keratinocytes (figure 3.41) could not be cultured and failed to survive 
after approximately day 2 to 3. This was probably due to the nature of rasHa 
activation (both line 1276 and 1205) which may have affected the ability of the 
keratinocytes to attach to the culture surface from which they easily became 
detached leading to their terminal differentiation, similar to a programme of 
oncogene induced senescence (Yaswen and Campisi, 2007).  
 
The data from this study showed that overall transgenic primary keratinocytes 
maintained their growth in low calcium before undergoing differentiation following a 
high calcium switch.  However in repeated western analysis an altered 
differentiation profile was found in 4-HT-treated primary K14.cre/lsl.ROCKer 
cultures with respect to both keratin K1 and K6 expression. Whilst the expected 
high keratin K1 expression in K14.cre/lsl.ROCKer keratinocytes appeared upon 
increased calcium, elevated K1 expression also appeared in low calcium medium 
(with 4-HT). This premature K1 expression was consistent with previous in vitro 
studies, where in a reverse of this model, ROCK2 knockdown suppressed terminal 
differentiation (Lock and Hotchin, 2009). In addition, the lack of K6 expression 
upon ROCK2 activation in low calcium medium again, showed that ROCK2 
activation alters expression of hyperproliferative or stress associated keratin 
markers and this further supports significant roles for ROCK2 in differentiation. 
These roles appeared to be consistent with in vivo analysis where low levels and 
patchy expression of keratin K6 markers were seen in K14.cre/lsl.ROCKer 
hyperplasia. 
 
In addition, both K14.cre/lsl.ROCKer/Δ5PTENflx and K14.cre/Δ5PTENflx 
keratinocytes showed an unexpected and reduced keratin K1 expression in high 
calcium medium; and in this genetic context, this unusual K1 inhibition in high 
calcium was not demonstrated in low calcium medium as both 
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K14.cre/lsl.ROCKer/Δ5PTENflx and K14.cre/Δ5PTENflx keratinocytes exhibited very 
unusual and increased levels of K1 in low calcium medium. This finding seemed to 
be tailored with the keratinocytes morphology (figure 3.40) in 0.15mM Ca2+, which 
was not completely differentiated when compared to other transgenic keratinocyte 
morphology in the same conditions and cultured at the same time (figure 3.38 and 
3.39).  
 
It is that this observation is linked to PTEN phenotypes rather than those of ROCK, 
and more experiments are required, however the analysis demonstrates a 
difference between in vitro vs in vivo. For instance, in respect to K6 expression, as 
shown earlier, the in vivo loss of K6 in Δ5PTENflx hyperplasia was completely 
reversed in the in vitro situation, and this may depend upon the altered AKT roles 
that mediate a response in culture against the whole animal. In the 
K14.cre/Δ5PTENflx epidermis, p-AKT1 expression is selective and typically 
confined to supra-basal layers, but in vitro, it is expressed all the time (Yao et al., 
2006), thus inducing proliferation and this restores K6 expression in low calcium. 
Hence, K6 expression was rescued in both K14.cre/lsl.ROCKer/Δ5PTENflx and 
K14.cre/Δ5PTENflx keratinocytes. In high calcium medium, these oncogenic 
activities of AKT may inhibit differentiation as manifest by a lack of K1 regardless 
of ROCK status. But, this apparently conflicts with induction of K1 in low calcium 
medium. Here, the answer may lie in the fact that normally AKT expression is 
supra-basal and counters p53, so that terminal differentiation (not apoptosis) is the 
outcome (Calautti et al., 2005, Yao et al., 2008, Macdonald et al., 2014). Thus, in 
the in vitro context, K14.cre/lsl.ROCKer/Δ5PTENflx and K14.cre/Δ5PTENflx 
keratinocytes cultured in low calcium medium respond to AKT by anomalous 
expression of early differentiation markers (keratin K1). Furthermore, adding 
HK1.fos activation to cultured ROCK2 keratinocytes was shown to rescue the 
normally strong K6 expression profile and here, K1 expression also returned to 
normal and remained unaltered in 4-HT-treated or untreated bi-genic keratinocytes 
from K14.cre/lsl.ROCKer/fos and HK1.fos genotypes. Collectively, these data 
suggest that whilst ROCK2 alters differentiation in some instances, fos activation 
exerts a more dominant nature in terms of differentiation. 
 
In experiments designed to assess whether ROCK2, bi-genic ROCK/Δ5PTENflx or 
ROCK/fos could induced immortalisation or transformation, these in vitro data 
showed that none of the transgenic primary keratinocytes possessed the classic 
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resistance to high Ca2+ indicative of a malignant phenotype (Morgan et al., 1992) 
by producing colonies following 4 to 5 weeks culture in high calcium medium; a 
result consistent with the in vivo findings. Although none of the transgenic primary 
keratinocytes showed signs of transformation, cell lines of ROCK2, bi-genic 
ROCK/Δ5PTENflx and ROCK/fos were successfully established by the end of this 
approach which will be valuable for future studies (see appendix A). 
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3.7 Co-operation of ROCK2, HK1.ras and HK1.fos in 
transgenic mouse skin carcinogenesis 
 
A major goal of this study was to assess ROCK2 activation in skin carcinogenesis 
and mimic the two-stage DMA/TPA studies performed earlier on K14.ROCKer mice 
(Samuel et al., 2011) with a view to identifying the co-operating genes and 
determining at which stage ROCK2 becomes active and causal. Subsequently, 
experiments would begin to analyse the downstream mechanisms and establish a 
stage-specific tumour archive for this and future studies. Earlier, bi-genic 
ROCK/ras1205 studies showed that co-operation appeared to centre on conversion 
from benign papillomas to carcinoma, and this required wound-associated 
promotion to achieve the correct papilloma context for ROCK causality. Excitingly, 
for the first time, co-operation between fos and ROCK2 activation in bi-genic 
ROCK/fos revealed a novel early co-operation in benign papilloma formation, a 
result consistent with ROCK being a downstream effector of ras signalling and 
possibly performing an initiating role for co-operation with fos. However, again in 
this benign ROCK/fos context, no conversion was observed in the absence of ras 
activation suggesting its requirement or that of another similar event. This would 
be consistent to some extent with the lack of tumours produced by TPA promotion 
alone controls in the two-stage K14.ROCKer chemical carcinogenesis studies 
(Olson, - unpublished data).  
As outlined in the introduction, the early rasHa/fos models were initially considered 
to mimic two-stage chemical carcinogenesis (Greenhalgh and Yuspa, 1988, 
Greenhalgh et al., 1990); consistent with a lack of tumours in ras-infected c-fos 
knockout mice (Saez et al., 1995). Bi-genic HK1.ras1276/fos mice exhibited co-
operation during papillomatogenesis but instead of malignancy, this model 
produced persistent papillomas with no sign of regression (Greenhalgh et al., 
1993c); possibly due to elevated p53/p21 (Macdonald et al., 2014). However, the 
lack of spontaneous tumour progression exhibited by HK1.ras1276/fos papillomas 
(Greenhalgh et al., 1996) makes them ideal to study the requirements for 
malignant conversion.  
 
Previously, as reported by Greenhalgh et al., (1993c), mice from HK1.fos line 488 
crossed with HK1.ras lines 1205 exhibited a degree of co-operation resulting in 
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numerous tumours and this tumour burden was deemed far too excessive for UK 
animal experimentation. Fortunately, the majority of mice from HK1.fos488 bred 
with HK1.ras1276 survived, and co-operation typically produced bi-lateral benign 
squamous papillomas on both ears regardless of the wound promotion stimulus, 
together with increased skin hyperplasia and hyperkeratosis giving a scruffy 
appearance. Therefore, inducible ROCKer activation was assessed in 
HK1.ras1276/HK1.fos transgenic mice to study this tri-genic synergism and to 
compare these tri-genic mice with two tri-genic (PTEN models) where the 
K14.cre/lsl.ROCKer line was employed (below). 
 
3.7.1 ROCK2 co-operates with HK1.ras/fos to elicit malignant 
progression 
 
In repeat experiments, 6-7 week old K14.cre/lsl.ROCKer/ras1276/fos mice (cohorts 
of 10) were treated with RU486 for 1 week to ablate the stop cassette, and 
express ROCKer in all epidermal layers and hair follicles, then, activated by 
treatment with 4-HT 3 times per week. Appropriate control cohorts (5 per 
genotype): HK1.ras1276/fos received 4-HT treatment without RU486, or RU486 and 
ethanol alone for control K14.cre/lsl.ROCKer/ras1276/fos were included. At 13 
weeks of continuous 4-HT treatment, K14.cre/lsl.ROCKer/ras1276/fos mice exhibited 
quite large tumours (figure 3.44a,b) in both ears. These tumours were keratotic, 
pale and relatively flattened compared to tri-genic ROCK/ras1205/Δ5PTENhet 
tumours (below) that appeared more rounded and red. The increased keratosis 
reflected alterations in differentiation elicited by ROCK2 and fos co-operation 
(above). However, these tumours approached the Home Office UK limits, 
therefore these mice were not maintained for periods longer than 16 weeks. In 
contrast, all sibling control groups of 4-HT-treated HK1.ras1276/fos (figure 3.44c,d) 
and RU486-treated/4-HT-untreated K14.cre/lsl.ROCKer/ras1276/fos (figure 3.44e,f) 
mice displayed mainly thickened ears at this stage with some showing the early 
formation of smaller keratotic tumours, typical of previous HK1.ras1276/fos at three 
months (Greenhalgh et al., 1993c).  
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Figure 3.44 Phenotypes of K14.cre/lsl.ROCK
er
/ras
1276
/fos transgenic mice at 13 weeks. (a, b) 
RU486-/4-HT-treated tri-genic ROCK/ras
1276
/fos mice exhibit large tumours with a keratotic 
appearance. (c, d) 4-HT-treated HK1.ras
1276
/fos and (e, f) RU486-treated/4-HT-untreated 
K14.cre/lsl.ROCK
er
/ras
1276
/fos mice appear to show the formation of early keratotic tumours.  
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Interestingly, as shown in figure 3.45, K14.cre/lsl.ROCKer/ras1276/fos 
histopathology often comprised a mixed histotypes of both papilloma and well-
differentiated carcinoma, and also showed that an epidermal nest of more 
aggressive SCC (figure 3.45a - arrow) had begun to infiltrate the dermal areas. 
This suggests that ROCK2 not only induced malignant conversion in the context of 
a late stage ras1276/fos papilloma, but possibly has begun to accelerate invasion 
and malignant progression from wdSCC to SCC (figure 3.45a). Moreover, at 
higher magnification, in these SCC malignant areas, the tissue architecture 
became disoriented, with gaps between the tumour keratinocyte populations, 
giving a sponge-like feature (figure 3.45b). This may reflect a failure in cell-cell 
adhesion as these keratinocytes became increasingly mobile and invasive, or 
speculatively, this feature may possibly relate to brittle nature of these tumours 
due to increased ROCK-mediated stiffness (Samuel et al., 2011), as it was 
noticed, anecdotally, that these tumour sections were oddly prone to ripping during 
the H&E histology processing (yet, not to the same degree as observed in the final 
model of ROCK/ras1205/Δ5PTENhet pdSCCs – below). At this time, bi-genic 
HK1.ras1276/fos histopathology remained as that of benign papillomas that 
exhibited well-ordered differentiation under higher magnification (figure 3.45c-f), 
with expanded epidermal layers given the ras roles in proliferation and fos 
associated with differentiation. 
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Figure 3.45 Histopathology of K14.cre/lsl.ROCK
er
/ras
1276
/fos and HK1.ras
1276
/fos tumours at 13 
weeks. (a) RU486-/4-HT-treated tri-genic ROCK/ras
1276
/fos epidermis exhibits a mixed histotype of 
papilloma and wdSCC with nests of more aggressive SCC (arrows). (b) At higher magnification, 
RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/ras
1276
/fos carcinoma shows an increasingly disorganised 
basal layer with sponge-like gaps appearing between cells. (c) Low and (d) higher magnification of 
4-HT-treated HK1.ras
1276
/fos papilloma histotypes show an organised basal layer. (e) Low and (f) 
higher magnification of RU486-treated/4-HT-untreated K14.cre/lsl.ROCK
er
/ras
1276
/fos epidermis 
also exhibit a similar organised benign papilloma histotypes. (Scale bar: 100µm in a,c,e; 50µm in 
b,d,f). 
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3.7.2 Expression of differentiation markers in tri-genic 
ROCK/ras1276/fos 
 
Tumour biopsies were routinely analysed for the expression of the early 
differentiation marker, keratin K1 to confirm the malignant conversion and /or 
assess what stage this tri-genic co-operation had achieved, together with keratin 
K6 the standard epidermal hyperproliferation marker. As shown in figure 3.46a, K1 
(green) expression was reduced upon malignant conversion and the retained K1 
expression in tri-genic ROCK/ras1276/fos papilloma gradually disappeared (figure 
3.46a – box) as tri-genic ROCK/ras1276/fos wdSCCs achieved a more aggressive 
SCC malignancy (figure 3.46b). In contrast, K1 expression remained ordered and 
was expressed normally in the supra-basal layers of HK1.ras1276/fos benign 
papilloma histotypes (figure 3.46c) showing that differentiation remained relatively 
undisturbed in this benign tumour context. Analysis of K6 in RU486-/4-HT-treated 
K14.cre/lsl.ROCKer/ras1276/fos mixed tumour histotype demonstrated a uniform 
expression in all epidermal layers (figure 3.46d) showing that ras/fos signalling 
returned expression of this hyperproliferation keratin. Control HK1.ras1276/fos 
papillomas also showed strong K6 expression throughout epidermal keratinocytes 
(figure 3.46e).  
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Figure 3.46 Immunofluorescence analysis of K1/K14 and K6/K14 expression in RU486-/4-HT-
treated K14.cre/lsl.ROCK
er
/ras
1276
/fos tumours at 13 weeks. (a) K14.cre/lsl.ROCK
er
/ras
1276
/fos 
tumours display K1 expression which is being lost on progression from wdSCC to aggressive SCC 
(box). (b) At higher magnification, the SCC area shows complete loss of K1 expression. (c) 4-HT-
treated HK1.ras
1276
/fos papillomas show strong K1 expression in the supra-basal layers consistent 
with a typical benign papilloma histotype. (d) Strong and uniform K6 expression in all epidermal 
layers appears in K14.cre/lsl.ROCK
er
/ras
1276
/fos mixed histotype and (e) HK1.ras
1276
/fos papilloma. 
(Scale bar: 100µm). 
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3.7.3 Expression of p53 and p21 in tri-genic ROCK/ras1276/fos mice 
 
As a routine part of tumour analysis in this model, the expression profiles of 
tumour suppressor genes, p53 and p21 were analysed in 
K14.cre/lsl.ROCKer/ras1276/fos histotypes. It was anticipated that p53 expression 
would be depleted consistent with malignant progression in tri-genic 
ROCKer/ras1276/fos histotypes; although in a similar approach, large 
HK1.fos/Δ5PTENflx tumours exhibited unexpectedly high levels of p53 and this 
was the first indications that fos/Δ5PTENflx tumours had progressed to 
keratoacanthoma and not SCC (Yao et al., 2008). As shown in figure 3.47a, 
composite micrographs of tri-genic ROCK/ras1276/fos mixed tumours showed that 
the protective, high level p53 expression appearing in all epidermal compartments 
of the papilloma histotypes (as determined in K1 analysis of serial sections), had 
gradually decreased and became lost in the areas of wdSCC or SCC nests 
histotype (figure 3.47a - box); as clearly demonstrated at higher magnification 
(figure 3.47b). In contrast, HK1.ras1276/fos papilloma demonstrated a strong 
expression of p53 in all epidermal layers (figure 3.47c) which is consistent with 
their lack of spontaneous progression to malignancy. 
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Figure 3.47 IHC analysis of p53 expression in malignant RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
/ras
1276
/fos histotypes. (a) Composite micrograph shows p53 expression fading 
from pre-malignant to malignant areas. (b) High magnification of malignant area shows expression 
of p53 becoming gradually lost. (c) Benign papilloma of 4-HT-treated HK1.ras
1276
/fos histotype 
exhibit elevated p53 expression. (Scale bar: a: 150µm; b-c: 100µm). 
 
 
 
 
 
 
 
 
 
 
Chapter 3  184 
 
Analysis of p21 expression, normally considered a downstream effector of p53, 
proved to be more interesting, as its expression can be either dependent or 
independent of p53 (Ng et al., 1999). Previously, persistent p21 expression in the 
basal layer was shown to be a significant response to p53 loss in tri-genic 
ras1276/fos/Δ5PTENflx models (Macdonald et al., 2014), although not to the high 
levels observed in papillomas on cessation of 4-HT in bi-genic ROCK/ras1205 mice 
(above). Here, in this IHC analysis, whilst p53 expression became reduced and 
eventually disappeared during malignant progression, p21 expression remained 
persistent in both papillomas and carcinomas of tri-genic ROCK/ras1276/fos mixed 
histotypes (figure 3.48a). At higher magnification, persistent p21 expression was 
still observed in p53/K1 negative areas of wdSCC and SCC nests (figure 3.48b).  
 
In a subtle contrast, in HK1.ras1276/fos papillomas, p21 expression became 
elevated (figure 3.48c) along with strong p53 expression in all supra-basal layers, 
however p21 expression was often reduced in the basal layer. This would be 
consistent with a reduced level of differentiation exerted by ras1276/fos co-operation 
as p21 was associated with increased differentiation (Topley et al., 1999, Devgan 
et al., 2006) as observed in bi-genic fos/Δ5PTENflx mice (Yao et al., 2008) and this 
also suggests that, as found for previous tri-genic ras1276/fos/Δ5PTENflx tumours, 
p21 expression becomes basal and protective once p53 has become reduced or 
lost in the basal layer (Macdonald et al., 2014). This feature of elevated p21 levels 
following conversion may also contribute to the predominance of wdSCCs and 
limited progression. This may also be due to the lack of p-AKT1 observed in the 
tri-genic ROCK/ras1276/fos pathway (below); and which became a recurrent theme 
in this ROCK2 mediated progression mechanism. Thus, these results indicate that 
upon malignant progression in tri-genic ROCK/ras1276/fos synergism, p53 
expression became lost whilst p21 levels persisted. 
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Figure 3.48 IHC Analysis of p21 expression in RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/ras
1276
/fos 
malignant histotypes. (a) Composite micrograph shows strong and elevated p21 expression. (b) 
High magnification of malignant area showing p21 expression that remained persistent in both 
nucleus and cytoplasm. (c) Benign papilloma of 4-HT-treated HK1.ras
1276
/fos histotype exhibits a 
delayed, supra-basal p21 expression. (Scale bar: a: 150µm; b-c: 100µm). 
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Next, p-AKT1 expression was analysed in K14.cre/lsl.ROCKer/ras1276/fos using 
immunofluorescence. Previously, in bi-genic fos/Δ5PTENflx models (Yao et al., 
2008), it was theorised that compensatory p53 and p21 expression inhibited AKT 
activity and in tri-genic ras1276/fos/PTENflx models (Macdonald et al., 2014), loss of 
p53 expression may have contributed to the persistence of p21 in order to combat 
the threat of activated AKT (Macdonald et al., 2014, Greenhalgh, – manuscript in 
preparation). Hence, to assess the role of PTEN/AKT signalling in this context, the 
expression of activated AKT1 and AKT2 were assessed. 
 
In K14.cre/lsl.ROCKer/ras1276/fos epidermis and tumours, p-AKT2 was not 
expressed (not shown) which is again consistent with the earlier finding that p-
AKT2 was not expressed in bi-genic ROCK/Δ5PTENflx hyperplasia (above). 
However interestingly, as shown in figure 3.49(a,b), little to no expression of p-
AKT1 appeared in K14.cre/lsl.ROCKer/ras1276/fos, even with loss of p53. In addition, 
p-AKT1 was not detectable in HK1.ras1276/fos benign papilloma (figure 3.49c) 
consistent with strong p53/p21 expression profiles that halted the p-AKT1 activities 
in bi-genic fos/Δ5PTENflx mice (Yao et al., 2008). Thus, this finding indicates that 
malignancy in K14.cre/lsl.ROCKer/ras1276/fos does not appear to involve the p-AKT 
signalling pathway. This was assessed again (below) to compare with the previous 
study by Macdonald et al., (2014), where expression of p-AKT, in theory, was 
mediated by loss of exon5 PTEN in ras1276/fos/Δ5PTENflx models and this helped 
drive malignant progression. 
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Figure 3.49 Immunofluorescence analysis of p-AKT1 expression in RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
/ras
1276
/fos malignant histotypes. (a) Lack of p-AKT1 expression is displayed in 
a composite micrograph of K14.cre/lsl.ROCK
er
/ras
1276
/fos mixed papilloma and wdSCC histotypes. 
(b) Little to no p-AKT1 expression is seen in high magnification of K14.cre/lsl.ROCK
er
/ras
1276
/fos 
wdSCC histotype. (c) 4-HT-treated HK1.ras
1276
/fos benign papilloma histotype p-AKT1 expression 
is undetectable perhaps due to high p53/p21 expression profiles. (Scale bar: a: 150µm; b: 50µm; c: 
100µm). 
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3.7.4 BrdU-labelling of tri-genic ROCK/ras1276/fos tumours 
 
Analysis of cell proliferation rates was carried out using BrdU-labelling. As shown 
in figure 3.50, RU486-/4-HT-treated K14.cre/lsl.ROCKer/ras1276/fos wdSCCs/SCCs 
possessed higher cell proliferation rates (69.5%, figure 3.50a) compared to bi-
genic ras1276/fos papillomas (4-HT-treated and 4-HT-untreated HK1.ras1276/fos 
cohorts: 37.5% (figure 3.50b) and 35.6%; RU486-treated/4-HT-untreated 
K14.cre/lsl.ROCKer/ras1276/fos 38.6%). These findings demonstrate that as tri-
genic ROCK/ras1276/fos undergo malignant progression, higher cell proliferation 
rates were recorded in comparison to bi-genic ras1276/fos synergism which still 
remained benign papillomas. IFC analysis showed that the increased numbers in 
BrdU-labelled keratinocytes was not only confined to basal layer but also 
appeared in the supra-basal layer. Furthermore, this significant increase in 
proliferation rates in K14.cre/lsl.ROCKer/ras1276/fos malignancy corresponds to loss 
of p53 expression (figure 3.47b). 
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Figure 3.50 BrdU-labelling of tri-genic ROCK/ras
1276
/fos carcinogenesis. Graph displays increased 
cell proliferation activity in RU486-/4-HT-treated K14.ROCK
er
/ras
1276
/fos wdSCC/SCC compared to 
bi-genic ras
1276
/fos papillomas. (a,b,c,d : Significantly difference between 
K14.cre/lsl.ROCK
er
/ras
1276
/fos (+ 4-HT) and all transgenic cohorts; p<0.05).  
(a) RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/ras
1276
/fos wdSCC histotype show high BrdU-labelling 
compared to (b) low BrdU-labelling in 4-HT-treated HK1.ras
1276
/fos benign papilloma histotype. 
(Scale: 50µm). 
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3.7.5 Summary 
 
Collectively, this tri-genic synergism of K14.cre/lsl.ROCKer/ras1276/fos produced 
conversion to carcinoma in 100% of animals. These findings indicate that the 
consequence of activated ROCK expression in co-operation with ras1276/fos is to 
achieve malignant transformation and progression; whereas tumours in bi-genic 
ROCK/fos (or HK1.ras1276/fos) mice remained benign papillomas and 
ROCK/ras1276 mice exhibited hyperplasia. Furthermore, this study showed that 
K14.cre/lsl.ROCKer/ras1276/fos tumours produced a mixed histotype of papilloma 
and wdSCC/SCC by 13-14 weeks, as confirmed by loss of keratin K1 expression 
in the SCC histotype and consistent with p53 loss together with the significant 
increase in proliferation rates from Brdu-labelling analysis. However, this 
malignant histotype was mainly limited to a wdSCC with only nests of more 
aggressive SCC. This may have been due to the persistent p21 expression that 
still remained strong in all tri-genic ROCK/ras1276/fos tumour tissues, despite p53 
loss that limit or protect the tissue from further progression. Interestingly these 
tumours showed lack of p-AKT1 expression despite loss of p53 expression in the 
K14.cre/lsl.ROCKer/ras1276/fos carcinoma area (wdSCC progression to SCC). This 
may indicate that p-AKT1 was not involved in progression in this tri-genic 
ROCK/ras1276/fos model, an idea supported by the lack of p-AKT1 expression in 
HK1.ras1276/fos benign papillomas that may be due to strong p53/p21 expression 
profiles. Thus, this suggests that ROCK inhibitors may be a good idea for cancer 
treatment where ras/MAPK signalling drives tumour progression, rather than 
targeting anti p-AKT as these tumours still continue to progress even in the 
absence of p-AKT expression. 
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3.8 Co-operation of ROCK2, HK1.fos and 
K14.cre/Δ5PTENflx in transgenic mouse skin 
carcinogenesis 
 
In the bi-genic model, activated ROCK2 and fos oncogene co-operation resulted in 
highly keratotic, benign papilloma formation but unlike bi-genic ROCK/ras1205, no 
conversion was observed. Nonetheless, these data revealed a novel co-operation 
between ROCK and fos signalling deregulation, but now in the early stages of 
carcinogenesis where ROCK, being downstream of ras may substitute for its 
initiation role. In addition to this finding, which appears to be the first to describe 
such early roles, the previous sections also showed that ROCK2-mediated 
carcinogenesis in a bi-genic cohort required additional events, such as both rasHa 
for initiation and then wounding or constitutive fos-mediated promotion to achieve 
highly keratotic papillomas. This was also anticipated for co-operation with 
Δ5PTENflx mutation and subsequent loss of p-AKT regulation; but this was not the 
case as very little synergism was observed in K14.cre/lsl.ROCKer/Δ5PTENflx 
cohorts. Hence, the co-operation to achieve even a benign tumour by ROCK2 
activation appeared to be specific to deregulation of the MAPK pathway and the 
lack of p-AKT expression in tri-genic ROCK/ras1276/fos mice (above) also 
suggested that the PTEN/PI3K/AKT pathway was not involved in ROCK2 
mediated tumour mechanisms. This seemed unlikely, and instead it may be that 
the appropriate contexts were not supplied in the K14.cre/lsl.ROCKer/Δ5PTENflx, 
either due to a similarity in oncogenic insults resulting in redundancies or 
compensatory responses such as p53/p21 expression. Alternatively, the roles for 
PTEN mutation may have quite different outcomes depending upon context, as 
when introduced into the HK1.fos model (Yao et al., 2008), keratoacanthomas 
were produced giving a less aggressive scenario than that observed following TPA 
promotion (c-fos activated) of HK1.ras1276/Δ5PTENflx cohorts which gave pdSCCs 
(Yao et al., 2006).  
 
The co-operation between HK1.fos and inactivation of PTEN mediated AKT 
regulation following topical RU486 treatment (K14.cre/Δ5PTENflx) had resulted in 
keratoacanthoma (KA) formation (Yao et al., 2008). In this context, no evidence of 
malignancy was recorded due to sudden compensatory p53 and p21 expression 
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that diverted prolifertive papilloma keratinocytes into a dead-end programme of 
terminal differentiation; resulting in huge amounts of keratosis and classic KA 
formation (Yao et al., 2008). Co-operation between K14.cre/lsl.ROCKer and 
Δ5PTENflx was also implicated in an increased degree of epidermal differentiation 
instead of tumour formation, as demonstrated by an anomalous lack of K6 
expression and the appearance of K1 in low calcium culture conditions. In this 
instance even with the promotion from wounding, their synergism appeared almost 
redundant; suggesting some similar functions in epidermal homeostasis.  
 
Thus, given this background, generation of these 
K14.cre/lsl.ROCKer/fos/Δ5PTENflx cohorts in essence to assess whether additional 
mutation events in ROCK2 signalling would change the outcome from KA to SCC, 
and if so, would allow investigation of how (and when) the protective p53/p21 
expression was circumvented. Alternatively, in the context of papillomatogenesis 
as in ROCK/fos signalling, so, would this tri-genic ROCK/fos/Δ5PTENflx synergism 
remain redundant and still produce papillomas; yet to be determined via p53/p21 
profiles and AKT status. 
 
3.8.1 ROCK2 co-operates with HK1.fos/5PTENflx to produce 
malignant progression to SCC not keratoacanthomas. 
 
To analyse tri-genic ROCK/fos/Δ5PTENflx synergism in multistage carcinogenesis, 
these cohorts exploited the RU486-inducible K14.cre/lsl.ROCKer transgenic line in 
order to hit the same keratinocyte populations as that of Δ5PTENflx driven by 
K14.creP promoter in transgenic mice expressing activated fos (HK1.fos). In 
repeat experiments, 10 individual K14.cre/lsl.ROCKer/fos/Δ5PTENflx transgenic 
mice at 6-7 week old were treated with RU486 in the week 1 to ablate the stop 
cassette to express lsl.ROCKer transgene and ablate exon5 PTEN to induce loss of 
AKT regulation (Δ5PTENflx). Then, routine 4-HT treatments, 3x per week 
maintained an activated ROCKer transgene with appropriate controls: 
K14.cre/fos/Δ5PTENflx (n= 5) receiving RU486 and 4-HT whilst 
K14.cre/lsl.ROCKer/fos/Δ5PTENflx controls (n= 5) receiving RU486 alone.  
 
Excitingly, at only 9 weeks of 4-HT treatment, tri-genic 
K14.cre/lsl.ROCKer/fos/Δ5PTENflx mice had formed large tumours on both the 
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tagged and untagged ears as compared to control cohorts (figure 3.51a-g); a 
result again consistent with the promotion stimulus received from HK1.fos. The 
ears possessed a very thick keratotic phenotype but with a pale appearance 
(figure 3.51 a,b) and without the large keratin structures that typified KA formation 
(later) (figure 3.51g) (Yao et al., 2008). At this time, both RU486-/4-HT-treated 
K14.cre/fos/Δ5PTENflx and RU486-treated/4-HT-untreated 
K14.cre/lsl.ROCKer/fos/Δ5PTENflx control mice displayed thickened ears only, and 
possibly the early beginning that eventually develop into KAs (figure 3.51 c-f). 
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Figure 3.51 Phenotypes of K14.cre/lsl.ROCK
er
/fos/Δ5PTEN
flx transgenic mice at approximately 9 
weeks. (a, b) RU486-/4-HT-treated tri-genic ROCK/fos/Δ5PTEN
flx
 mice exhibit large tumours with 
keratotic appearance. (c, d) RU486-/4-HT-treated K14.cre/fos/Δ5PTEN
flx and (e, f) RU486-
treated/4-HT-untreated K14.cre/lsl.ROCK
er
/fos/Δ5PTEN
flx mice display thickened keratotic ears with 
early sign of KA formation; (g) But not the overt obvious KAs seen in older RU486-treated 
K14.cre/fos/Δ5PTEN
flx
. 
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Due to this rapid growth and tumour size, most K14.cre/lsl.ROCKer/fos/Δ5PTENflx 
mice underwent biopsy as early as 9 weeks. These phenotypes now suggest a 
significant co-operation that has bridged any gaps in carcinogenesis between tri-
genic ROCK/fos/Δ5PTENflx mice in terms of a massive degree of both proliferation 
and differentiation. Most importantly, the outcome was very different to the KAs 
exhibited in K14.cre/fos/Δ5PTENflx co-operation reported by Yao et al., (2008) and 
also the mechanism observed in tri-genic ROCK/ras1276/fos (above). In addition, 
the histopathology of K14.cre/lsl.ROCKer/fos/Δ5PTENflx tumours also reflected an 
antagonism between keratinocyte proliferation and differentiation that gave rise to 
a very confused differentiation pattern.  
 
At only 9 weeks of 4-HT treatment, a typical K14.cre/lsl.ROCKer/fos/Δ5PTENflx 
tumour showed a massive keratosis possibly associated with 
K14.cre/fos/Δ5PTENflx synergism (Yao et al., 2008) and /or bi-genic ROCK/fos co-
operation (above), but now all tumours exhibited malignant conversion to a 
wdSCC histotype. In addition, the benign areas comprised a mix of highly keratotic 
papilloma pathology (as determined by K1 expression) and carcinoma histotypes 
(figure 3.52a) as they possessed a very confused pattern of keratinocyte 
differentiation, with granular cells in the proliferative basal layer (most likely 
malignant keratinocytes in the upper layers, as demonstrated by differentiation and 
BrdU labelling - below) and this was similar to that early papillomatous KA 
histotypes exhibited by K14.cre/fos/Δ5PTENflx (Yao et al., 2008). This odd degree 
of anomalous differentiation gave a question to an initial impression that this 
wdSCC; as KAs and SCCs are often confused. However, the rapid nature of their 
growth, the increased areas of non-keratosis and the analysis of p53/p21 status 
below are consistent with malignant conversion to wdSCC, plus the appearance 
again of ripped sections (figure 3.52c – red arrow) and mitotic cells. 
 
At higher magnification (figure 3.52 b,c), while the layers of keratinocytes in these 
areas of wdSCC looked massively disorganised and the multiple layers of 
proliferative cells possessed patches of micro-acanthosis (typified by strands of K1 
expression; below (figure 3.53)) and micro-cysts (figure 3.52b,c – black arrows), 
with some intercellular gaps between the malignant keratinocytes, these areas 
showed a rip in this tissue (figure 3.52c – red arrow). A similar disorganised 
histopathology was also exhibited by K14.cre/fos/Δ5PTENflx keratotic papillomas, 
here with more significant hyperkeratosis and pre-mature differentiation that 
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offered cornified cells embedded in very prominent granular layers and growth of 
micro-cysts in the epidermal layers (figure 3.52d,e - arrows). However, these pre-
malignant histotypes possessed fewer proliferative layers and were devoid of 
invasive areas, mitotic figures, the unique intercellular gap and possessed clear 
differences in terms of differentiation markers. 
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Figure 3.52 Histotypes of K14.cre/lsl.ROCK
er
/fos/Δ5PTEN
flx 
biopsies at 9 weeks. (a) RU486-/4-HT-
treated K14.cre/lsl.ROCK
er
/fos/Δ5PTEN
flx 
biopsy shows mixed histotypes of papilloma and SCC 
with massive keratosis. (b, c) At higher magnification, tri-genic ROCK/fos/Δ5PTEN
flx
 areas of both 
wdSCC and SCC exhibit highly disorganisation in epidermal architecture, prominent intercellular 
gaps (red arrow) and appearance of micro-cysts (black arrows). (d) RU486-treated/4-HT-untreated 
K14.cre/lsl.ROCK
er
/fos/Δ5PTEN
flx and (e) RU486-/4-HT-treated K14.cre/fos/Δ5PTEN
flx
 biopsies 
display hyperkeratotic papilloma histotypes with irregular differentiation giving rise to micro-cysts 
formation (arrows). (Scale bar: 150µm in a; 50µm in b,c; 100µm in d,e). 
a 
b c 
d e 
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3.8.2 Expression of tumour progression marker keratin K1 in tri-
genic ROCK/fos/Δ5PTENflx carcinogenesis 
 
The loss of keratin K1 has been an essential indicator of tumour progression to 
malignancy and progression to aggressive SCC in this model. In addition, in 
previous K14.cre/fos/Δ5PTENflx studies (Yao et al., 2008), K1 expression was 
employed in a more conventional manner and used as an indicator of keratinocyte 
differentiation. Indeed, the very odd K1 expression in the basal layers of pre-KA 
papillomas was amongst the first indications that the sudden appearance of 
compensatory p53 and p21 in K14.cre/fos/Δ5PTENflx KAs (Yao et al., 2008) led to 
a highly confused state of premature differentiation or supra-basal proliferation, as 
now also observed histologically in K14.cre/lsl.ROCKer/fos/Δ5PTENflx tumours.  
 
Therefore, whilst immunofluorescence analysis of keratin K1 was mainly 
performed to confirm progression of K14.cre/lsl.ROCKer/fos/PTENflx wdSCC 
histotypes (figure 3.53), it was recognised that in certain instances, K1 was 
expressed in an anomalous fashion; e.g. in the microcysts that formed in response 
to these anomalous differentiation signals. This is shown in figure 3.53a, where 
reduced K1 (green) expression was demonstrated in tri-genic 
ROCK/fos/Δ5PTENflx mixed histotypes upon transformation of keratotic papillomas 
to wdSCC and subsequently to more aggressive SCC. However, consequently 
here in these K14.cre/lsl.ROCKer/fos/Δ5PTENflx wdSCC/SCC tumours, at higher 
magnification, K1 expression became lost upon progression but could remain in 
patches of anomalous differentiation exhibiting the normal intense green staining 
in the areas of microcysts (figure 3.53b). These islands were often surrounded by 
yellow due to reduced K1 in wdSCC or by red in SCC based on the keratin K14 
(red) counterstain. Thus, this staining pattern again confirms malignant coversion 
and progression to wdSCC and SCC due to the tri-genic synergism. However, this 
staining pattern also possessed similarities to the premature differentiation that 
switched progression to KA (not SCC) in bi-genic fos/Δ5PTENflx shown by Yao et 
al., (2008) and thus, prompted analysis of markers of late stage differentiation: 
filaggrin and loricrin in this study. Indeed in the 4-HT-treated 
K14.cre/fos/Δ5PTENflx keratotic papillomas, all controls exhibited strong K1 
expression that remained intact and uniform in the supra-basal layer (figure 3.53 
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c), similar to K1 expression in RU486-treated/4-HT-untreated 
K14.cre/lsl.ROCKer/fos/Δ5PTENflx histotype (not shown). Note that this strong 
supra-basal K1 expression in control bi-genic fos/Δ5PTENflx was displayed at 9 
weeks and it was shown in the previous study (Yao et al., 2008) that K1 
expression appeared in the basal layer of later KAs in bi-genic fos/Δ5PTENflx. In 
addition, in these tri-genic tumours, the typical K6 expression profiles were 
restored and strong K6 expression now appeared in uniform throughout the 
epidermal compartments in RU486-/4-HT-treated 
K14.cre/lsl.ROCKer/fos/Δ5PTENflx and K14.cre/fos/Δ5PTENflx tumours (figure 
3.53d,e). 
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Figure 3.53 Immunofluorescence analysis of K1/K14 and K6/K14 expression in 
K14.cre/lsl.ROCK
er
/fos/Δ5PTEN
flx
 carcinogenesis. (a) Tri-genic ROCK/fos/Δ5PTEN
flx 
tumours 
exhibit reduced K1 (green) expression that became gradually lost together with elevated yellow 
colour upon progression to SCC. (b) Higher magnification of a wdSCC/SCC area of 
K14.cre/lsl.ROCK
er
/fos/Δ5PTEN
flx
 has a band of K1 expression in an overtly K1 negative area 
(arrow) and an oval expression pattern highlighting a microcyst (box). (c) RU486-/4-HT-treated 
K14.cre/fos/Δ5PTEN
flx 
keratotic papilloma showed strong K1 expression in supra-basal layers. (d) 
RU486-/4-HT-treated of K14.cre/lsl.ROCK
er
/fos/Δ5PTEN
flx
 and (e) K14.cre/fos/Δ5PTEN
flx
 display 
K6 expression in all epidermal compartments. (Scale bar: 100µm in a,c,d,e; 50µm in b). 
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3.8.3 Expression of late differentiation markers filaggrin and 
loricrin in tri-genic ROCK/fos/Δ5PTEN flx carcinogenesis 
 
To investigate the status of later markers of terminal differentiation, a double-
labelled IFC analysis of filaggrin and loricrin was performed (Yao et al., 2008). 
Typically expression of loricrin appears in the granular layer and is one of the most 
common proteins in these upper layers (Hohl et al., 1991). Whilst filaggrin 
migrates from granular layer to the upper cornified layer (Rothnagel and Steinert, 
1990, Steven et al., 1990). It is worth noting that, here, both loricrin and filaggrin 
are regulated by c-fos possessing three AP1 binding sites (Yuspa, 1994, Mehic et 
al., 2005) and both proteins are essential for epidermal barrier maintenance. 
Indeed, reduction in the levels of filaggrin has been shown to compromise the 
cornified layers and in some individuals, this leads to eczema (McLean, 2011). 
Typically in skin carcinogenesis, as in most malignancies, there is a trend towards 
less differentiation and thus, loss of both filaggrin and loricrin expression is a 
common event and for filaggrin expression to be lost quite early in both 
hyperplasia and papillomas (Yao et al., 2006, 2008). Since both 
K14.cre/lsl.ROCKer/fos/Δ5PTENflx and K14.cre/fos/Δ5PTENflx produced keratotic 
papillomas with a very odd confused keratinocyte differentiation histotypes, the 
expression of loricrin and filaggrin was investigated in this tri-genic 
ROCK/fos/Δ5PTENflx tumour progression mechanism and compared to the 
p53/p21 and p-AKT expression profiles.  
 
K14.cre/lsl.ROCKer/fos/Δ5PTENflx wdSCC/SCC histotypes showed a complete loss 
of filaggrin expression (figure 3.54a), but had persisted in the earlier biopsies 
consistent with the degree of papilloma keratosis. The loss of filaggrin expression 
indicates less differentiation upon progression to malignancy in tri-genic 
ROCK/fos/Δ5PTENflx synergism and this contrasted to the KAs observed 
previously (Yao et al., 2008). Conversely, filaggrin expression in 
K14.cre/fos/Δ5PTENflx keratotic papilloma (early, pre-KA) histotype appeared 
strong in most supra-basal layers as opposed to being restricted to the granular 
layer; which again suggests premature differentiation (figure 3.54b). In 
comparison, filaggrin expression was confined to the upper granular layers in 
typical control cohorts; e.g. K14.cre/lsl.ROCKer/fos papilloma (figure 3.54c), 
HK1.fos hyperplasia (figure 3.54d), K14.cre/lsl.ROCKer/Δ5PTENflx papillomatous-
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like hyperplasia (figure 3.54e), K14.cre/Δ5PTENflx mild hyperplasia (figure 3.54f) 
and K14.cre/lsl.ROCKer hyperplasia (figure 3.54g). However, filaggrin was difficult 
to detect in normal ICR histotypes due to the thin nature of normal murine 
epidermis (figure 3.54h).  
 
These findings relating to filaggrin expression in controls (figure 3.54c-g) are 
consistent with limited tumour progression as mentioned in earlier results; which is 
mostly due to p53/p21 responses. Of note, these new findings demonstrated that 
filaggrin expression in activated ROCK hyperplasia (figure 3.54g) appeared 
stronger than in Δ5PTENflx hyperplasia (figure 3.54f), which is again consistent 
with ROCK roles and links in the barrier of an epidermis. As mentioned earlier, the 
literature clearly shows that ROCK2 provides the tensile strength to epidermis 
(Samuel et al., 2011). 
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Figure 3.54 Immunofluorescence analysis of filaggrin/K14 expression in RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
/fos/Δ5PTEN
flx
 tumours. (a) Filaggin expression disappeared upon malignant 
progression in tri-genic ROCK/fos/Δ5PTEN
flx 
wdSCC/SCC. (b) RU486-/4-HT-treated 
K14.cre/fos/Δ5PTEN
flx 
early KA exhibits high level of filaggrin expression in supra-basal layers 
indicating active premature differentiation.  (c) Filaggrin expression remained persisted in RU486-
/4-HT-treated K14.cre/lsl.ROCK
er
/fos papilloma, (d) 4-HT-treated HK1.fos hyperplasia, (e) RU486-
/4-HT-treated K14.cre/lsl.ROCK
er
/Δ5PTEN
flx
 papillomatous-like hyperplasia, (f) RU486-/4-HT-
treated K14.cre/Δ5PTEN
flx
 hyperplasia, and (g) RU486-/4-HT-treated K14.cre/lsl.ROCK
er
 
hyperplasia in granular and cornified layers. (h) Filaggrin was hardly detected in normal non-
transgenic ICR histotype due to layer being one cell thick. (Scale bar: a,b,d-h: 100µm; c: 50µm). 
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Analysis of loricrin protein in K14.cre/lsl.ROCKer/fos/Δ5PTENflx tumours also 
demonstrated a lower level of expression compared to age-matched 
K14.cre/fos/Δ5PTENflx control cohorts in which it disappeared upon malignant 
conversion prior to progression to SCC (figure 3.55a). This result was typical of 
progression in this model and contrasted to the premature loricrin expression 
found in the supra-basal layers of K14.cre/fos/Δ5PTENflx keratotic papilloma 
(figure 3.55b). This would support the idea that initially, in pre-malignant stages 
where both p53/p21 are expressed, the overlay of bi-genic ROCK/fos signalling 
inducing proliferation to the differentiation stimulus, plus ROCK/Δ5PTENflx gave 
rise to this confused keratinocyte differentiation pattern. Hence, in highly keratotic 
papillomas in the context of tri-genic K14.cre/lsl.ROCKer/fos/Δ5PTENflx, this 
resulted in tumours prone to conversion due to additional ROCK2 activities. 
Whereas in the context of bi-genic K14.cre/fos/Δ5PTENflx tumours the continuous 
p53/p21 response led to a stall in progression, where continuous papilloma 
proliferation now gives rise to the excess differentiation leading to the keratosis of 
classic KAs. In control mice, loricrin expression remained confined to an expanded 
granular layer in cohorts of K14.cre/lsl.ROCKer/fos papilloma (figure 3.55c). Whilst 
in HK1.fos hyperplasia (figure 3.55d), K14.cre/lsl.ROCKer/Δ5PTENflx 
papillomatous-like hyperplasia (figure 3.55e), K14.cre/Δ5PTENflx mild hyperplasia 
(figure 3.55f) and K14.cre/lsl.ROCKer hyperplasia (figure 3.55g), loricrin remained 
restricted to a relatively normal granular layer which coincided with their lack of 
tumour progression. As found similar to filaggrin (above), loricrin was also difficult 
to detect in a normal epidermal histotype of this non-transgenic ICR mice (figure 
3.55h). 
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Figure 3.55 Immunofluorescence analysis of loricrin/K14 expression in RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
/fos/Δ5PTEN
flx
 tumours. (a) Loricrin expression appears at a low level and is 
gradually lost in tri-genic ROCK/fos/Δ5PTEN
flx 
SCC. (b) RU486-/4-HT-treated 
K14.cre/fos/Δ5PTEN
flx 
keratotic papilloma exhibits a high level of loricrin in the supra-basal layer 
indicating atypical differentiation. (c) Loricrin expression remained confined in RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
/fos papilloma, (d) 4-HT-treated HK1.fos hyperplasia, (e) RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
/Δ5PTEN
flx
 hyperplasia; (f) RU486-/4-HT-treated K14.cre/Δ5PTEN
flx
 mild 
hyperplasia and (g) RU486-/4-HT-treated K14.cre/lsl.ROCK
er
 hyperplasia to the granular layer, 
indicative of limited tumour progression. (h) Loricrin was not detectable in normal, thin ICR 
epidermal layer (Scale bar: a,b,d-h: 100µm; c: 50µm).  
 
Chapter 3  206 
 
3.8.4 Expression of p53 and p21 in tri-genic ROCK/fos/Δ5PTENflx 
tumours 
 
The expression profiles of p53 and p21 tumour suppressor genes were analysed 
to determine their status in K14.cre/lsl.ROCKer/fos/Δ5PTENflx tumours by IHC 
analysis. Since K14.cre/lsl.ROCKer/fos/Δ5PTENflx tumours achieved malignant 
progression as confirmed by loss of K1, filaggrin and loricrin markers, it was 
expected that at least p53 expression may be down regulated as observed in other 
malignant histotypes from earlier models. Whereas in the K14.cre/fos/Δ5PTENflx 
model, both p53 and p21 were not expressed in early hyperplasia, their expression 
became elevated and appeared in basal layers in the overt KAs following GSK3β 
inactivation (Yao et al., 2008). Interestingly, p53 expression, which was quite 
strong in the K14.cre/lsl.ROCKer/fos/Δ5PTENflx hyperplasia and keratotic 
papillomas, faded and became lost upon malignant progression (figure 3.56a). 
Furthermore, at higher magnification (figure 3.56b), p53 expression had 
completely disappeared on progression to K14.cre/lsl.ROCKer/fos/Δ5PTENflx SCCs. 
In contrast, a typical K14.cre/fos/Δ5PTENflx KA histotype showed strong and 
uniform p53 expression throughout the epidermal compartments (figure 3.56c). 
Again, it was noted that wdSCC and particularly SCC areas exhibited clear rips in 
the tumour tissue (figure 3.56a) suggesting a brittle nature possibly caused by 
ROCK2 mediated increased tissue stiffness and this was less prominent in the 
benign areas.  
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Figure 3.56 IHC analysis of p53 expression in RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
/fos/Δ5PTEN
flx 
tumours. (a) Composite micrograph shows diminishing p53 
expression in the late stage papilloma areas and faded in the wdSCC/SCC histotypes. (b) High 
magnification of K14.cre/lsl.ROCK
er
/fos/Δ5PTEN
flx
 SCC area (from box) exhibits complete loss of 
p53 expression. (c) RU486-/4-HT-treated K14.cre/fos/ΔPTEN
flx 
keratotic papilloma displays strong 
p53 expression in all epidermal layers. (Scale bar: a: 150µm; b: 50µm; c: 100µm). 
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While p53 expression reduced and disappeared as 
K14.cre/lsl.ROCKer/fos/Δ5PTENflx tumours became malignant, analysis of p21 
which is an effector of p53 function remained expressed (figure 3.57a). Not only 
was p21 expression persistent in the areas of keratin K1 loss (wdSCC/SCC 
histotype), p21 expression also appeared to increase based on the IHC staining 
upon p53 loss. This too was observed in tri-genic ROCK/ras1276/fos model (above) 
and also in tri-genic ras/fos/Δ5PTENflx study (Macdonald et al., 2014) suggesting 
that persistent p21 expression is a major response to p53 loss. At higher 
magnification in such overt and highly invasive SCC areas, p21 expression 
appeared cytoplasmic and peri-nuclear; and also began to fade particularly in the 
proliferative fingers of invasive basal layer SCC keratinocytes (figure 3.57b). Over 
careful analysis of repeated biopsies, serial sections showed that the areas of 
wdSCC possessed significant p21 expression and sometimes a reasonable 
amount of residual but supra-basal p53. This suggests that reduction of p21 
protection is a potential for further progression, and that this invasive mechanism 
was possibly enhanced by ROCK2 activation in conjunction with AKT activation; 
an idea clearly supported in the K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx model given 
the degree of progression to pdSCC histotypes observed (below).  
 
In contrast, comparison of aged-matched sibling controls 4-HT-treated 
K14.cre/fos/PTENflx or 4-HT-untreated K14.cre/lsl.ROCKer/fos/Δ5PTENflx keratotic 
papillomas displayed increasing levels of p21 expression which in much later overt 
KAs (Yao et al., 2008), showed intense and uniform p21 expression in all 
epidermal keratinocytes (figure 3.57c). The initial lack of p53 or p21 was observed 
in bi-genic ROCK/Δ5PTENflx mice (above) and previously in pre-neoplastic bi-
genic fos/Δ5PTENflx (Yao et al., 2008); and this p21 increase appeared to counter 
any Δ5PTENflx mediated AKT expression, also giving rise to patchy p-AKT1 
expression in bi-genic ROCK/Δ5PTENflx mice. Whilst in bi-genic fos/Δ5PTENflx 
mice, this persistent high level of p21 prevented progression to SCC and also 
limited keratinocyte proliferation alongside p53 in these fos/Δ5PTENflx tumours as 
determined by Brdu-labelling. 
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Figure 3.57 IHC analysis of p21 expression in RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
/fos/Δ5PTEN
flx 
tumours. (a) Composite micrograph shows that p21 expression 
remained intact in all epidermal compartments. (b) High magnification of more aggressive SCC 
area shows p21 expression is reduced and appears in a more cytoplasmic and peri-nuclear 
manner, and has begun to fade particularly in the epidermal basal layer. (c) RU486-/4-HT-treated 
K14.cre/fos/Δ5PTEN
flx
 keratotic papilloma exhibits strong and uniform p21 expression. (Scale bar: 
a: 150µm; b: 50µm; c: 100µm). 
 
 
 
 
 
 
 
 
 
 
Chapter 3  210 
 
3.8.5 BrdU-labelling of tri-genic ROCK/fos/Δ5PTENflx mice 
 
Next, cell proliferation activity was analysed by positive BrdU-labelling in epidermal 
cells of K14.cre/lsl.ROCKer/fos/Δ5PTENflx tumours. As shown in figure 3.58, 
RU486-/4-HT-treated K14.cre/lsl.ROCKer/fos/Δ5PTENflx wdSCC/SCC histotypes 
have significantly higher proliferation rates and higher BrdU-labelling that scattered 
throughout all epidermal layers (89.1%, figure 3.58a) than bi-genic fos/Δ5PTENflx 
keratotic papilloma histotypes (RU486-/4-HT-treated and RU486-treated/4-HT-
untreated K14.cre/fos/Δ5PTENflx cohorts: 34.1%, figure 3.58b and 34.7%; RU486-
treated/4-HT-untreated K14.cre/lsl.ROCKer/fos/Δ5PTENflx 32.1%). This finding is 
consistent with increased proliferation activity upon malignant progression in 
K14.cre/lsl.ROCKer/fos/Δ5PTENflx SCC coinciding with loss of filaggrin and loricrin, 
together with p53 loss. Moreover, this BrdU-labelling finding demonstrated a large 
difference between K14.cre/lsl.ROCKer/fos/Δ5PTENflx SCC and 
K14.cre/fos/Δ5PTENflx KA histotypes reported by Yao et al., (2008), where a much 
lower mitotic index in the KA histotypes due to strong expression of p53 and p21 
together with loricin and filaggrin was observed.  
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Figure 3.58 BrdU-labelling of RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/fos/Δ5PTEN
flx 
carcinogenesis. Graph displays high cell proliferation activity in tri-genic ROCK/fos/Δ5PTEN
flx 
tumours compared to bi-genic fos/Δ5PTEN
flx
 keratotic papillomas. (a,b,c,d : Significantly difference 
between K14.cre/lsl.ROCK
er
/fos/PTEN
flx 
(+ 4-HT) and each cohort; p<0.05).  
(a) RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/fos/Δ5PTEN
flx
 SCC histotype showed high BrdU-
labelling that scattered throughout epidermal layers, compared to (b) low levels of BrdU-labelled 
cells in RU486-/4-HT-treated bi-genic fos/Δ5PTEN
flx
 keratotic papilloma and the BrdU-labelling 
remained confined to basal layers. (Scale: 50µm). 
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3.8.6 Expression of p-AKT1 in tri-genic ROCK/fos/Δ5PTENflx 
tumours 
 
K14.cre/lsl.ROCKer/fos/Δ5PTENflx tumours were next analysed for AKT activation 
status since it is well known that PTEN acts as the inhibitory antagonist for AKT in 
the PTEN signalling pathway. Thus, it was logical to predict that AKT activation 
would be a significant contributor to tri-genic ROCK/fos/Δ5PTENflx carcinogenesis; 
as opposed to its absence in the tri-genic ROCK/ras1276/fos model (above). As 
shown in figure 3.59, double-labelled IFC analysis of p-AKT1 against a K14 
counterstain showed elevated levels of expression in 
K14.cre/lsl.ROCKer/fos/Δ5PTENflx SCCs compared to a complete lack of p-AKT1 
expression (strong p53/p21 expression) in the K14.cre/fos/Δ5PTENflx keratotic 
papilloma histotype (figure 3.59(a,b) versus c). However, this p-AKT expression 
profile remained quite patchy; and showed a low level of expression in the p53/p21 
positive areas of papilloma. Furthermore, in areas of high premature keratin K1 
expression, the (confused) micro-cysts also displayed p-AKT1 expression in their 
mini-suprabasal layers. This latter feature was consistent with the finding that 
normally AKT is activated in the supra-basal epidermis to halt p53-mediated 
apoptosis and maintain barrier function (Calautti et al., 2005). 
 
Hence, these data indicate that increasing p-AKT1 expression in tri-genic 
ROCK/fos/Δ5PTENflx carcinomas is possibly mediated by reduced p53/p21 
expression and this is consistent with increased proliferation rates from Brdu-
labelling data (figure 3.58); whereas the patchy areas of p-AKT1 expression may 
derive from residual p53 and strong p21 expression to induce differentiation. 
Further, in this study, following p53 loss, p21 expression appears to be increased 
in the basal layers of wdSCCs. This may explain why p-AKT1 remained essentially 
confined in supra-basal, until basal layer p21 expression faded in the SCCs. Thus, 
at this point, increased p-AKT1 expression may co-operate with ROCK2 roles in 
the later stages of carcinogenesis and this might drive malignant progression to 
give increased levels of SCC invasion; an idea that was again suggested by the 
tri-genic ROCK/ras1205/Δ5PTENhet model (below) which exhibited very rapid 
progression to pdSCCs in a matter of weeks. 
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Figure 3.59 Immunofluorescence analysis of p-AKT1 expression. (a,b) RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
/fos/Δ5PTEN
flx
 wdSCC/SCC histotypes show elevated p-AKT1 expression in 
both cytoplasm and nucleus. (c) RU486-/4-HT-treated K14.cre/fos/Δ5PTEN
flx 
keratotic papilloma 
displays a complete lack of p-AKT1 expression. (Scale bar: 100µm: a,c; 50µm: b). 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3  214 
 
3.8.7 Summary 
 
These data indicate that tri-genic ROCKer/fos/Δ5PTENflx synergism successfully 
converted papillomas to SCC as early as 9 weeks, and diverted tumourigenesis 
away from a KA outcome, back to the pathway outcome of a wdSCC and further 
progression to overt SCC. This result was similar to that found for additional rasHa 
activation in fos/Δ5PTENflx mice (Macdonald et al., 2014); although in 
ras/fos/Δ5PTENflx models, papillomatogenesis was more rapid and tumours were 
less keratotic. Here, in this current tri-genic model, malignant conversion was 
again consistent with the loss of K1 and p53 in all epidermal layers. This loss of 
p53 is likely to be the factor that prevented a KA outcome and progression thus 
switching back to carcinogenesis, suggesting that ROCK2 activation dictated the 
route of progression after keratotic papilloma formation, possibly due to its co-
operation with HK1.fos in papillomatogenesis as a substitute for rasHa activation. 
In this study, tri-genic ROCK/fos/Δ5PTENflx mice also displayed a persistent p21 
profile, and some indication of an increase in wdSCCs upon p53 loss; although not 
to the very intense levels observed following cessation of 4-HT in bi-genic 
ROCK/ras1205 carcinomas where massive p21 expression was associated with the 
outgrowth of benign papillomas. Further, in bi-genic ROCK/ras1205, p21 expression 
was lost on progression to pdSCCs and this feature began to appear in these tri-
genic ROCK/fos/Δ5PTENflx SCCs which exhibited reduced p21 that was lost in the 
basal layer. It is this loss of p21 in the basal layers which appeared to follow the 
complete loss of p53 in all epidermal layers that may reflect the appearance of 
elevated p-AKT1 expression and thus aid further tumour progression via co-
operation with the ROCK activation which is known to be highly associated in late 
stage of carcinogenesis (Croft et al., 2004, Samuel et al., 2011). On the other 
hand, one difference between the previous study of tri-genic ras/fos/Δ5PTENflx 
(Macdonald et al., 2014) and this current tri-genic ROCK/fos/Δ5PTENflx model was 
the continuation of the disturbed epidermal architecture that is a common feature 
in bi-genic fos/Δ5PTENflx which was noted in the tri-genic ROCK/fos/Δ5PTENflx 
tumours. 
 
Interestingly, as observed in both bi-genic fos/Δ5PTENflx and 4-HT-untreated 
K14.cre/lsl.ROCKer/fos/Δ5PTENflx tumour controls, the conflicting proliferation 
versus proliferation signals in the tri-genic ROCK/fos/Δ5PTENflx cohorts gave a 
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confused differentiation and little apoptosis. Hence, the default position for skin 
keratinocytes is not apoptosis but terminal differentiation to avoid progression from 
early stages if possible and in this study, highly keratotic papillomas were 
produced which resembled early KAs. Indeed, the main reason for a lack of KA 
formation in K14.cre/fos/PTENflx histotypes was because in the previous study 
(Yao et al., 2008), the mice were kept on procedure for 5 to 6 months for KAs to 
form; compared to this study where all mice were kept for just over 2 months. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3  216 
 
3.9 Analysis of the co-operation between ROCK2 and 
ras
Ha
 activation, and loss of PTEN regulation in 
transgenic mouse skin carcinogenesis 
 
In the previous sections, results in the K14.cre/PTENflx background demonstrated 
that 4-HT-activated ROCKer, together with loss of PTEN-mediated AKT regulation, 
showed little co-operation; with no evidence of tumour formation even after 7 
months. In these experiments, the ROCK2 transgenic lines (K14.cre/lsl.ROCKer 
and K14.ROCKer) instead displayed an altered epidermal differentiation in terms of 
keratin K6 and K1 expression, and possibly suggested a premature basal layer 
commitment to terminal differentiation, mediated by initial Δ5PTEN mutation and 
again altered by ROCK2 co-expression over time in the context of a hyperplastic 
epidermis. Moreover, this lack of tumours contrasted with K14.cre/PTENflx co-
operation with HK1.ras1276 which demonstrated papillomatogenesis and showed no 
sign of malignant conversion unless treated with TPA (to activate c-fos) (Yao et 
al., 2006), a result now consistent with malignant conversion observed in the tri-
genic HK1.ras/fos/Δ5PTENflx model (Macdonald et al., 2014). In comparison, co-
operation between ROCKer and HK1.ras line 1205 did achieve malignant 
conversion, and this appeared dependent upon the promotion stimulus received 
from wounding, similar to co-operation in HK1.ras line 1276, which required 
constitutive promotion from additional HK1.fos to achieve conversion (above). In 
all these previous models, the majority of mice exhibited well-differentiated SCCs 
with the occasional mix of more aggressive SCCs, and this was likely due to 
persistent p21 following loss of p53, possibly antagonising p-AKT1 in a 
compensatory response to inhibit the early stages of malignant progression.  
 
With time in K14.ROCKer/HK1.ras1205 tumours, it appeared that exogenous 
ROCK2 could drive progression to overt SCC/pdSCC histotypes and once this 
was achieved, exogenous ROCK2 appeared no longer necessary. Therefore, this 
ultimate tri-genic genotype was geared to assess whether ROCK2 co-operation 
with HK1.ras1276 (and later with HK1.ras1205) but now in the context of mutated 
PTEN, could achieve an accelerated malignant progression to elicit SCC/pdSCC 
mediated by an overlay of ROCK/ras1276 and a Δ5PTENflx- mediated loss of AKT 
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regulation and to investigate the mechanism to assess whether this combination 
overcame the compensatory p53/p21 responses. 
 
3.9.1 ROCK2 co-operates with HK1.ras1276/5PTENflx to elicit 
malignant progression 
 
In initial experiments, very few tri-genic K14.cre/lsl.ROCKer/ras1205/Δ5PTENflx mice 
survived as the HK1.ras1205/Δ5PTENflx co-operation gave an increased epidermal 
hyperplasia that resolved into a severe hyperkeratosis at day 8 to 10, deemed too 
excessive for further experimentation. This has been observed in earlier HK1.ras 
genotypes and thus HK1.ras1205 has not been used, e.g. in HK1.fos co-operation 
(Greenhalgh et al., 1993a,c). Thus in this study, experiments employed the lesser 
HK1.ras1276 line that has already successfully been bred with inducible lsl.ROCKer 
mice in the ROCK/ras1276/fos model (above), which also facilitated breeding and 
provided additional comparison controls. Nonetheless, as these 
ROCK/ras1276/Δ5PTENflx phenotypes (and ideas regarding the underlying 
mechanism) developed, experiments returned to assessment of PTEN loss in the 
original ROCK/ras1205 system, but employing mice heterozygous for the Δ5PTEN 
allele (K14.cre/lsl.ROCKer/ras1205/Δ5PTENhet). Therefore, in tri-genic 
ROCK/ras/Δ5PTENflx synergism, inducible lsl.ROCKer activation was examined in 
transgenic mice expressing activated HK1.ras1276 and K14.cre/Δ5PTENflx. In 
repeat experiments, age-matched sibling cohorts of 5 to 6 week old 
K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx (n= 10) were treated with RU486 at week 1 
to ablate the stop cassette in lsl.ROCKer transgene and express ROCKer, and to 
induce PTEN mutation (Δ5PTENflx). Subsequent topical treatment with 4-HT to 
activate ROCKer transgene followed three times per week from the second week, 
with controls receiving either RU486 or ethanol alone. 
 
At 22 weeks of 4-HT treatment, K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx mice had 
displayed only the typical thickened ears observed in bi-genic mice and only now 
for the first time, exhibited signs of tumour formation (figure 3.60a,b) as compared 
to the lack of tumours in either ROCK/ras1276 or ROCK/Δ5PTENflx cohorts (above). 
However, it was noted that these tumours were now independent of wound 
promotion, as they appeared on both tagged and untagged ears of the tri-genic 
ROCK/ras/Δ5PTENflx mice virtually simultaneously. Conversely, at this same time 
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point, RU486-/4-HT-treated K14.cre/ras1276/Δ5PTENflx and RU486-treated/4-HT-
untreated K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx control mice (n = 6 per cohort) 
showed only the mild keratotic appearance of their parental bi-genic genotypes 
(Yao et al., 2006) regardless of ear tagging (figure 3.60c-f). In contrast to tumours 
observed in bi-genic ROCK/ras1205 models, all 100% of 
K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx mice only developed this keratotic frill-like 
structure appearing at each edge of the ears (figure 3.60a,b) suggested a lack of 
co-operation and prompted early termination of the experiments. This was a 
premature decision as following histological analysis a clear synergism had indeed 
developed; hence, why final experiments were prompted to return to co-operation 
with activated (original) K14.ROCKer genotypes but now in the 
HK1.ras1205/Δ5PTENhet background. 
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Figure 3.60 Phenotypes of K14.cre/lsl.ROCK
er
/ras
1276
/Δ5PTEN
flx transgenic mice at 22 weeks. (a, 
b) RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/ras
1276
/Δ5PTEN
flx mice show early formation of tumour 
with keratotic phenotypes. (c, d) RU486-/4-HT-treated K14.cre/ras
1276
/Δ5PTEN
flx and (e, f) RU486-
treated/4-HT-untreated K14.cre/lsl.ROCK
er
/ras
1276
/Δ5PTEN
flx mice display thickened ear and mild 
keratotic phenotypes. 
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Given the relative lack of large tumours at 22 weeks, there was a total surprise at 
the unexpected malignant histotype produced by these smaller and highly 
keratotic appearing lesions. Here remarkably, the histopathology of 
K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx ear biopsies at 22 weeks 4-HT treatment 
showed that these lesions had transformed to malignancy (figure 3.61a). 
Moreover, despite their small size, at higher magnification, 
K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx tumours actually possessed an aggressive 
SCC histotype (figure 3.61b), and in many areas of a wdSCC the histotype 
exhibited an increasing disorganisation to the surrounding epidermal architecture 
(figure 3.61c). Furthermore, these tri-genic SCC keratinocytes appeared to 
infiltrate into the dermis in tight finger-like projections (figure 3.61b), which may 
indicate the onset to a rapid progression to highly invasive pdSCC as observed 
following the spontaneous malignant progression mechanism in the bi-genic 
ROCK/ras1205 models at 16/18 weeks. Thus, ROCK2 in this context may aid in 
both the conversion of benign tumours and also to drive the early mechanism of 
malignant progression. The question remained as to why it took until 22 weeks for 
this to occur? The answer again may be due to the persistence of p53/p21 
expression and AKT status (investigated below). In contrast, control RU486-/4-HT-
treated K14.cre/ras1276/Δ5PTENflx (figure 3.61d,e) and RU486-treated/4-HT-
untreated K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx (figure 3.61f,g) biopsies showed a 
hyperplasia histotype as seen previously with well-organised epidermal layers at 
this stage. 
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Figure 3.61 Histotypes of RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/ras
1276
/Δ5PTEN
flx biopsies at 
22 weeks. (a) Composite micrograph of tri-genic ROCK/ras/Δ5PTEN
flx
 biopsy shows SCC histotype 
with rapid disorganisation in all layers of the surrounding epidermis. (b) At higher magnification, 
K14.cre/lsl.ROCK
er
/ras
1276
/Δ5PTEN
flx carcinoma exhibits finger-like projection that may imply a 
progression to highly invasive pdSCC. (c) Whilst higher magnification at 
K14.cre/lsl.ROCK
er
/ras
1276
/Δ5PTEN
flx wdSCC areas exhibit disorganised basal layers. (d) RU486-
/4-HT-treated K14.cre/ras
1276
/Δ5PTEN
flx and (e,f) RU486-treated/4-HT-untreated 
K14.cre/lsl.ROCK
er
/ras
1276
/Δ5PTEN
flx histopathologies display similar hyperplasia histotypes and 
well-ordered epidermal architecture at higher magnification. (Scale bar: 150µm in a; 100µm in 
b,c,d,f; 50µm in e,g). 
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3.9.2 Expression of tumour progression marker keratin K1 in 
ROCK/ras1276/Δ5PTENflx carcinogenesis 
 
Routine analysis of keratin K1 expression was now of more significant interest 
given the small tumour size achieved at 22 weeks. As shown in composite 
micrographs of K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx tumours (figure 3.62a), 
despite their size and keratotic appearance, K1 (green) expression had virtually 
disappeared in the areas of SCC confirming both conversion and malignant 
progression to this more aggressive histotype; compared to the areas of wdSCC 
(figure 3.62a(box),b ) where K1 expression still appeared, but as ever, was 
becoming gradually reduced. In control cohorts, both RU486-/4-HT-treated 
K14.cre/ras1276/PTENflx and RU486-treated/4-HT-untreated 
K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx biopsies displayed hyperplasia with strong 
K1 expression, that remained confined to supra-basal layers (figure 3.62 c,d), thus 
with little changes to the ordered nature of differentiation in this context. 
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Figure 3.62 Immunofluorescene analysis of K1/K14 expression at 22 weeks. (a) Composite 
micrograph of RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/ras
1276
/Δ5PTEN
flx
 cohort showed K1 
expression disappeared on progression to carcinoma indicating many areas of aggressive SCC 
and possible progression to invasive pdSCC. (b) High magnification at tri-genic 
ROCK
er
/ras
1276
/Δ5PTEN
flx
 wdSCC areas (figure 3.62a-box) showed reduced K1 expression.  (c) In 
comparison, keratin K1 expression appear strong and uniform in supra-basal layer of RU486-/4-
HT-treated K14.cre/ras
1276
/Δ5PTEN
flx
 and (d) RU486-treated/4-HT-untreated 
K14.cre/lsl.ROCK
er
/ras
1276
/Δ5PTEN
flx
 papillomatous hyperplasia histotypes. (Scale bar: a: 150µm, 
b: 50µm; c,d: 100µm). 
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3.9.3 Expression of p53 and p21 in tri-genic 
ROCK/ras1276/Δ5PTENflx mice 
 
The expression profiles of tumour suppressor genes p53 and p21 were routinely 
analysed in these malignant K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx tumours. 
Consistent with earlier finding involving either bi-genic or tri-genic models, 
composite micrographs of K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx wdSCCs/SCCs 
displayed a loss of p53 expression (figure 3.63a) and at higher magnification of the 
SCC area demonstrated that p53 had completely disappeared throughout 
epidermal layers (figure 3.63b). Whilst p53 expression in the 
K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx wdSCC area also showed disappearance 
and has totally disappeared at this stage (figure 3.63a(box),c) consistent with other 
wdSCC histotypes from earlier cohorts (e.g. ROCK/ras1205). However, 
K14.cre/ras1276/Δ5PTENflx hyperplasia showed strong p53 expression in all 
epidermal layers (figure 3.63d), as observed in all bi-genic benign papillomas, e.g. 
HK1.ras1276/fos (above). 
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Figure 3.63 IHC analysis of p53 expression. (a) Composite micrograph of RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
/ras
1276
/Δ5PTEN
flx
 wdSCC/SCC
 
shows no p53 expression in a uniform manner. 
(b) At higher magnification, p53 expression disappeared throughout epidermal layers in the SCC 
areas; and also (c) in the wdSCC area (box). (d) RU486-/4-HT-treated K14.cre/ras
1276
/Δ5PTEN
flx
 
hyperplasia exhibits strong p53 expression in all epidermal layers that limited further tumour 
progression. (Scale bar: a: 150µm; b,c: 50 µm; d: 100µm). 
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In parallel to the loss of p53 expression upon malignant conversion in 
K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx wdSCCs/SCCs, analysis of p21, which had 
persisted in all previous models of conversion (above), turned out to be completely 
lost also at this time point (figure 3.64a). Again, and unique to the tumour context 
produced by this tri-genic ROCKer/ras1276/Δ5PTENflx model, at higher 
magnification, all K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx SCCs, exhibited an 
expanded invasive basal layer where p21 expression was completely absent 
(figure 3.64b). This contrasted to the more typical persistent profiles of basal layer 
p21 expression; which can become reduced or appear cytoplasmic (above). This 
finding was similar to a previous study of bi-genic ras1276/Δ5PTENflx mice treated 
with TPA where analysis of papillomas and even hyperplasia revealed that p21 
was eliminated as rapidly as p53 (Yao et al., 2006, Macdonald et al., 2014). 
Interesingly, this loss of basal p21 expression also appeared in the wdSCC area 
(figure 3.64a(box),c) and was weaker in the papilloma histotypes; where p21 
became reduced or appeared cytoplasmic. Again, this finding was different from 
earlier cohorts of wdSCC histotypes where p21 expression still remained and was 
confined to the epidermal layers (e.g. ROCK/ras1276/fos). Conversely, in 
K14.cre/ras1276/Δ5PTENflx hyperplastic or benign control histotypes, p21 
expression as expected showed strong and uniform expression in all epidermal 
compartments (figure 3.64d). 
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Figure 3.64 IHC analysis of p21 expression. (a) Composite micrograph of RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
/ras
1276
/Δ5PTEN
flx
 wdSCC/SCC shows p21 expression becomes faded and 
disappears in all epidermal compartments. (b) At higher magnification, p21 expression disappears 
throughout epidermal layers in the SCC area; and also (c) in the wdSCC area (figure 3.64a-box). 
(d) RU486-/4-HT-treated K14.cre/ras
1276
/Δ5PTEN
flx
 hyperplasia exhibits strong and uniform p21 
expression. (Scale bar: a: 150µm; b,c: 50 µm; d: 100µm). 
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3.9.4 BrdU-labelling of tri-genic ROCK/ras1276/Δ5PTENflx tumours 
 
BrdU-labelling analysis of cell proliferation rates was performed on tri-genic 
ROCK/ras1276/Δ5PTENflx SCCs. As shown in figure 3.65, RU486-/4-HT-treated 
K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx SCCs scored the highest cell proliferation 
rates (90.9%, figure 3.65a) recorded in this model (and also compared to other 
malignant histotypes in earlier models). In addition, the mitotic index in RU486-/4-
HT-treated K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx wdSCCs followed as the second 
highest in this model (62.2%, figure 3.65b). Conversely, low mitotic activity was 
observed in bi-genic ras1276/Δ5PTENflx hyperplasia (RU486-/4-HT-treated and 
RU486-treated/4-HT-untreated K14.cre/ras1276/Δ5PTENflx cohorts: 21.2%, figure 
3.65c and 20%; RU486-treated/4-HT-untreated 
K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx 16.4%). This data demonstrate that 
K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx SCC has the highest proliferation index as 
compared to other malignancies from earlier results. In addition, this finding is 
consistent with synchronised loss of p53 expression followed by p21 in a similar 
manner to the tri-genic ROCK/ras1276/Δ5PTENflx SCC. Moreover, as shown in 
figure 3.65(a,b) the BrdU-labelling was scattered throughout epidermal layers of 
RU486-/4-HT-treated K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx wdSCC/SCC as 
compared to Brdu-labelling in RU486-/4-HT-treated K14.cre/ras1276/Δ5PTENflx 
hyperplasia that remained in the basal layers (figure 3.65c). 
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Figure 3.65 BrdU-labelling of K14.cre/lsl.ROCK
er
/ras
1276
/Δ5PTEN
flx
 carcinogenesis. Graph displays 
a rapid increase in cell proliferation activity in tri-genic ROCK/ras
1276
/Δ5PTEN
flx
 SCC that is almost 
five times higher than bi-genic ras
1276
/Δ5PTEN
flx
. (a,b,c,d,e : Significantly difference between 
K14.cre/lsl.ROCK
er
/ras
1276
/Δ5PTEN
flx
 (+ 4-HT) and each cohort; p<0.05).  
(a) RU486-/4-HT-treated K14.cre/lsl.ROCK
er
/ras
1276
/Δ5PTEN
flx
 SCC histotype and (b) RU486-/4-
HT-treated K14.cre/lsl.ROCK
er
/ras
1276
/Δ5PTEN
flx
 wdSCC histotype show high BrdU-labelling that is 
scattered throughout epidermal layers, compared to (c) low BrdU-labelling in RU486-/4-HT-treated 
bi-genic ras
1276
/Δ5PTEN
flx
 hyperplasia histotype. (Scale: 50-100µm). 
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3.9.5 Expression of p-AKT1 in tri-genic ROCK/ras1276/Δ5PTENflx 
tumours 
 
The PTEN tumour suppressor gene is one of the most commonly mutated genes 
for tumour development, with a frequency that rivals that of p53 mutation (Wang et 
al., 2003, Yao et al., 2006, 2008). The main mutation in PTEN, often leads to a 
failure to regulate PI3K/AKT signalling pathways via inhibition of AKT activities 
through its dephosphorylation. Thus, in this Δ5PTENflx model, inactivation of this 
PTEN function via ablation of exon 5 contributes to the upregulation of AKT 
(Carnero and Paramio, 2014). Therefore, as above, IFC analysis of p-AKT1 
expression was performed to investigate the association between the loss of 
PTEN phosphatase activity (Δ5PTENflx) in tri-genic ROCK/ras1276/Δ5PTENflx 
synergism via analysis of the activated AKT1 (p-AKT1) expression profile. 
 
In the previous chapters, AKT1 rather than AKT2 was shown to be the major AKT 
isoform expressed in the epidermis and was unexpectedly shown to be either 
inhibited in the presence of p53 and p21; or restricted to supra-basal layers even 
in malignant wdSCCs/SCCs via the persistence of p21 in the basal layer. As 
shown in figure 3.66a, analysis of p-AKT1 in this more aggressive tumour context 
showed very high levels of expression in K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx 
SCC as compared to its expression in K14.cre/ras1276/Δ5PTENflx hyperplasia 
(figure 3.66b). Further, this p-AKT1 expression appeared in all layers of these 
aggressive carcinomas including the basal layers and thus exhibited an 
expression profile reverse of the expression profiles of p53 and p21 observed in 
either K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx or control K14.cre/ras1276/Δ5PTENflx 
cohorts (figure 3.63, 3.64).  
 
In addition, p-AKT1 expression was now also elevated in the 
K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx wdSCC histotype (figure 3.66c) in the 
absence of persistent p21 suggesting that these tumours were now likely to 
progress. This was consistent with the data from papillomas and carcinomas 
analysed in the previous models, in which the low level of p-AKT1 or its supra-
basal expression was associated with compensatory p53 and /or p21 expression 
in the proliferative basal layer keratinocytes. Thus, these data suggest that the 
loss or low levels of p53/p21 expression in the context of relatively small but 
Chapter 3  231 
 
clearly aggressive K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx wdSCCs/SCCs mediated 
an acceleration in malignant progression following conversion, driven in part by p-
AKT1 expression.  
 
This feature of p21/AKT antagonism in early stage malignancy has also been 
previously observed in HK1.ras1276/fos/Δ5PTENflx mice (Greenhalgh, – manuscript 
in preparation). Therefore, it may be that AKT-mediated inhibition of the 
compensatory p21 subsequently facilitates the oncogenic functions of ROCK2 in 
driving the latter stages of carcinogenesis in this context, consistent with many 
reports on ROCK2 activities. These data are also consistent with a sudden burst of 
excessive proliferation in the tri-genic ROCK/ras1276/Δ5PTENflx SCC histotypes as 
demonstrated by the finding of the highest proliferation rates to date from BrdU-
labelling analysis (figure 3.65). Again, a result consistent with the invasive profiles 
induced by ROCK2 activation in co-operation with ras1276 activation and Δ5PTENflx 
loss. 
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Figure 3.66 Immunofluorescence analysis of p-AKT1 expression in RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
/ras
1276
/Δ5PTEN
flx
 tumours. (a) K14.cre/lsl.ROCK
er
/ras
1276
/Δ5PTEN
flx
 SCC 
showed high level of cytoplasmic p-AKT1 expression in all epidermal layers compared to (b) little p-
AKT1 expression in RU486-/4-HT-treated K14.cre/ras
1276
/Δ5PTEN
flx
hyperplasia. (c) Interestingly, 
elevated expression of p-AKT1 was displayed in RU486-/4-HT-treated 
K14.cre/lsl.ROCK
er
/ras
1276
/Δ5PTEN
flx
 wdSCC due to loss of p53/p21 expression. (Scale bar: a,c: 
50µm; b: 100 µm). 
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3.9.6 ROCK2 rapidly elicits malignant conversion and progression 
to aggressive, poorly differentiated SCCs in co-operation with 
HK1.ras1205/5PTENhet mice 
 
The surprising malignant nature of the histotypes produced from such overtly small 
tumours suggested that once a specific context of aggressive yet benign papilloma 
had been achieved [i.e. in this case not until 22 weeks of 4HT treatment in the 
K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx model] ROCK2-induced conversion to 
malignancy. If so, it was theorised that the aggressive, and automonous 
papillomas created by HK1.ras1205 co-operation with heterozygous PTEN loss 
(Δ5PTENhet) (Yao et al., 2006) would provide this context. Thus, the original 
K14.ROCKer transgene was employed and introduced into this heterozygous 
Δ5PTENhet background in order to compare the original bi-genic ROCK/ras1205 
observations of similar pdSCC formation in these two contexts.  
 
Following the standard RU486 and 3x per week of 4-HT treatments, it became 
very clear that tumourigenesis in K14.ROCKer/HK1.ras1205/Δ5PTENhet occurred 
rapidly (less than 3 weeks) and produced a completely different class of overt 
tumours. As shown in figure 3.67, typical RU486-treated HK1.ras1205/Δ5PTENhet 
(figure 3.67a - left) which required more than 3 months to reach the size of RU486-
/4-HT-treated K14.ROCKer/HK1.ras1205/Δ5PTENhet transgenic mouse tumours 
(figure 3.67a – middle and right), which had appeared very rapidly over the first 2 
to 3 weeks and had to be sacrificed by 6-7 weeks due to their increasing size. 
Note also that the control mice (HK1.ras1205/Δ5PTENhet) exhibited a typical 
papilloma cluster, which could be large in size but were completely different from 
the SCCs in K14.ROCKer/HK1.ras1205/Δ5PTENhet (figure 3.67a). Indeed the 
dissected papilloma cluster from control animals shows a typical cauliflower-like 
appearance (figure 3.67b), whereas the K14.ROCKer/HK1.ras1205/Δ5PTENhet 
tumours are more uniform, less keratotic, well vascularised and possess a smooth, 
darker centre (figure 3.67c). This appearance was similar to the aggressive SCCs 
which rapidly appeared following TPA promotion of HK1.ras1276/Δ5PTENflx mice 
(Yao et al., 2006).  In comparison, RU486-treated/4-HT-untreated 
K14.ROCKer/HK1.ras1205/Δ5PTENhet (figure 3.67d) and RU486-treated/4-HT-
treated HK1.ras1205/Δ5PTENhet mice (figure 3.67e) at 14 weeks showed no 
differences in tumour phenotypes to those of control RU486-treated 
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HK1.ras1205/Δ5PTENhet mice (figure 3.67a - left). In addition, control cohorts of 
K14.ROCKer-K14.creP/Δ5PTENhet (Δ5PTENflx) and also showed that the original 
K14.ROCKer transgenic line produced identical phenotypes either in homozygous 
or heterozygous Δ5PTEN backgrounds (figure 3.67f,g) to that of the new 
lsl.ROCKer line studied above (in bi-genic ROCK/Δ5PTENflx).  
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Figure 3.67 Rapid tumourigenesis developed in K14.ROCK
er
/HK1.ras
1205
/Δ5PTEN
het 
transgenic 
mice. (a) Left: papilloma cluster on RU486-treated HK1.ras
1205
/Δ5PTEN
het
 at 14 weeks; versus 
Middle and Right:  large and smooth SCCs produced in RU486-/4-HT-treated 
K14.ROCK
er
/HK1.ras
1205
/Δ5PTEN
het
 mice at only 6 weeks. (b) Dissection of papilloma cluster 
compared to (c) individual halves of tri-genic ROCK/ras
1205
/Δ5PTEN
het 
mice reveal distinctly 
different architectures to their appearance consistent with a benign or malignant histotype. (d) 
Control genotypes at 14 weeks: RU486-treated/4-HT-untreated 
K14.ROCK
er
/HK1.ras
1205
/Δ5PTEN
het 
and (e) RU486-treated/4-HT-treated HK1.ras
1205
/Δ5PTEN
het
 at 
14 weeks show similar papilloma cluster appearance to RU486-treated HK1.ras
1205
/Δ5PTEN
het 
papilloma. (f) RU486-/4-HT-treated K14.ROCK
er
-K14.creP-Δ5PTEN
het
 and (g) RU486-/4-HT-
treated K14.ROCK
er
-K14.creP-Δ5PTEN
flx
 mice display thickened ears and mild keratotic 
phenotypes. 
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The histotype confirmed the expected SCC histotypes (figure 3.68a-f and figure 
3.69a-e) and these tumours exhibited large areas of aggressive pdSSCs and an 
odd feature manifested in their processing. In the areas of aggressive 
SSC/pdSCC, a unique ripping occurred during cutting of these sections (figure 
3.68a-c – arrows); but this did not happened in the control tumours that 
wereprocessed at the same time. Hence, it is tempting to conclude that these 
tumours were of a brittle nature and this phenotype was derived from an increased 
stiffness and rigidity mediated by ROCK2 signalling (Samuel et al., 2011). At 
higher magnification (figure 3.69a-e), areas of SCC and pdSCC not only manifest 
as being brittle and easily ripped on sectioning, but also contained numerous 
mitotic figures (figure 3.69 – circles) indicative of a rapid proliferation rate as 
observed in the tri-genic ROCK/ras1276/Δ5PTENflx version. Also, many areas 
exhibited clear spaces between groups of basal layer SCC cells (figure 3.69e); a 
result also observed in the tri-genic ROCK/ras1276/Δ5PTENflx model. Exactly what 
this spacing indicates is still unclear, but it may be a precursor necessary to 
facilitate increased cellular migration and invasive potential. In support of this idea, 
these spaces between cells are very clear and appear to be devoid of the typical 
intercellular projections that define the spinous layer and give it its integrity. This 
too would be consistent with the observation that this intercellular histotype was 
often separate to that of the brittle/ripped tissue (figure 3.69c,d versus figure 
3.69e). This suggests that in one case ROCK2 is increasing tissue stiffness via 
actomyosin contraction, or changes in the extracellular matrix and tumours invade 
on a wide front (Samuel et al., 2011). On the other hand, ROCK2 mediated intra-
cellular changes may facilitate cell motility (Croft et al., 2004), for rapid invasion via 
the finger-like projections observed in the tri-genic ROCK/ras1276/Δ5PTENflx model 
(above) as shown in figure 3.68(b,f) and figure 3.69(a,b & d).  These speculations 
have already been theorised in previous study of ROCK2-mediated 
carcinogenesis through tissue stiffness and may involve changes in β-catenin 
signalling (Samuel et al., 2011). If so, this would in turn affect adherens junctions 
such as E-cadherin (Holeiter et al., 2012), and thus may possibly account for the 
lack of spinous projections observed in this histotype suggesting a failure to form 
appropriate adheren junctions or desmosomes that maintain cellular integrity 
(Brandner et al., 2010, Simpson et al., 2011). 
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Figure 3.68 Histotypes of RU486-/4-HT-treated K14.ROCK
er
/HK1.ras
1205
/Δ5PTEN
het biopsies at 6 
weeks. (a-f) Composite low magnification micrographs of tri-genic ROCK/ras
1205
/Δ5PTEN
het
 
biopsies show mainly SCC (a,c) and mainly pdSCC (b,d-f) histotypes with highly invasive cells. In 
addition, all these examples exhibited rips in the tissue sections (arrows) together with areas of 
disorganised basal layer cells. Serial sections from (a-c) [mouse 9423] were employed for p53 
analysis and (d-f) [mouse 9422] were used to investigate p21 expression.  (Scale bar: approx 
200µm in a,d-f;approx 150µm in b,c). 
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Figure 3.69 Histotypes of RU486-/4-HT-treated K14.ROCK
er
/HK1.ras
1205
/Δ5PTEN
het biopsies at 6 
weeks. (a,b) At higher magnification, K14.ROCK
er
/HK1.ras
1205
/Δ5PTEN
het carcinomas exhibit highly 
invasive pdSCCs with numerous easily detected mitotic figures (circles). (c,d) This example of 
pdscc histotype shows that the ripped areas appeared to be separate to the disorganised basal 
layer shown in (e). Here there a fewer mitotic cells but the spaces between cells are very clear and 
appear to be devoid of the typical intercellular projections that define the spinous layer. (Scale 
bar:100µm in  a,c; 50µm in b,d; 25µm e). 
 
 
 
 
 
 
Chapter 3  239 
 
Experiments to the analysis of p53 and p21 status (figures 3.70 and 3.71) in this 
rapid carcinogenesis were carried out. As expected, all examples tested had lost 
the p53 tumour suppressor gene (figure 3.70a,b) and it was noted that in this 
context, areas of keratin K1-positive, late-stage papilloma had also already lost 
p53 expression by 5- 6 weeks (figure 3.70c-e). This was in contrast to control 
papilloma cohorts (not shown) where p53 expression was maintained in all 
epidermal layers (Macdonald et al., 2014).  
 
A similar result was observed for p21 expression. Here in the RU486-/4-HT-
treated ROCK/ras1205/Δ5PTENhet mouse tumour from 9422, p21 expression had 
appeared in the smaller areas of less aggressive histotypes (figure 3.71), unlike 
that for p53 loss, but as these papilloma/wdSCC rapidly progressed to SCC and 
pdSCC, any remaining p21 expression disappeared. However, just as observed in 
the ROCK/ras1276/Δ5PTENflx version, and unlike progression in all the other 
contexts, here little or no persistent p21 expression appeared in the basal layers, 
with occasional supra-basal cells expressing barely detectable levels in the 
presence of numerous mitotic figures (figure 3.71e-g).  This p53 and p21 result 
was again similar to the rapid carcinogenesis observed following TPA promotion of 
HK1.ras1276/Δ5PTENflx mice (Yao et al., 2006, Macdonald et al., 2014), in which 
both p53 and p21 expression were lost, suggesting that neither had been 
expressed. Whereas in this tri-genic ROCK/ras1205/Δ5PTENhet carcinogenesis, 
whilst p53 was lost very early, it appears that there was an attempt at a 
compensatory p21 response; but this was lost/bypassed relatively quickly, thus 
leading to a rapid progression to aggressive carcinomas in these 
K14.ROCKer/HK1.ras1205/Δ5PTENhet mice.  
Chapter 3  240 
 
 
Figure 3.70 IHC analysis of p53 expression in K14.ROCK
er
/HK1.ras
1205
/Δ5PTEN
het
 carcinogenesis. 
(a) Low magnification composite micrograph of RU486-/4-HT-treated SCC and pdSCC (box) from 
mouse 9423 and (b) higher mag of boxed area, shows complete loss of p53 expression in a 
uniform manner. (c-e) Ear tumour from mouse 9423 also possessed some areas of late-stage 
papilloma which were also devoid of p53 despite these areas being K1 positive. (Scale bar: a: 
150µm; b,d,e: 50 µm; c: 200µm). 
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Figure 3.71 IHC analysis of p21 expression in K14.ROCK
er
/HK1.ras
1205
/Δ5PTEN
het
 carcinogenesis. 
(a, b) Low magnification composite micrograph of p21 expression in RU486-/4-HT-treated mouse 
tumour from 9422 shows p21 loss as papilloma/wdSCC progressed to larger areas of more uniform 
SCC with increased regions of pdSCC. (c) The remaining p21 expression in SCC remains localised 
to the keratotic layer of the wdSCC/SCC, disappears in SCC and no p21 expression was observed 
in the basal layers; whilst again a rip appeared in the SCC tumour tissue. (d, e) Higher 
magnification of this wdSCC/SCC area confirms p21 loss in the majority of keratinocytes with 
occasional supra-basal cells expressing just detectable low levels and numerous mitotic figures. (f, 
g) High magnification of the boxed area (from b) again confirms uniform loss of p21 in this 
SCC/pdSCC (K1 negative - see below); with very faint staining observed in some mitotic figures 
(circles). (Scale bars: a,b: 200 µm; c: 100 µm; d,e,f: 50 µm; g:25 µm). 
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Therefore, given the data from above, the status of activated AKT1 was also 
assessed. As shown in figure 3.72(a,b), p-AKT1 expression followed the similar 
outline as observed earlier in tri-genic ROCK/ras1276/Δ5PTENflx version; but here 
given the loss of both p53 and now the lack of persistent p21, the elevated p-AKT1 
expression became rapidly uniform and also appeared in the basal layers of SCCs 
(p21-negative). This observation suggests that among the many progression 
pathways, in these aggressive tumours, the very rapid progression to SCC and 
appearance of pdSCC, may be driven by basal layer ROCK2 and (sporadic) basal 
rasHa activation in co-operation with Δ5PTEN-associated p-AKT1 activation. This 
happened in the context where malignant conversion had been achieved and 
mediated by ROCK2 and HK1.ras1205 co-operation as observed in the 
spontaneous progression pathways of the original bi-genic ROCK/ras1205 model 
(above). 
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Figure 3.72 Immunofluorescence analysis of p-AKT1 and keratin K1 expression in 
K14.ROCK
er
/HK1.ras
1205
/Δ5PTEN
het
 carcinogenesis. (a) Activated p-AKT1 expression in a late 
stage papilloma/SCC area of mouse tumour 9423 and (b) SCC area of tumour 9422 shows 
increasing expression throughout epidermal layers. (c) Typical uniform loss of keratin K1 
expression in SCC/pcSCC in a serial section of the (d) tumour 9422 SCC/pdSCC (Scale bars: a,b: 
150 µm; c,d: 100 µm). 
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3.9.7 Summary 
 
In this study, inducible ROCK2 activation showed direct co-operation with 
ras1276/Δ5PTENflx in malignant conversion and progression (at 22 weeks) 
supported by loss of keratin K1, p53 and p21, together with strong basal 
expression of p-AKT1. Moreover, epidermal architecture of 
K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx SCC/pdSCC appeared massively 
disorganised with finger-like projections into the dermis making it difficult to 
distinguish each epidermal layer. Intriguing finding from this tri-genic 
ROCK/ras1276/Δ5PTENflx study was shown on the tumour phenotypes. Even 
though tri-genic ROCK/ras1276/Δ5PTENflx mice gave no large tumours in 
comparison to the massive tumour size from other tri-genic models (e.g. tri-genic 
ROCK/ras1276/fos and ROCK/fos/Δ5PTENflx mice); yet the tumours have shown a 
very progressive malignancy. Another important feature from this study was the 
contrast between these tri-genic mice to the bi-genic ras1276/Δ5PTENflx mice which 
showed hyperplasia histotypes only at this time point due to persistent p53/p21 
expression profiles. Whereas during co-operation of ROCK2 activation in a context 
of ras1276/Δ5PTENflx, once the hyperplastic histotype had been bypassed; 
presumably by p53 loss, these tiny tumours rapidly progressed to SCCs, 
accompanied by loss of p21 and increased AKT expression. Thus, these data 
indicated a significant role of ROCK2 in malignant conversion and progression 
when both MAPK kinase signalling and PTEN/PI3K/AKT signalling combined.  
 
This conclusion proved to be correct in experiments investigating the co-operation 
between ROCK2 and ras1205/Δ5PTENhet using the original bi-genic ROCK/ras1205 
model. Here, even with a normal PTEN allele, rapid papillomatogenesis occurred 
in tri-genic ROCK/ras1205/Δ5PTENhet mice, and this study has not only 
demonstrated the important role of ROCK2 in malignant conversion but also in 
malignant progression; as these tumours rapidly progressed to pdSCC as early as 
6 weeks. Further, both p53/p21 expressions in this tri-genic 
ROCK/ras1205/Δ5PTENhet model disappeared early in a similar pattern to that seen 
in the tri-genic ROCK/ras1276/Δ5PTENflx model, where total loss of p53 in 
SCC/pdSCC expression followed by gradual loss of p21 from late stage 
papillomas prior to complete loss of p21 expression in the SCC/pdSCC areas was 
observed. Thus, the loss of p53/p21 along with strong and basal expression of p-
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AKT1 in tri-genic ROCK/ras1205/Δ5PTENhet model is consistent to a previous study 
by Yao et al., (2006) upon TPA promotion in bi-genic ras1276/Δ5PTENflx mice. In 
addition, one important observation in this tri-genic ROCK/ras1205/Δ5PTENhet 
model is the appareance of several rips/broken areas in the aggressive 
SCC/pdSCC areas. Since ROCK2 activation in this tri-genic 
ROCK/ras1205/Δ5PTENhet model showed the most severe malignancy to date, the 
rip/broken tissue observation may imply that activated ROCK2 contributed to an 
increase tissue stiffness during tumourigenesis (Samuel et al., 2011) and thus, 
these fixed sections became brittle, harder to cut and this feature manifests in the 
SCC areas of H&E sections. 
Chapter 4 
Chapter 4 – Discussion 
 
4.1 ROCK2 activation in transgenic mouse skin 
carcinogenesis 
 
Carcinogenesis is a complex process that evolves through different stages of 
tumour development. From a clinician’s point of view, the conversion of benign 
tumours to malignancy and further progression to metastasis are the most 
significant stages for cancer patients and thus understanding the cancer 
pathogenesis is essential in this context. One of the most successful models used 
to study the multistage mechanism in carcinogenesis is the mouse skin model of 
two-stage chemical carcinogenesis, which allows the exploration of the 
mechanisms of tumour progression using DMBA to initiate and TPA to promote 
(Yuspa et al., 1991). Through development of transgenic mice, the initiation and 
promotion steps of DMBA and TPA have been mimicked in many skin models 
typically with the introduction of activated oncogene rasHa, the oncogene activated 
most following DMBA treatment (Balmain and Pragnell, 1983, Balmain et al., 1984, 
Roop et al., 1986)  and addition of fos oncogene activation (Greenhalgh et al., 
1993b), a major facet of TPA promotion (Schlingemann et al., 2003). With the 
respect to rasHa activation acts an initiator of carcinogenesis and fos activation as 
a promoter, and when driven by a HK1 promoter modified to express in 
proliferative basal layers (Greenhalgh et al., 1993a), HK1.ras/fos co-operation 
gave benign papillomas without a spontaneous malignancy (Greenhalgh et al., 
1993c, 1996). This stability of phenotype enabled analysis of malignant conversion 
such as co-operation with inducible PTEN loss at exon 5 which deregulated AKT 
activity (Macdonald et al., 2014).  
 
Therefore, with the main aim to identify the specific stage of tumour events, 
combination of well characterised mutations that signify some of the most altered 
interacting signalling pathways in carcinogenesis has been chosen. In this study, 
inducible ROCK2 activation was introduced into a transgenic mouse skin model in 
co-operation with rasHa and /or fos oncogene activation and inducible PTEN 
tumour suppressor gene loss. This has been employed to identify ROCK2 
activation roles in producing benign tumours, driving conversion to malignancy and 
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/or promoting further progression to aggressive tumours; and at the same time 
investigated the involvement of ROCK2 in the process of normal epidermal 
differentiation. In addition, this study also introduced the latest and unpublished 
lsl.ROCKer model that is driven by the universal CAG promoter following cre 
mediated ablation of stop cassette and is conditionally activated by 4-HT 
regulation (Samuel et al., 2009a). This lsl.ROCKer model offered ROCK 
expression in the same target cells to the PTEN ablation at exon 5 by K14.creP, 
which is in the proliferative keratinocytes (Berton et al., 2000b). 
 
These studies commenced with an initial analysis of the original transgenic mouse 
model of ROCK activation (K14.ROCKer) (Samuel et al., 2009a) to show that 4-HT 
treatment produced the same phenotypes in the background strain of ICR mice 
employed in the HK1 models (Greenhalgh et al., 1993a-c). Accordingly, 
K14.ROCKer mice resulted in epidermal hyperplasia but no tumour formation, and 
gave identical results in terms of GFP analysis that confirm its expression in each 
epidermal layer and phosphorylated Mypt (p-Mypt1) expression to confirm ROCK 
activation mediated by 4-HT (Samuel et al., 2009a, 2011). Given the hyperplasia 
histotypes produced by K14.ROCKer mice in this study, it appeared to be very 
similar to the hyperplasia formed by young HK1.ras or HK1.fos mice prior to 
papilloma formation in terms of e.g keratin K1 differentiation marker expression 
(Greenhalgh et al., 1993a,b),. However, K14.ROCKer hyperplasia also expressed 
changes in e.g keratin K6, which appeared unique to ROCK deregulation and this 
may reflect ROCK2 functions in actomyosin contraction that seems to affect the 
cellular composition. This finding also echoed a previous observation that PTEN 
mice exhibited a very unusual lack of this hyperproliferative associated keratin in 
their hyperplasia (Yao et al., 2006); whereas typically K6 is strong and uniform in 
epidermal hyperplasia (Greenhalgh et al., 1993a,b). This suggests links and 
similarities between deregulation of the ROCK2 and PTEN signalling systems in 
an epidermis that may be accountable for an apparent lack of synergism in 
papillomatogenesis and thus effects in differentiation were explored in vivo and in 
vitro (below). 
 
In addition, these studies also employed a new ROCK2 transgenic line, 
lsl.ROCKer. This line which is a 4-HT-inducible ROCKer transgene driven by a 
generic CAG promoter was designed using the cre/loxP system, and following cre 
recombinase activity to ablate a series of stop cassette in a target gene. Thus, 
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depending upon which promoter drives the regulator of cre expression, now 
ROCKer can be expressed in most cell types and not just the epithelia. Therefore, 
these lsl.ROCKer mice were mainly chosen so that the identical keratinocytes 
would express ROCKer in the same keratinocyte populations when crossed into 
the K14.creP/Δ5PTENflx genotype and mice were treated with RU486 to 
translocate cre activity from the cytoplasm to the nucleus following dimerization of 
the progesterone ligand binding domain (Berton et al., 2000b). Thus, a series of 
experiments were conducted to establish this lsl.ROCKer genotype into the 
K14.creP background and assess the phenotypes produced in K14.cre/ lsl.ROCKer 
genotype and compare to the original K14.ROCKer model (Samuel et al., 2009a). 
In both strains, phenotypes from these studies were identical, and as for the 
K14.ROCKer in ICR mice, RU486/4-HT treatments in K14.cre/ lsl.ROCKer 
genotypes again demonstrated that ROCK2 activation produced an identical skin 
thickening associated with keratinocyte hyperplasia identical to that of previous 
studies (Samuel et al., 2009a, 2011), but no tumour formation at this stage. 
 
Previously, a study by Berton et al., (2000b) has crossed K14.creP mice with mice 
carrying a similar reporter construct (CAG-CAT-Z reporter gene) to that of the 
CAG-lsl.ROCKer construct. Despite K14 expression in all epidermal compartments 
including hair follicles and stem cells following RU486 mediated cre activity, CAG 
driven β-gal expression showed expression only in the differentiated supra-basal 
layers. Thus, even though the clear hyperplasia histotypes has been produced by 
K14.cre/lsl.ROCKer cohorts in the beginning of this study, given an unexpected 
lack of bi-genic ROCK/Δ5PTENflx co-operation, concerns existed that lsl.ROCKer 
transgene may be expressed from a similar CAG promoter and would follow the 
same expression, and also be limited in the supra-basal layers. This proved to be 
unfounded, as again in an identical fashion to K14.ROCKer mice, uniform 
expression of GFP and p-Mypt1 appeared throughout epidermal layers, including 
hair follicles in K14.cre/lsl.ROCKer epidermal hyperplasia (and in 
K14.cre/lsl.ROCKer/Δ5PTENflx mice) and thus have answered these concerns. 
 
Now that the activated ROCK transgenic mice have been characterised and found 
to be consistent in phenotypes and histotypes to that observe previously (Samuel 
et al., 2009a, 2011). Hence, this study proceeds to assess the co-operation of 
ROCK with ras and /or fos oncogenes activation employed in the HK1 models 
(HK1.ras, HK1.fos). Thus, several questions were posed given the previous 
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DMBA/TPA chemical carcinogenesis study on ROCK2 (Samuel et al., 2011). It 
was anticipated that ROCK2 would co-operate with rasHa which is the well-known 
oncogene that acts as an initiator in the multistage carcinogenesis model; but the 
question is at what stage that ROCK2 becomes causal? Yet, there is there is still 
lack of evidence on the effect of either DMBA or TPA alone on ROCK2 in 
carcinogenesis. In addition, given the 2 types of HK1.ras lines in this study where 
HK1.ras1276 line is insensitive to wound promotion whilst HK1.ras1205 line produces 
papillomatogenesis in response to wound promotion; thus this allows this study to 
test whether ROCK2 activation would co-operate with rasHa and if so, as a 
converter or promoter?. Further, in co-operation study between ROCK2 and fos 
activation, this would testify the ROCK2 ability as an initiator since fos activation is 
a constitutive promoter. In addition, as targeting several pathways in combination 
offers potential insight for most cancer therapies, thus co-operation between 
ROCK2 and PTEN in this study would introduce the link between AKT pathway 
and MAPK deregulation. 
 
ROCK expression has shown high expression in human cutaneous SCC (Ibbetson 
et al., 2013) complies with the roles of ROCK in late cancer event (Croft et al., 
2004). This observation is also consistent to the introduction analysis of each 
tumour stage of ras/fos/ΔPTENflx transgenic mouse skin carcinogenesis 
(Macdonald et al., 2014), which displayed an elevated expression of both ROCK1 
and ROCK2 upon poor prognosis of tumours. Moreover, it was revealed that both 
ROCK1 and ROCK2 expression became greater in all epidermal compartments of 
wdSCCs and SCCs, but expression was lesser in papillomas and remained 
confined to supra-basal layers. Thus, one of many questions to be addressed in 
this study was aimed to answer whether ROCK2 can be the causal to drive the 
malignant conversion prior to its more familiar roles in malignant progression. 
Hence, this led to the first co-operation study between ROCK2 and rasHa 
activation. Previous studies have shown the effect of two-stage chemical 
carcinogenesis (DMBA/TPA) on ROCKer mice (Samuel et al., 2011) which resulted 
in increased number of SCCs. Therefore, it was logical to assume that ROCK2 
could co-operate with rasHa, but no directed evidence existed until now in this new 
HK1 study. Furthermore, a result found by induction of DMBA alone on ROCKer 
mice revealed no tumour formation (Olson, - unpublished data), a result that has 
now been answered in this study by the need for promotion (e.g. wounding or fos 
promotion). Indeed, the fact that both activated rasHa and fos mimics the 
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DMBA/TPA carcinogenesis as activated rasHa induced initiation and activated fos 
induced promotion (Greenhalgh and Yuspa, 1988, Greenhalgh et al., 1990, 
Greenhalgh et al., 1993a-c), thus, the co-operation between ROCK2 and rasHa and 
/or fos was not only mimicked chemical carcinogenesis models (Samuel et al., 
2011, Balmain and Yuspa, 2014), but also revealed the stages when oncogenic 
ROCK2 activation can actually contribute, now including the early stage of 
carcinogenesis.  
 
4.2 Co-operation of ROCK2 and HK1.ras in transgenic 
mouse skin carcinogenesis 
 
In this study, the direct co-operation between ROCK and ras has identified the 
important roles of ROCK to drive malignant conversion of benign tumours, as 
activated HK1.ras1205 alone controls produced papillomas only without malignant 
conversion in 100% of animals. Indeed, when activated HK1.ras1205 developed a 
papilloma, bi-genic ROCK/ras1205 cohorts at the same time (8 weeks) have already 
showed a sign of papilloma progression; given the reduced keratin K1 expression. 
This then continued on carcinoma conversion to wdSCCs/SCCs, with all animals 
exhibiting wdSCC histotypes upon additional treating time (until 12 weeks), whilst 
HK1.ras1205 tumours remained as benign papillomas. This intriguing finding has 
confirmed the roles of ROCK2 activation in conversion but with the necessary 
addition of wounding which in this context was required to facilitate the formation 
of appropriate papillomas before activated ROCK2 becomes causal and convert 
these late-stage papillomas to malignant tumours. Although there are few studies 
that have reported the link between ras and Rho/ROCK pathway (Olson et al., 
1998, Sahai et al., 2001), and since ROCK is a downstream effector of RhoA is 
considered as a member of the Ras superfamily, this interaction between ROCK 
and ras is predictable. Yet, it was possible that these roles were redundant in 
beign upon the same pathway, but now are proven to be additive. However, this 
co-operation did require the correct papilloma context prior to the direct co-
operation between ROCK2 and rasHa and now this study has shown that ROCK2 
plays its roles as a converting agent. In addition, expression of ROCKer transgene 
and its substrate, p-Mypt1 appeared in all epidermal compartments and together 
with tenascin C expression which became elevated upon malignancy. Since it is 
transpired that high expression of tenascin C is linked to poor prognosis (Dang et 
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al., 2006, Orend and Chiquet-Ehrismann, 2006) and it is also highly expressive in 
solid malignant tumours (Orend and Chiquet-Ehrismann, 2006, Midwood and 
Orend, 2009). Thus, these data suggest that it is the increased in stiffness 
mediated by ROCK activation which aids in conversion as well as in progression. 
  
Analysis of p53 and p21 proved to be very informative regarding the underlying 
mechanism. Besides, p53 expression that became gradually lost in all epidermal 
layers typically prior to and definitely following malignant conversion at 12 weeks, 
a major finding was that this p53 loss was countered by p21 expression that 
remained confined in all epidermal layers to suppress further malignant 
progression (Efeyan et al., 2007, Macdonald et al., 2014). Since p21 acts as an 
important component for p53 in tumour suppression, study has shown significant 
depletion in tumour suppression in the super-p53 mice but in the absence of p21 
expression (Efeyan et al., 2007). This was demonstrated by continuous malignant 
progression in bi-genic ROCK/ras1205 to pdSCC histotypes with loss of both 
p53/p21 expressions at 16 weeks. Moreover, it has also been reported by Yao et 
al., (2006) that the loss of both p53 and p21 expression in bi-genic 
ras1276/Δ5PTENflx after TPA induction lead to pdSCCs formation, showing their 
potency as tumour suppressor genes. In contrast, therefore in the absence of 4-
HT, bi-genic ROCK/ras1205 stayed as benign papillomas and showed no sign of 
conversion as observed in rasHa (Greenhalgh et al., 1993a) due to strong 
expression of both p53 and p21. 
 
Several intriguing findings in this current study emerged from cessation of 4-HT 
treatments. One showed that the bi-genic ROCK/ras1205 wdSCCs/SCCs continued 
to pdSCCs even without exogenous ROCK (cessastion of 4-HT). Here at this 
stage, p21 expression was lost in the invasive pdSCC areas at 16 weeks, but in 
the wdSCC area, p21 expression persisted; consistent with the data that appeared 
at 12 weeks. This persistence plus the altered disturbed basal layers observed in 
these wdSCC histotypes suggests that at this stage, malignancy depended on 
exogenous ROCK being a downstream regulator of ras and when both are 
activated, it provides more proliferation and a benefit for tumour progression 
(Molina and Adjei, 2006). The lack of requirement for exogenous ROCK in the 
pdSCCs may be due to the levels of endogenous ROCK which took control in 
continuous progressive SCC and this idea was not unexpected since it is well-
known that high expression of ROCK (1 and 2) occurred correlated to poor 
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prognosis of tumours (Croft et al., 2004, Samuel et al., 2011). Samuel et al., 
(2011) have also shown that high expression of endogenous ROCK was 
demonstrated in almost all cases of human SCCs, coincided with high levels of 
ROCK (1 and 2) displayed in tri-genic ras/fos/Δ5PTENflx carcinomas. Therefore, 
this suggests that once tumours achieved progressive carcinomas, thus, it is 
possible that the additional exogenous ROCK activity is no longer considered as a 
rate limiting factor.  
 
At the same time, this study found a remarkable tumour growth and larger rather 
than smaller tumour size in bi-genic ROCK/ras1205 mice after the cessation of 4-
HT. Indeed the fact that this new tumour growth turned out to be a late stage 
papilloma would suggest that ROCK was required for maintaining malignancy, but 
this sudden massive tumour growth was accompanied by K1 expression and also 
a very rare intense expression of p21 in all epidermal compartments that may 
sustain these papillomas from conversion. Previous study has shown that RhoA, 
the upstream regulator of ROCK was responsible to suppress the p21 expression 
in ras transformed cells (Sahai et al., 2001). Since RhoA-induced transformed 
cells (NIH3T3 fibroblasts) required ROCK signalling to establish and maintain the 
transformation (Sahai et al., 1999), thus, in this study where there is no exogenous 
ROCK activity due to cessation of 4-HT may implicate in the p21 expression. 
However, Sahai et al., (2001) have shown that ROCK activation which was 
required for RhoA-induced ras-transformed cells showed no responsibility in 
regulating p21 levels. Further, turned out that ERK/MAPK signalling down-
regulated ROCK(1 and 2) activity in the RhoA-induced ras-transformed cells 
(Sahai et al., 2001). Thus, these observations may suggest two potential 
possibilities. First, ROCK was required to maintain malignancy, and the highly 
intense p21 level in bi-genic ROCK/ras1205 after cessation of 4-HT was due to 
induction by ERK/MAPK signalling from ras oncogene activation. Second, it is also 
possible that after cessation of 4-HT, the rapid growth of late stage papilloma were 
maintained in a benign state due to this novel and rare intense of p21 expression. 
This was highly expressed presumably to compensate for the lack of p53 
expression which did not appear to be restored and at the same time suppress 
further progression, as observed previously in tri-genic ras/fos/Δ5PTENflx mice 
(Macdonald et al., 2014). On the other hand, the additional tumour growth and size 
in the bi-genic ROCK/ras1205 mice after cessation of 4-HT leads to an idea of anti 
tumour effect of 4-HT which inhibits the formation of papilloma subtype in certain 
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contexts. Thus, cessation of 4-HT allowed this odd, p53 negative intense p21 
expression tumours to develop. However, this is still unclear since data showed 
that HK1.ras1205 tumours remained benign papillomas with or without induction of 
4-HT.  
 
Furthermore, this study also indicated that the promotion stimulus received from 
wounding is required to develop a mature or appropriate papilloma before ROCK2 
driven malignancy started to happen. In both bi-genic ROCK/ras1205 and 
HK1.ras1205 mice, benign papillomas developed at the ear tag in response to 
wound promotion and would regress upon loss of ear tag (no promotion). Even if 
loss of tag on bi-genic ROCK/ras1205 mice occurred in the early period when only a 
small proper papilloma developed, tumours remained benign and failed to convert 
to malignancy. Thus, the tagged ear was responsible to create a wounding 
environment that established mature papilloma formation where ROCKer 
expression achieved malignancy; a result confirmed by bi-genic ROCK/ras1276 
experiments that failed to produce tumours as HK1.ras1276 mice are insensitive to 
wound promotion. Subsequently, given that HK1.ras1205 remained benign 
papillomas, this study shows direct co-operation between ROCK2 and rasHa 
activation in facilitating tumour conversion into the beginning of the malignant 
stages with the presence of wound promotion; thus this study has assessed the 
co-operation between ROCK2 and fos activation which can mimic the TPA 
promotion to observe ROCK2 potential as an initiator.  
 
4.3 Co-operation of ROCK2 and HK1.fos in transgenic 
mouse skin carcinogenesis 
 
The next bi-genic line in this study is ROCK/fos which has shown novel direct co-
operation between ROCK and fos activation in early stage of carcinogenesis with 
benign squamous papillomas formation. Interestingly, as reported in previous 
study, initially HK1.fos activation produced slow development of phenotype and 
resulted in hyperplasia/hyperkeratosis after a period of 4 to 6 months (Greenhalgh 
et al., 1993b). Moreover, to date there is still no definite answer whether ROCK2 
activation can co-operate with fos in carcinogenesis. Adding to the fact that 
transcription factor fos regulates differentiation and proliferation (Basset-Seguin et 
al., 1990, Saez et al., 1995, Mehic et al., 2005). Since c-fos expression is not only 
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limited to the basal layers (Basset-Seguin et al., 1990) but it is also expressed in 
the supra-basal layers (Fisher et al., 1991, Mehic et al., 2005), thus, it is thought 
that fos plays an important role to switch the state between differentiation and 
proliferation. Fisher et al., (1991) have shown that sudden burst of massive c-fos 
expression in late stage differentiation just before cornification and cell death 
which linked the roles of fos in keratinization thus associated with keratosis 
feature. Since fos oncogene is highly targeted upon TPA induction, thus makes fos 
activation mimic the promotion stage (Dotto et al., 1986). Further, expression of v-
fos driven by HK1 construct resulted in both hyperplasia and hyperkeratotis and 
required long period before benign papillomas appeared (Greenhalgh et al., 
1993b). Moreover, v-fos gene (Curran et al., 1984) is stable and potentiates all of 
c-fos activities (Greenhalgh and Yuspa, 1988, Greenhalgh et al., 1990). It is also 
known that fos is a major transcription factor target for the ras/MAPK signalling 
pathway (Greenhalgh and Yuspa, 1988, Greenhalgh et al., 1990) thus given the 
co-operation observed between ROCK2 and fos activation above, and the 
previous studies on ras and fos synergisms (Greenhalgh et al., 1993c). This has 
led to the idea that links may exist between deregulated ROCK2 and fos functions, 
given that ROCK is considered to be an effector of ras signalling elements and to 
date, there is still lack of study on direct co-operation between fos and ROCK2 
activation and what would be the final outcome from this co-operation? As ROCK 
is a late stage event driving malignant conversion, so, the question lies on would 
ROCK2 and fos synergism be too distant in the context of oncogenic insults, giving 
a lack of tumours, or be redundant in outcome as observed in bi-genic 
ROCK/Δ5PTENflx (below). In this context, could ROCK2 acts even earlier as a 
weak initiator for constitutive fos promotion, as the fos oncogene mimics the 
promotion stage in multistage cancer model (Greenhalgh and Yuspa, 1988, 
Greenhalgh et al., 1990) and ROCK2 is typically thought to becomes active in later 
stage of cancer (Croft et al., 2004, Samuel et al., 2011). This study has 
demonstrated for the first time that ROCK2 contributes in the early stage of cancer 
as an initiator to induce benign papilloma formation in co-operation with fos. 
Initially, when HK1.fos mice developed hyperplasia and hyperkeratosis histotypes, 
bi-genic ROCK/fos mice at this period (12 weeks) also resulted in 
hyperplasia/hyperkeratosis, except it is much thicker with acanthosis appearance 
which have expanded stratum spinosum layer. Then, continued on benign 
papilloma formation at 18 weeks as shown by strong K1 expression in supra-basal 
layer, whilst HK1.fos mice still remained as hyperplastic/hyperkeratotic. This novel 
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data showed ROCK2 activation possessed as an initiator and thus confirmed 
ROCK2 roles in the early stage of tumourigenesis. Though previous study has 
shown the link between ROCK and fos where ROCK activation induced the 
transcriptional activity of c-fos serum response element in fibroblasts through in 
vitro study (Chihara et al., 1997). Yet, it was not in the context of multi-stage 
cancer events and now this study has revealed the importance role of ROCK2 as 
an initiator. Thus, data showed different roles of ROCK2 with each ras and fos; 
hence, co-operation between ROCK2 and ras/fos (below) would be beneficial to 
match the link between each gene.  
 
One major and remarkable feature to the results in this novel bi-genic ROCK/fos 
activation model was the complete lack of malignant conversion. This happened in 
100% of all animals created to date ( > 50 if include the later bi-genic control 
cohorts in a variety of aged matched tri-genic siblings from different transgenic 
lines over a 2 year period). None of the mice exhibited even the signs of a 
potential for additional progression as late as 20 weeks unlike that observed in bi-
genic ROCK/ras1205 papillomas by approximately 8 to 10 weeks (e.g. reduced K1 
expression). In addition, though bi-genic ROCK/fos benign papillomas showed an 
increased in the proliferation rates via Brdu analysis, yet it was considered low 
when compared to the bi-genic ROCK/ras papillomas (eight weeks). Thus, this 
intrigues a question of what was preventing the conversion to malignancy?, was it 
simply due to the context of correct papilloma had not been reached? Or was the 
wound promotion not sufficient and may need an additional event.  
 
Hence, another recurrent theme appearing in all the skin models to date was the 
compensatory roles of p53 and p21 (Yao et al., 2006,2008, Macdonald et al., 
2014) and it has been highlighted in respect to p21 expression in the cessation of 
4-HT study on bi-genic ROCK/ras1205 synergism (above). Yet, this bi-genic 
ROCK/fos model did not elicit the keratoacanthoma (KA) tumours of bi-genic 
fos/Δ5PTENflx where p53 and p21 expression were delayed and only expressed in 
overt benign tumours which is in the keratotic KA histotypes (Yao et al., 2008); 
whilst in bi-genic ROCK/ras1205, p53/p21 expression seemed to appear relatively 
quickly. Further, analysis of p53/p21 expression profiles in bi-genic ROCK/fos 
cohorts showed high levels of p53 and p21 expression which appeared relatively 
early. In this study, both p53 and p21 expression remained strong over all the time 
periods analysed in ROCK/fos papillomas and just as observed in bi-genic 
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ras/Δ5PTENflx model (Yao et al., 2006, Macdonald et al., 2014) where both 
expression  appeared to prevent further tumour progression. Indeed, bi-genic 
HK1.ras/fos control papillomas also possessed elevated p53/p21 profiles 
consistent with their lack of malignant progression (below). These data is in 
contrast to bi-genic ROCK/ras1205 tumours, where p53 loss in early malignant 
conversion and then trailed by p21 loss from the highly invasive pdSCC 
histotypes. This strong expression of both p53 and p21 in all epidermal layers of 
bi-genic ROCK/fos tumours is similar to the p53/p21 expression profiles in 
HK1.ras1205 tumours that remained benign; and indeed were prone to regression in 
the absence of wound or fos promotion. Initially, this study found that the 
phenotype for K14.cre/lsl.ROCKer/HK1.fos tumours at 20 weeks was relatively 
similar to the phenotype of HK1.fos/PTENflx tumours, where both set of papillomas 
appeared highly keratotic (Yao et al., 2008). However, with time in this 
HK1.fos/PTENflx context, papillomas progressed to a KA histotype. In this alternate 
mechanism, the timing of p53/p21 expression was quite different and these highly 
keratotic KAs subsequently possessed with a unique premature expression of K1 
in the basal layer which indicated acceleration in differentiation (Yao et al., 2008) 
geared to counter the excessive proliferation. Whilst the typical supra-basal 
expression of keratin K1 in bi-genic ROCK/fos and p53/p21 clearly demonstrated a 
different mechanism of papillomatogenesis which had a greater similarity to bi-
genic ROCK/ras1205 papilloma formation. In addition, the uniform expression of 
keratin K6 in all epidermal layers of bi-genic ROCK/fos tumours gave a different 
result to the low level and patchy expressions of K6 in ROCK hyperplastic 
histotypes. This demonstrates that fos expression over rides the ROCK2 
activation-mediated changes in K6 and this is consistent with the finding from in 
vitro studies. Here, keratin K6 expression was resqued back in 4-HT-treated of bi-
genic ROCK/fos low Ca2+ medium similar to its expression in normal keratinocytes 
when compared to no expression of K6 in 4-HT-treated of K14.cre/lsl.ROCKer (low 
Ca2+ medium). Thus, this K6 expression in bi-genic ROCK/fos tumours which is 
similar to a typical K6 expression in HK1.ras and HK1.fos hyperplasia (Greenhalgh 
et al., 1993a,b) may reflect in the differentiation and proliferation activities by both 
ROCK and fos activation, and it is possible that the differentiation activity induced 
by ROCK2 alone in terms of K6 expression were over-ridden upon co-operation 
with fos activation given its major responsibilities in keratinocyte differentiation 
(Mehic et al., 2005). However, this study showed that the papilloma context in bi-
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genic ROCK/fos was insufficient to convert to malignancy thus required an 
additional mutation which link to tri-genic co-operation studies (below). 
 
4.4 Co-operation of ROCK2 and K14.cre/Δ5PTENflx in 
transgenic mouse skin carcinogenesis 
 
In contrast to bi-genic ROCK/ras and ROCK/fos studies, the third bi-genic 
ROCK/Δ5PTENflx model in this study failed to show evidence of tumour formation; 
yet showed its co-operation in epidermal differentiation. The majority of mutation 
studies on PTEN are widely focused on its role in tumour suppression via 
interactions with e.g. p53 and proliferation (Freeman et al., 2003) and the failure to 
regulate AKT (Mayo and Donner, 2002). However, not all roles leading to tumour 
formation which is p53/AKT related (Yao et al., 2006, 2008, Macdonald et al., 
2014). An often neglected series of PTEN studies show that in some cancers, 
such as prostate cancer and lymphoma, disruption of cytoskeleton proteins and 
adherens junctions appear to be a significant component following PTEN mutation 
(Subauste et al., 2005). As loss of adherens junctions typically occurs in tumour 
cells and studies by Subauste et al., (2005) have shown that disruption in 
adherens junctions can suppress the level of PTEN protein expression. In addition, 
it is transpired that loss of PTEN induced migration activity independent of AKT 
and involved a complex with focal adhesion kinase (FAK) pathway (Yamada and 
Araki, 2001). Thus, in theory, this role of PTEN has a linkage to the role of ROCK 
in regulating adherens junctions (Sahai and Marshall, 2002) that may be essential 
in the context of cytoskeleton remodelling and cell adhesion (Holeiter et al., 2012) 
which help mediate carcinogenesis. Therefore, the lack of tumours in this bi-genic 
ROCK/Δ5PTENflx model may be due to a redundancy effect between ROCK and 
PTEN at this initiation stage that gives a weak oncogenic hit to the epidermal 
layers. Hence, the response results in epidermal hyperplasia/hyperkeratosis only; 
yet the changes to proliferative give a folded papillomatous appearance even at 
almost seven months instead of tumour formation.  
 
These data clearly support a need for more potent, additional events perhaps 
needed to overcome important compensatory responses to ROCK/Δ5PTENflx 
induced hyperplasia in this case such as p53 and p21; and this reflects the 
importance of ROCK and PTEN to epidermal physiology. On the other hand, this 
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result may be technical, as here ROCK2 expression in ROCK/Δ5PTENflx mice is 
driven by CAG promoter, thus lack of tumours may be an old report that CAG 
promoter may be off in the proliferative basal layers (Berton et al., 2000b). This 
concern was eliminated as analysis of both GFP and p-Mypt1 in bi-genic 
ROCK/Δ5PTENflx displayed strong expression throughout epidermal layers 
including hair follicles, consistent with the expression in K14.cre/lsl.ROCKer 
hyperplasia histotypes outlined above. Thus, these two hits may again be similar 
in terms of carcinogenesis. As previous studies implicate Δ5PTENflx in changes to 
epidermal differentiation, they also found that it acts as a weak initiator for TPA 
promotion (e.g. fos activation) leading to tumour (KA) formation, but after long 
latency period (> 20 weeks) (Yao et al., 2006). ROCK2 activation only resulted in 
hyperplasia, thus, these data combined suggest this bi-genic ROCK/Δ5PTENflx 
model indicate that ROCK cannot acts as a weak initiator in co-operation with 
Δ5PTENflx compared to its co-operation with fos.  
 
This is also reflecting in the expression profiles of both p53 and p21 in 
ROCK/Δ5PTENflx cohorts. As demonstrated in bi-genic ROCK/fos benign 
papillomas, high expression profiles of p53/p21 throughout epidermal layers 
became the reason for lack of malignant conversion (Yao et al., 2006, 2008). 
Interestingly, when compared to these ROCK/Δ5PTENflx cohorts, this study found 
low and patchy expression of both p53 and p21 appeared in the hyperplastic 
histotypes which indicate an inhibition of papilloma formation. However, it may not 
be as straight forward as it seems. Whilst both p53 and p21 are important tumour 
suppressor genes, previous study by Greenhalgh et al., (1996) showed a very odd 
and paradox effect of p53 loss on papillomatogenesis, where HK1.ras1205/p53 
knockout mice failed to produce any tumours and their bi-genic epidermis stayed 
hyperplastic which implicates the importance and requirement of p53 for papilloma 
formation in some cases. On the other hand, it was expected that p-AKT1 would 
display a high level of expression due to inactivation of PTEN’s ability to 
dephosphorylate AKT (Suzuki et al., 2003, Freeman et al., 2006). Here, 
surprisingly p-AKT1 showed only low and patchy expression in the bi-genic 
ROCK/Δ5PTENflx hyperplasia which would also contribute to the lack of tumours. 
Nevertheless, through careful observation, as noted in the p53/p21 expression 
profiles of ROCK/Δ5PTENflx hyperplasia, in the area of p53 loss, p21 showed 
strong expression leading to low level of p-AKT1 in the specific area. Thus, this 
lack of tumours in bi-genic ROCK/Δ5PTENflx cohorts may be accountable from the 
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elevated level of p21 expression either counterbalancing AKT activation or 
preventing its expression; a recurrent theme in this model discussed further below.  
 
In addition, the complex roles in epidermal differentiation may be associated in this 
context too, as in formation of KAs in fos/Δ5PTENflx mice that showed lack of p53 
and p21 expression during papilloma formation and expressed elevated AKT 
activation (Yao et al., 2008). This situation reversed once GSK3β inactivation 
achieved a certain level when p53 expression followed by p21 appeared and AKT 
was evicted from the basal layer and expression reduced, thus keratinocytes 
switched from proliferation to differentiation giving keratosis that highlights KAs 
(Yao et al., 2008). In this study, bi-genic ROCK/Δ5PTENflx hyperplasia possessed 
this potent compensatory response of patchy p53 and an elevated p21 countered 
the oncogenic p-AKT1 returning it to supra-basal expression. Both these profiles 
would not only prevent papillomatogenesis but would alter keratinocyte 
differentiation. Despite the absence of tumours in bi-genic ROCK/Δ5PTENflx, the 
hyperplastic histotypes in K14.cre/lsl.ROCKer/Δ5PTENflx model were completely 
different to the hyperplastic in ROCK2 activation and PTENflx. In addition, 
anomalous K1 expression by an expansion of proliferative basal layers, together 
with low level of K6 expression and patchy in the bi-genic ROCK/Δ5PTENflx 
papillomatous hyperplasia may reflect in both proliferation and differentiation on 
the epidermal layers. It may be that epidermal hyperproliferation in bi-genic 
ROCK/Δ5PTENflx as signified by the increased in mitotic index, was countered by 
an accelerated differentiation activity via ROCK2 and Δ5PTENflx which may be the 
clues for lack of tumours similar to the switch to KAs (not SCCs) formation in 
fos/Δ5PTENflx mice (Yao et al., 2008).  
 
Nonetheless, data showed that bi-genic ROCK/Δ5PTENflx required an additional 
event such as fos activation; whilst earlier data in this study has shown that bi-
genic ROCK/fos model also required additional mutation for conversion and for bi-
genic ROCK/ras, the correct context of wound promotion that prepared proper 
papilloma formation was essential before malignant conversion. Therefore, this 
investigation proceeds with tri-genic co-operation studies (below) in similar context 
of bi-genic tumours and at the same time matches a possible connection between 
ras/MAPK/fos and /or PTEN/AKT pathways with ROCK2 activation in tumour 
formation. 
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4.5 Analysis of ROCK2 activation in vitro: effects on 
differentiation not carcinogenesis. 
 
Given the lack of tumours in K14.cre/lsl.ROCKer/Δ5PTENflx, primary keratinocytes 
were established to address changes in differentiation, or transformation by 
increasing calcium concentrations (Hennings et al., 1980) and assessing if they 
grew in high calcium conditions (Morgan et al., 1992). Thus, primary transgenic 
mouse keratinocytes were established from bi-genic K14.cre/lsl.ROCKer/fos and 
K14.cre/lsl.ROCKer/Δ5PTENflx or K14.cre/lsl.ROCKer keratinocytes and challenged 
with different concentrations of calcium to differentiate or grow in high calcium 
media. Their responses were compared to control HK1.fos and K14.cre/Δ5PTENflx 
via western analysis. Unfortunately, K14.cre/lsl.ROCKer/ras1276 and HK1.ras 
keratinocytes failed to grow in this study due to oncogene ras induced senescene. 
Interestingly, keratin K1 expression which is normally weak in low calcium medium 
appeared at high expression levels in activated K14.cre/lsl.ROCKer keratinocytes, 
whilst the hyperproliferative keratin K6 in the same condition showed abnormally 
low levels of expression. These data suggest that ROCK2 is involved in 
keratinocyte differentiation. This idea is supported by previous studies of ROCK2 
knockdown in HaCat cells which showed reduced in differentiation (Lock and 
Hotchin, 2009). Therefore, these previous studies, as well as this in vitro study 
have highlighted the roles of ROCK2 activation in keratinocyte differentiation which 
is an important component in epidermal homoestasis. Moreover, given that ROCK 
expression which typically appeared in supra-basal layers in vivo, as shown in 
ras/fos/Δ5PTENflx hyperplastic and papillomas histotypes, but in the in vitro 
context, when ROCK activity was forced to express in low calcium medium, it 
affects in the increased levels of early K1 expression which associated with 
ROCK2 functions in differentiation.  
 
Intriguingly, keratin K1 status appeared completely reversed in both 
K14.cre/lsl.ROCKer/Δ5PTENflx and K14.cre/Δ5PTENflx keratinocytes giving high 
levels in low calcium medium but low levels of K1 expression in high calcium 
medium, which is in sharp contrast to typical K1 expression in normal 
keratinocytes. Typically in normal mouse keratinocytes, K1 appeared in a higher 
degree of expression upon induction of high calcium as keratinocytes naturally 
differentiate. This unique low level of K1 expression in high calcium medium could 
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correspond to the delay in K1 expression given the increased in basal layers 
observed in hyperplastic K14.cre/lsl.ROCKer/Δ5PTENflx and the later 
K14.cre/Δ5PTENflx histotypes due to an increase in keratinocyte proliferation. One 
thing is clear is that inactivation of PTEN phenotypes is linked to this observation. 
It may be due to activated AKT acitivity that alter the keratinocyte differentiation, 
since both K14.cre/lsl.ROCKer/fos and HK1.fos keratinocytes showed the typical 
fashion of K1 expression similar to normal keratinocytes. Moreover, this is still in 
speculation since it is concern that the outcome from in vitro may not be the same 
as in vivo. One possibility is that in the K14.cre/Δ5PTENflx epidermis, p-AKT 
expression is selective and typically observed in supra-basal layers compared to 
p-AKT expression in K14.cre/Δ5PTENflx keratinocytes culture where it is 
expressed all the time (Yao et al., 2006). Thus, it is speculate that high K1 
expression in the low calcium media of both K14.cre/lsl.ROCKer/Δ5PTENflx and 
K14.cre/Δ5PTENflx keratinocytes may be due to activated AKT mediating 
proliferation that was countered by more keratinocyte differentiation leading to K1 
expression. Therefore, this may explains for the higher expression of the 
differentiation keratin K1 in low calcium medium of both 
K14.cre/lsl.ROCKer/Δ5PTENflx and K14.cre/Δ5PTENflx keratinocytes. Whilst, in the 
context of high calcium medium, these data suggest that activated AKT is now a 
potent oncogenic insult, thus induce inhibition of differentiation as reflected by the 
low levels of K1 expression in both K14.cre/lsl.ROCKer/Δ5PTENflx and 
K14.cre/Δ5PTENflx keratinocytes. Thus, this may explains that the appearance of 
both K14.cre/lsl.ROCKer/Δ5PTENflx and K14.cre/Δ5PTENflx keratinocytes were not 
fully deteriorated even after induction of second high calcium switch (0.15 mM) 
compared to other transgenic keratinocytes in the same condition. 
 
At the same time, the elevated of K1 expression in low calcium medium which 
indicates the roles of ROCK2 in differentiation activity was accompanied by lack of 
K6 expression in the same condition upon ROCK2 activation. This is consistent 
with early findings of low levels and patchy of K6 expression in K14.cre/lsl.ROCKer 
hyperplasia histotypes, despite the fact that K6 marker is typically express strongly 
in response to hyperproliferation or wounding (Schermer et al., 1989). On the 
other hand, keratin K6 expression in low calcium medium was noteably restored in 
K14.cre/lsl.ROCKer/fos and K14.cre/lsl.ROCKer/Δ5PTENflx keratinocytes parallel to 
K6 expression in normal keratinocytes. For K14.cre/lsl.ROCKer/fos keratinocytes, 
this outcome is consistent with strong and uniform K6 expression accompanied by 
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hyperproliferation or in response to wounding in K14.cre/lsl.ROCKer/fos benign 
papillomas. However, in K14.cre/lsl.ROCKer/Δ5PTENflx and K14.cre/Δ5PTENflx 
keratinocytes, again, restored K6 expression may be responsive to p-AKT-
mediated proliferation activity as it is expressed all the time (Yao et al., 2006). 
Nonetheless, none of the bi-genic keratinocytes showed resistance to high calcium 
which is a classic indicator of malignant transformation (Morgan et al., 1992) and 
this outcome is in accordance to the in vivo data where there is no evidence of 
malignancy in K14.cre/lsl.ROCKer, K14.cre/lsl.ROCKer/fos and 
K14.cre/lsl.ROCKer/Δ5PTENflx mice.  
 
4.6 Co-operation of ROCK2, HK1.ras and HK1.fos in 
transgenic mouse skin carcinogenesis 
 
A major goal of this study was to assess ROCK2 activation in skin carcinogenesis 
via a mimic of the two-stage DMBA/TPA studies performed earlier on K14.ROCKer 
mice with a view to identifying the co-operating genes, determine at which stage 
the 4-HT-activated ROCK2 becomes causal and investigate the subsequent 
progression mechanism. As outlined in the introduction, the bi-genic rasHa/fos 
model is a mimic of the two-stage chemical carcinogenesis model (Greenhalgh 
and Yuspa, 1988, Greenhalgh et al., 1990) where in vitro co-operation resulted in 
malignancy; whereas in transgenic mice HK1.ras1276/fos produced a persistent 
papillomas with no sign of regression (Greenhalgh et al., 1993c); a result now 
attributed to elevated compensatory p53/p21 profiles (Macdonald et al., 2014). 
The initial bi-genic ROCK/ras1205 studies found that co-operation mainly centred on 
the conversion stage from papilloma to carcinoma context. This apparently 
required wound-associated promotion to achieve the correct papilloma context for 
ROCK causality; which then drove malignant progression to the point where the 
spontaneous progression momentum no longer required exogenous ROCKer. 
Excitingly, bi-genic ROCK/fos revealed for the first time a novel early co-operation 
between ROCK2 and fos in benign papilloma formation. Thus, this finding was 
consistent with ROCK being a downstream effector of ras signalling; possibly 
performing an initiating role for co-operation with fos, similar but less potent to that 
observed in HK1.ras1276/fos mice (Greenhalgh et al., 1993c). However, no 
malignant conversion was observed in the bi-genic ROCK/fos context. These data 
also suggest that ras activation was required to achieve the correct papilloma 
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context that facilitated causal roles for ROCK in conversion and tested in the tri-
genic ROCK/ras1276/fos models and compared with ROCK/fos and ROCK/ras 
carcinogenesis involving mutant PTEN and deregulation of AKT signalling. 
 
Remarkably, all tri-genic lines (ROCK/ras1276/fos, ROCK/fos/Δ5PTENflx and 
ROCK/ras1276/Δ5PTENflx (and ROCK/ras1205/Δ5PTENhet)) resulted in a synergism 
that directly led to malignancy in 100% of animals. Here, in the first tri-genic 
K14.cre/lsl.ROCKer/ras1276/fos model, activated rasHa provides the initiation step 
and activated fos oncogene provides the promotion; thus co-operation of both 
oncogenes with ROCK2 activation then resulted in direct malignancy conversion 
but progression was still relatively limited and this tri-genic synergism achieved 
mainly wdSCC and SCC histotypes. This study was originally tailored to mimic the 
previous study by Samuel et al., (2011) where K14.ROCKer mice were induced 
with both DMBA/TPA resulted in increased carcinomas. This tri-genic 
ROCK/ras1276/fos synergism also gave a similar conclusion of malignant 
conversion and also identified that a specific context of papillomas had to develop 
since there was lack of papillomatogenesis in bi-genic ROCK/ras1276 mice; whilst 
both bi-genic ROCK/fos and ras1276/fos (Greenhalgh et al., 1993c) developed 
benign papillomas with no sign of malignant conversion. Furthermore, although in 
this ROCK/ras1276/fos model, both ras and fos appeared to provide the initiation 
and promotion elements (which mimic the DMBA/TPA carcinogenesis), but 
following ROCK2-mediated conversion, the tumours appeared mainly as wdSCCs 
with some progression of SCC nests histotypes.  
 
In comparison, the other two tri-genic (with PTEN) models demonstrated more 
aggressive SCC histotypes consistent with deregulation of both MAPK kinase and 
PTEN/AKT signalling in co-operation with ROCK2 activation; a result similar to 
TPA promotion of bi-genic ras1276/Δ5PTENflx mice (Yao et al., 2006). This 
difference was due to strong and persistent expression of p21 in all epidermal 
compartments of ROCK/ras1276/fos tumours in comparison to the other two tri-
genic models. Moreover, though p53 appeared faded, and is typically associated 
with reduced expression in late-stage papillomas (Macdonald et al., 2014). Whilst 
some traces of residual p53 expression were noted in the supra-basal layers, it 
was the high levels of basal p21 expression in the wdSCC/SCC histotypes that 
appears to inhibit the early stages of malignant progression. This compensatory 
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p53/p21 expression followed the same pattern in the previous tri-genic 
ras1276/fos/Δ5PTENflx carcinogenesis where p21 showed strong expression in the 
basal layer upon p53 loss that delays tumour progression through differentiation 
activity (Macdonald et al., 2014).  
 
This study proves that ROCK2 activation plays a key role in the malignant 
transformation; although it is undeniable that there is no tumour growth in 
HK1.ras1276 mice without fos promotion (Greenhalgh et al., 1993c) as confirmed in 
bi-genic ROCK/ras1276 and the need for wounding in ROCK/ras1205 cohorts. This 
model also identifies the role for ROCK as a malignant converter in bi-genic 
ras1276/fos mice since these tumours still remained benign papillomas (Greenhalgh 
et al., 1993c) and this was due to strong p53/p21 expression (Macdonald et al., 
2014) before ROCK2 activation managed to turn to carcinomas; as discussed 
above in bi-genic ROCK/ras1205 co-operation studies. Here, in tri-genic 
ROCK/ras1276/fos a similar compensatory p21 expression limited early stage 
progression, but given the goal to contrast with other tri-genic (with PTEN) models, 
AKT was investigated and these data showed that the lack of aggressive SCCs 
may be due to a lack of AKT deregulation. This proved to be a major difference in 
the models and shows the consequences of MAPK and PTEN/AKT in conjunction 
with ROCK mediated progression. This again has consequences for therapies and 
makes ROCK as a good dual target where both MAPK and AKT are disrupted. 
 
One more interesting outcome in this tri-genic ROCK/ras1276/fos model was 
analysis of AKT signalling, as here, the tri-genic histotypes exhibited no activated 
p-AKT1 expression even in the areas with p53 loss. Following malignant 
transformation in tri-genic ROCK/ras1276/fos mice, and histotypes confirmed by 
routine loss of keratin K1/p53 expression in the wdSCC/SCC area, thus it was 
expected that there would be high expression of activated AKT. It is known that 
there is an interrelationship between p53 and AKT roles in cell death versus cell 
growth that commonly being disrupted during cancer; as p53 can essentially 
trigger PTEN suppressor gene expression leading to deactivation of AKT activity 
(Haupt et al., 2003). Whilst in reverse, activated AKT can activate MDM2 activity 
and degrade p53 to promote proliferation and cell survival (Mayo and Donner, 
2002, Haupt et al., 2003). Therefore, from the evidence of no p-AKT1 expression, 
this study indicates that the malignancy transformation in tri-genic 
ROCK/ras1276/fos model appeared to have a unique lack of a link to p-AKT 
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activation in the presence of a fully functional PTEN tumour suppressor gene. This 
result is unclear, and may be due to the significant levels of p21 expression 
observed, or that p-AKT1 is unnecessary in this context of malignant progression 
mediate by ROCK/ras1276/fos co-operation. In a tri-genic study on 
ras1276/fos/Δ5PTENflx mice, increasing levels of p-AKT expression appeared 
following inactivation of PTEN activity and upon loss of p53/p21 expression in 
aggressive SCCs (Greenhalgh, – manuscript in preparation). However, in 
papillomatogenesis and malignant conversion, it was mTOR activation that 
appeared to drive the mechanism and superceed by AKT on progression of 
wdSCC to SCC (Greenhalgh, - manuscript in preparation).  
 
These observations again highlight the differences and similarities involving these 
pathways and that the context produced by differing mutations is important to the 
final outcome. Thus, this study shows that the interaction between ROCK and 
ras/MAPK signalling pathway essentially provides the correct papilloma context 
where ROCK2 activation contributes to the later stages of carcinogenesis. These 
data are importance to the design of new therapeutic targets, in particular this 
designed to find an Achilles Heel to counter ras-mediated carcinogenesis. As to 
date, there are still continuous studies to find a clinically-approved way to inhibit 
ras in context of cancer therapy. Therefore, this study suggests that targeting 
ROCK2 signalling could be an effective approach to target ras signalling since 
ROCK acting downstream of ras family, not only functions as an initiatior in 
papillomatogenesis alongside fos activation, but also act as a key role in malignant 
conversion and progression. Moreover, based on data below, it appears that 
ROCK plays a primary role in malignant progression to quite aggressive 
carcinomas when both MAPK and AKT signalling are disrupted. 
 
4.7 Co-operation of ROCK2, HK1.fos and 
K14.cre/Δ5PTENflx in transgenic mouse skin 
carcinogenesis 
 
In the bi-genic models, activated ROCKer and fos co-operation resulted in highly 
keratotic, benign papilloma formation, but unlike bi-genic ROCK/ras1205, no 
malignant conversion was observed. These data revealed a novel early co-
operation between ROCK and fos signalling deregulation in papillomatogenesis 
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where ROCK2, being downstream of ras, may substitute an initiation role. In 
addition, the tri-genic ROCK/ras1276/fos section also demonstrated that ROCK2-
mediated carcinogenesis required the late stage autonomous papilloma context 
supplied by HK1.ras1276/fos synergism, but only achieved a limited progression to 
wdSCC/SCC; possibly due to elevated p21 and the surprising lack of AKT 
activation. Given that very little synergism was observed in 
K14.cre/lsl.ROCKer/Δ5PTENflx cohorts and this lack of AKT in tri-genic 
ROCK/ras1276/fos models, these data suggested that ROCK2 activation appeared 
to be a specific partner in crime to deregulation of the MAPK; and that the 
PTEN/PI3K/AKT pathway was not involved in ROCK mediated mechanisms. If so, 
this would have serious implications for the design of new therapies. This seemed 
unlikely, and as observed above, a simple explanation was that the appropriate 
context was not achieved in this tri-genic context; as observed by 
K14.cre/lsl.ROCKer/Δ5PTENflx synergism, either due to redundancies or 
compensatory responses such as rapid elevation of p53/p21 expression or a lack 
of AKT activation. As noted for K14.ROCKer/HK1.ras1205 co-operation, a significant 
oncogenic gap exists between event supplied by PTEN mutation at the initiation 
stage and roles for ROCK activation at the later stages of carcinogenesis. 
 
Further, it was possible that PTEN mutation may drive a different mechanism of 
carcinogenesis, as discovered when introduced into the HK1.fos model resulting in 
KAs (Yao et al., 2008). In this fos/Δ5PTENflx context, no evidence of malignancy 
was recorded due to GSK3β inactivation; which induced a compensatory p53/p21 
expression that had been previously missing in the early hyperplasia, a result 
different to these ROCK2 models here, and this expression of p53/p21 diverted 
proliferative papilloma keratinocytes into programme of terminal differentiation and 
keratosis/KA formation (Yao et al., 2008). Indeed, this roles of GSK3β would be of 
major interest to these studies given the putative interactions of ROCK signalling 
with β-catenin (Samuel et al., 2011) which is a prime degradation target of GSK3β 
(Ghosh and Altieri, 2005). Also, K14.cre/lsl.ROCKer/Δ5PTENflx co-operation 
already identified changes in epidermal differentiation in vivo and in vitro (lack of 
K6 /premature K1) that are consistent with an inhibition of early neoplasia. 
 
Hence, given this background from the bi-genic synergisms of ROCK/ras1205 and 
ROCK/fos to tri-genic ROCK/ras1276/fos model, the data demonstrated that the 
deregulation of MAPK signalling pathway appears to be a crucial partner for 
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ROCK2-mediated tumourigenesis. If so, generation of these 
K14.cre/lsl.ROCKer/fos/Δ5PTENflx cohorts in essence assessed whether additional 
mutation events in ROCK signalling coupled to addition of deregulated AKT 
signalling would change the outcome from KA to SCC; and if so, this allowed 
investigation of how (and when) the protective p53/p21 expression was 
circumvented. Indeed, it seems that PTEN/PI3K/AKT pathway is a weak target for 
co-operation with ROCK2 activation since bi-genic ROCK/Δ5PTENflx showed no 
evidence in papillomatogenesis even after almost 7 months. However, it was 
possible that introduction of p-AKT1 expression in the tri-genic 
ROCK/fos/Δ5PTENflx model could be the facet that produce the correct context for 
malignant conversion mediated by ROCK.  
 
This proved to be the case as K14.cre/lsl.ROCKer/fos/Δ5PTENflx mice 
demonstrated rapid formation of overt keratotic papillomas that transformed to 
aggressive SCC as early as 9 weeks. This tri-genic synergism showed direct co-
operation between ROCK2 activation and bi-genic fos/Δ5PTENflx to change the 
final outcome from KAs (Yao et al., 2008) to SCC. Moreover, whilst ROCK2 
activation clearly acts as an initiator with fos papillomatogenesis, this study 
suggests that ROCK2 activation now also acts to transform the fos/Δ5PTENflx 
papillomas into a carcinoma in this tri-genic model (ROCK/fos/Δ5PTENflx). Thus in 
this sense, the outcome seems to be more similar to previous tri-genic 
ras1276/fos/Δ5PTENflx synergism (Macdonald et al., 2014) and the outcome of tri-
genic ROCK/ras1276/fos (above). Here, a rapid increase in p53/p21 expression was 
displayed in the ROCK/fos/Δ5PTENflx earlier hyperplasias associated with loss of 
filaggrin and loricrin expression upon malignancy. This was very different pathway 
to that of KA formation in previous bi-genic fos/Δ5PTENflx mice (Yao et al., 2008) 
and suggests that the co-operation between ROCK and fos already locks in the 
final tumour outcome, but at this early stage as also observed in tri-genic 
ras1276/fos/Δ5PTENflx wdSCCs, where it was p21 expression that limited further 
malignant progression (Macdonald et al., 2014).  
 
However, in this study, the tri-genic ROCK/fos/Δ5PTENflx model managed to 
convert to wdSCC and also advanced to progressive SCC histotypes; and now it 
appears AKT activation is playing a role in driving this progression alongside 
ROCK activation. This mechanism involved loss of keratin K1 and p53 expression 
in late stage papillomas, and following conversion in 
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K14.cre/lsl.ROCKer/fos/Δ5PTENflx mice, p21 expression had also become reduced 
and now became supra-basal in the more aggressive SCCs. Thus, the activated 
AKT may now freely function in these wdSCC/SCC basal layers to induce more 
proliferation as shown by Brdu-labelling and this in turn suggests a loss of cell 
cycle control adds to ROCK co-operation in alterating tissue stiffness and driving 
further progression.  
 
This latter idea is supported by the observation that tri-genic ROCK/fos/Δ5PTENflx 
tumours also displayed thick and invasive proliferative layers with some 
intercellular gaps that are among the distinguish features of malignant progression. 
Therefore, this tri-genic outcome is consistent with ROCK activity being associated 
with late stage carcinogenesis (Croft et al., 2004, Samuel et al., 2011, Morgan-
Fisher et al., 2013) with now a clear role for its co-operation with deregulated 
PTEN/PI3K/AKT together with fos/MAPK. Further, as the tumours in tri-genic 
ROCK/fos/Δ5PTENflx appeared more aggressive than tri-genic ROCK/ras1276/fos, 
this dual activation of PTEN/AKT and fos/MAPK pathways may provide a 
proliferative context where ROCK2 functions in induction of tissue stiffness may 
accelerate epidermal proliferation and tumour progression.  
 
In addition, this ROCK2 activation mediated progression may be accompanied by 
changes in β-catenin transcriptional activity that adds to cell motility and stiffness 
(Kumper and Marshall, 2011, Samuel et al., 2011). If so, this increased tissue 
stiffness would also affect in changes of epithelial morphogenesis (Jaalouk and 
Lammerding, 2009), such as the gaps observed between SCC keratinocytes. 
Since it is become known that ROCK activation mediates actomyosin contraction 
which induce tissue stiffness (Kumper and Marshall, 2011, Samuel et al., 2011), a 
stiffer tissue associated with invasion phenotypes (Jaalouk and Lammerding, 
2009), may be more brittle and easily fractures during histological processing. 
Thus, this would explain the odd rips notably displayed in the SCC areas together 
with some intercellular gaps in the epidermis which do not appeared in 
fos/Δ5PTENflx keratotic papillomas or in any early bi-genic ROCK/fos benign 
tumours. Therefore this indicates that in tumour morphogenesis, the increased 
tensile strength that emerges due to ROCK activation is also an important 
biomechanical feature to influence the status of tumourigenesis in addition to 
biochemical signals. Thus, the availability of these tumours (and also in those of 
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K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx and K14.ROCKer/ras1205/Δ5PTENhet 
genotypes) will greatly aid in the investigation of this progression mechanism. 
 
The finding that tri-genic ROCK/fos/Δ5PTENflx co-operation produced SCCs was 
very different to the outcome of bi-genic fos/Δ5PTENflx synergism which 
progressed to KAs after 5 to 6 months (Yao et al., 2008). In this study, control 
fos/Δ5PTENflx mice were kept on procedure for 9 weeks only and thus, have yet to 
develop a KA histotype. Nonetheless, in terms of an altered differentiation profile, 
whilst the tri-genic mice shown few features of KA, they did display highly keratotic 
papillomas and some indications of pre-mature differentiation, e.g. formation of 
micro-cysts in the papillomas and wdSCCs. Further, in 
K14.cre/lsl.ROCKer/fos/Δ5PTENflx tumours, there are some microcysts embedded 
in the epidermal layers due to this fos/Δ5PTENflx-associated anomalous 
differentiation (Yao et al., 2008). However, although both 
K14.cre/lsl.ROCKer/fos/Δ5PTENflx and K14.cre/fos/Δ5PTENflx tumours have this 
anomalous differentiation feature, the tri-genic ROCK/fos/Δ5PTENflx mice did not 
exhibit the odd premature basal K1 expression (Yao et al., 2008), nor was tri-genic 
ROCK/fos/Δ5PTENflx differentiation accompanied by strong loricrin and filaggrin. 
These data again highlight that at quite early stages the progression mechanism 
had become quite different and also highlighted the difference between these two 
tumours highlighted that ROCK activation during papillomatogenesis may increase 
the chance of malignant outcome.  
 
Moreover, in K14.cre/lsl.ROCKer/fos/Δ5PTENflx tumours, although K1 expression 
persisted in the microcysts in response to the mixed proliferation/differentiation 
signals, rapid loss of K1, together with loss of loricrin and filaggrin was again 
displayed upon conversion to wdSCC and rapid progression to SCC. This loss of 
the later markers of terminal differentiation (loricrin and filaggrin) indicated an 
acceleration in keratinocyte proliferation possibly mediated by elevated AKT 
expression in conjunction MAP Kinase activation and this combination lead to the 
loss of compensatory p21 expression (Macdonald et al., 2014, Greenhalgh, - 
manuscript in preparation). In tri-genic ROCK/fos/Δ5PTENflx SCCs, the tumours 
demonstrated elevated p-AKT1 expression following loss of p53 expression and 
now p21 expression appeared more supra-basal. This observation is consistent 
with p53/p21 loss in tri-genic ras1276/fos/Δ5PTENflx mice where aggressive SCCs 
first co-express p-AKT1 and p21 in basal layers, but in older SCCs, expression of 
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p-AKT increased whilst p21 expression disappears (Greenhalgh, – manuscript in 
preparation).  
 
This finding was also observed to a greater degree in the ultimate tri-genic 
ROCK/ras/PTEN model; where it is consistent with low levels of p53/p21 status as 
in this study, supra-basal p-AKT1 expression became basal and upon loss of p21 
expression accelerated SCC progression to pdSCCs. This is in sharp contrast to 
lack of p-AKT1 expression in tri-genic ROCK/ras1276/fos model where only 
wdSCCs/SCCs resulted. Collectively, these observations imply that to the 
inactivation of PTEN activity and induction of AKT activity together with MAP  
Kinase deregulation, increases proliferation in this tri-genic ROCK/fos/Δ5PTENflx 
model where an overlay of ROCK mediated activities in for instance increasing 
tissue stiffness contributed to the progression (Kumper and Marshall, 2011, 
Samuel et al., 2011). This again suggest that ROCK may be a useful therapeutic 
target affecting both pathways (Downward, 2003, Rath and Olson, 2012) and in a 
final series of experiments, this idea of ROCK activity in tissue stiffness overlaid 
onto deregulated MAPK and PTEN/AKT was stringently tested in the more potent 
in tri-genic ROCK/ras/PTEN model. 
 
4.8 Co-operation of ROCK2, HK1.ras and 
K14.cre/Δ5PTENflx in transgenic mouse skin 
carcinogenesis 
 
As discussed above in a K14.cre/∆5PTENflx background, ROCK activation showed 
little co-operation; with no evidence of tumour formation even after seven months. 
Whilst there were alterations in differentiation indicated by K1/K6 analysis, this 
combination appeared impotent or was subjected to the elevated compensatory 
p53/p21 and thus lacked of p-AKT expression. This lack of 
K14.cre/lsl.ROCKer/Δ5PTENflx tumours also contrasted with previous 
K14.cre/∆5PTENflx co-operation with HK1.ras1276 which demonstrated a regular 
papillomatogenesis but malignant conversion required TPA (to activate c-fos) to 
elicit a very rapid progression to malignancy (Yao et al., 2006). Here, following 
only 2-3 weeks of TPA promotion, both p53 and p21 were early casualties in this 
rapid malignant progression (Yao et al., 2006); a result again consistent with 
malignant conversion mechanism observed in the tri-genic ras1276/fos/∆5PTENflx 
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models (Macdonald et al., 2014). For comparison, co-operation between ROCK 
and HK1.ras1205 did achieve malignant conversion, and this appeared dependent 
upon the promotion stimulus received from wounding. In all the previous ROCK 
models, the majority of mice exhibited wdSCCs with the occasional mix of more 
aggressive SCCs, and this was likely due to persistent p21 expression following 
loss of p53, possibly antagonising p-AKT1. Thus, this may suggest a common 
compensatory response to inhibit the early stages of malignant progression. 
However, as shown in K14.ROCKer/HK1.ras1205 mice, the tumours produced were 
prone to spontaneously progress (at 16 – 18 weeks) and it appeared that 
exogenous ROCK2 could drive the progression to pdSCC histotypes, but 
subsequent finding shows that once SCC histotype had been achieved, 
exogenous ROCK2 appeared no longer necessary; possibly given the elevated 
levels of endogenous ROCK (1 and 2) expressed upon malignant progression as 
displayed in the introduction (Samuel et al., 2011). 
 
Therefore, this ultimate tri-genic genotype was geared to assess whether ROCK2 
co-operation with HK1.ras1276 (and later HK1.ras1205) in the context of mutated 
PTEN, could achieve an accelerated malignant progression to elicit SCC/pdSCC. 
This would test the idea that the combination of ROCK/ras1276 and a Δ5PTENflx- 
mediated loss of AKT regulation overcame the compensatory p53/p21 responses. 
Indeed, this proved to be the case and also highlighted that once the appropriate 
context had been achieve, despite even taking a seriously long time to achieve a 
papilloma, malignant conversion and progression to aggressive SCC did not need 
large-sized tumours. Initially, in this final tri-genic model, ROCK2 co-operation had 
to be assessed in ras1276/∆5PTENflx as total loss of PTEN function in HK1.ras1205 
mice had proved to be too severe. Interestingly, not only was tri-genic 
ROCK/ras1276/∆5PTENflx synergism observed, but also this tri-genic model 
demonstrated that despite taking many weeks to achieve a papilloma, progression 
to SCC was rapid with a mix of pdSCC histotypes; which was one of the most 
aggressive histotypes produced when compared with other two tri-genic models 
(ROCK/fos/∆5PTENflx and ROCK/ras1276/fos). Although in the beginning, given the 
small size of tumours observed in these tri-genic ROCK/ras1276/∆5PTENflx mice 
compared to larger tumours produced in the other 2 tri-genic models, this histotype 
outcome was totally unexpected. Though, this outcome may be understandable 
due to lack of tumours in bi-genic ROCK/ras1276 and ROCK/Δ5PTENflx mice.  
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It became very clear that even in these tiny tumours, activated ROCK2 triggered 
malignant conversion and promoted malignant progression to pdSCCs. Whereas, 
previous bi-genic ras1276/∆5PTENflx models exhibited no evidence of malignancy, 
unless promoted with TPA (Yao et al., 2006), or had fos included but even here 
the tumour outcome was mainly wdSCC due to the p21/AKT interaction 
(Macdonald et al., 2014). In the tri-genic ROCK/ras1276/∆5PTENflx mice, malignant 
progression to pdSCC histotypes demonstrated numerous finger-like projections 
into the dermis, and was confirmed by complete keratin K1 loss. Moreover, despite 
their small size, these tri-genic tumours were accompanied by remarkable and 
complete loss of both p53/p21 expression. Also this was now coincided with 
increased p-AKT1 expression in all epidermal layers, and a massive BrdU labelling 
scattered throughout the tumour and indicated a massive increase in proliferation 
consistent with both p53 and p21 loss.  
 
This early loss of both p53 and p21 may be the significant highlight that driving the 
difference in malignant progression between tri-genic ROCK/ras1276/∆5PTENflx 
models and other tri-genic models of this study. Interestingly, lack of p21 
expression appeared even in the tri-genic ROCK/ras1276/∆5PTENflx wdSCC areas, 
following complete loss of p53. The most significant previous tri-genic observation 
closest to this tri-genic result was wdSCC progression to SCC of tri-genic 
ROCK/fos/∆5PTENflx mice where p21 expression became supra-basal upon p53 
loss, in which released p-AKT expression to drive progression to aggressive SCCs 
possibly in conjunction with ROCK2 activation. Thus, the p21 loss reflected strong 
and basal p-AKT1 expression and may help explain the development of the most 
aggressive carcinomas produced in this tri-genic model to date. This consistent 
finding of p-AKT1 expression even in K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx 
wdSCC basal histotypes induced more proliferation activity that coincided with 
total loss of p53 and p21 expression, compared to supra-basal p-AKT1 expression 
due to persisted p21 expression in K14.cre/lsl.ROCKer/fos/Δ5PTENflx tumours.  
 
Further, it is intriguing that this tri-genic ROCK/ras1276/∆5PTENflx model was able 
to achieve pdSCC histotypes, yet, it took about 5 to 6 months of 4-HT treatment 
before an apparent instant malignant conversion and rapid progression to 
pdSCCs. This may imply a lack of sensitivity to promotion during the 
papillomatogenesis phase in this tri-genic model, as HK1.ras line 1276 is 
insensitive to wound promotion (Greenhalgh et al., 1993a). This was shown in bi-
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genic ROCK/ras1276 mice, whereas in bi-genic ROCK/ras1205 mice, wound 
promotion was essential to achieve a proper papilloma formation to form before 
conversion to malignancy was mediated by ROCK. Therefore, is this was correct, 
it was theorised that in additional tri-genic ROCK/ras1205/∆5PTENhet models where 
HK1.ras line 1205 was sensitive to wound promotion (Greenhalgh et al., 1993a) 
would the large tumours produced be susceptible to malignant conversion. And if 
so, would they also exhibit a rapid progression to pdSCCs as observed at 16-18 
weeks in bi-genic ROCK/ras1205 mice (above) or as observed in TPA treated bi-
genic ras1276/Δ5PTENflx mice (Yao et al., 2006); where significant levels of 
endogenous ROCK (1 and 2) had been observed upon tumour progression as 
shown in the introduction. 
 
Indeed, this proved to be the case as large tumours appeared in all tri-genic 
ROCK/ras1205/∆5PTENhet mice which were obviously malignant whereas bi-genic 
ras1205/∆5PTENhet mice produced clusters of autonomous papillomas (Yao et al., 
2006). These tri-genic ROCK/ras1205/∆5PTENhet tumours rapidly produced SCCs 
that had progressed to pdSCCs in just 4 to 6 weeks. Here, again these data prove 
the important roles of ROCK2 activation in both malignant conversion and 
progression. Further, this ROCK/ras1205/∆5PTENhet synergism also resulted an 
immediate loss of both compensatory p53/p21 status; as observed in TPA-treated 
ras1276/Δ5PTENflx experiments, which again gave increased p-AKT activity 
throughout the tumours, as observed in the complementary tri-genic 
ROCK/ras1276/∆5PTENflx model. Moreover, p53 loss had occurred even during late 
stage papilloma followed by supra-basal p21 expression, before both p53/p21 
disappeared upon malignancy, and this highlight the remarkable rapid tumour 
progression in this tri-genic ROCK/ras1205/∆5PTENhet model as compared to 
p53/p21 status in other malignancies from tri-genic ROCK/fos/Δ5PTENflx and 
ROCK/ras1276/fos or bi-genic ROCK/ras1205 models.  
 
Furthermore, this feature of ripped tissue during histological processing of these 
ROCK/ras1205/∆5PTENhet SCCs which also appeared in tri-genic 
ROCK/fos/Δ5PTENflx SCCs, that provides strong evidence that ROCK2 activation 
mediated an increased tissue stiffness and possibly mediated cell migration that 
gave rise to the intercellular gaps (Kumper and Marshall, 2011, Samuel et al., 
2011). Although the appropriate mechano-analysis has yet to be performed 
(Samuel et al., 2011), the tenascin C data would seem to support this idea 
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together with data that have shown that ras oncogene mediated extracellular 
signal regulated kinase (ERK) activation can also induce tissue stiffness via 
increased cellular tension (Jaalouk and Lammerding, 2009). Thus, the link 
between ras/ERK and ROCK pathways-mediated tissue stiffness (Jaalouk and 
Lammerding, 2009) may lead to more malignant progression but it may be that 
ROCK roles involve cell-cell elements such as β-catenin activation (Samuel et al., 
2011) or failure in E-cadherin signalling and disrupt adherens junctions, which may 
be accountable for the intercellular gaps leading to brittle/ripped tissues in this tri-
genic ROCK/ras1205/∆5PTENhet model. Therefore, these two tri-genic models: 
ROCK/fos/Δ5PTENflx and ROCK/ras1276/∆5PTENflx (and ROCK/ras1205/∆5PTENhet) 
have proven the important relationships between ROCK2 activation and 
PTEN/PI3K/AKT and ras/MAPK/fos pathways in mediating tumourigenesis. 
Chapter 5 
Chapter 5 – Conclusions and future studies 
 
Collectively, this study identified direct co-operation between ROCK2 activation 
and ras, fos and /or PTEN-mediated loss of AKT regulation in multi-stage 
transgenic mouse skin carcinogenesis. Consistent with previous studies, ROCK2 
activation is mainly associated with the later stages of carcinogenesis and acts to 
drive malignant progression. However, this study also demonstrates that ROCK2 
is involved at the earlier stage of malignant conversion, one of the most important 
stages in clinical terms and also another important conclusion was that the final 
outcome depended on the co-operative partners. It was clear that the appropriate 
benign tumour context had to be achieved for ROCK2 co-operation and malignant 
conversion. Even in the novel findings where for the first time ROCK2 deregulation 
was shown to co-operate with fos and now produced tumours, these remained 
benign and showed no sign of conversion. In the absence of wound promotion, bi-
genic ROCK/ras tumours did not achieve malignancy; thus the appropriate 
papilloma context had to be achieved before ROCK2 was able to drive malignant 
conversion and progression. Further, in the tissue context created by ROCK and 
PTEN deregulation, it appeared that this combination failed to achieve even a 
benign tumour, suggesting either redundancy or the necessary events to bridge 
the oncogene gap. Hence, introduction of MAP Kinase deregulation into 
ROCK/PTEN epidermis via either fos or ras activation quite rapidly produced 
aggressive SCCs; which in some contexts rapidly progressed to pdSCCs. In 
reverse, in the absence of PTEN/AKT deregulation, whilst ras and fos provide the 
appropriate papilloma context for ROCK causality in the conversion stage, the 
progression was limited to mainly wdSCCs and this was due to persistent p21 
expression. 
 
In the bi-genic models, malignant conversion in the ROCK/ras1205 model was 
shown to be driven by ROCK2 activation but this required wound promotion. 
However, after the early stages of malignancy, it would appear that malignant 
progression occurred even without exogenous ROCK2 activation; possibly given 
the increased expression of endogenous ROCK upon malignant progression. 
Indeed, in the cessation experiments that this 4-HT-treated ROCK model is 
specifically designed to test, the results show that whilst exogenous ROCK2 was 
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required for conversion, once a SCC or pdSCC histotype was attained, exogenous 
ROCK2 was no longer rate limiting, and p21 was lost. However, the most 
astonishing result was the resultant rapid outgrowth of papilloma and the levels of 
p21 expression exhibited by these papillomas. That their histotype was benign 
papillomas would suggest that continuous exogenous ROCK activation was 
needed for conversion and to maintain a malignant histotype; i.e. these tumours 
were oncogene dependent. However, one additional conclusion suggested by 
these data may be that 4-HT treatment successfully inhibits the growth of a 
papilloma sub-type, which now appears and this type cannot convert, given the 
high levels of p21. Thus, in this context, ROCK2 may indirectly act earlier with ras 
in papillomatogenesis, and 4-HT actually selects for papillomas prone to 
conversion (but not in bi-genic ROCK/fos papillomas). Nonetheless, all these 
models show an important role for p21 in limiting carcinogenesis following p53 
loss. 
 
Here interestingly, the bi-genic ROCK/fos model showed a novel finding of ROCK2 
activation as it possessed roles as an initiator in co-operation with fos activation to 
induce benign squamous papillomas. In comparison to papilloma formation in 
early bi-genic ROCK/ras1205 (at eight weeks), this bi-genic ROCK/fos model 
showed no sign of conversion, and bi-genic ROCK/fos papillomas showed high 
level of compensatory p53/p21 expression when compared to bi-genic 
ROCK/ras1205 papillomas. Unlike bi-genic ROCK/fos papillomas, in bi-genic 
ROCK/ras1205 papillomas, p53 expression became lost allowing conversion 
followed by supra-basal p21 expression and loss of protection in the proliferative 
benign basal keratinocytes. Thus, these data showed the difference role of 
ROCK2 activation with each ras and fos in these early-stage cancer events; and 
that additional mutations are required to achieve malignancy which were assessed 
in the tri-genic synergism experiments.  
 
Also, for the first time, a new lsl.ROCKer model, designed to express from a 
universal promoter, was successfully employed in this study. These 
K14.cre/lsl.ROCKer/Δ5PTENflx data possessed identical phenotypes and histotypes 
to the original K14.ROCKer model upon activation by K14.creP. Thus, although 
some concerns existed regarding potential technical problems employing this 
lsl.ROCKer model, yet, this concern was eliminated as GFP and p-Mypt1 
expression were confirmed in all epidermal layers including hair follicles. Thus, the 
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fact that K14.cre/lsl.ROCKer/Δ5PTENflx mice developed no obvious tumours over 
an extended period, demonstrated a requirement of additional mutation events to 
fill in the oncogenic gap in this bi-genic ROCK/Δ5PTENflx model. Thus, the lack of 
tumours in this bi-genic model may be due to the unexpected low levels of p-AKT 
which was a possible consequence of compensatory elevated p21 expression. 
 
Alternatively, it may be due to a redundancy in the oncogenic hits supplied 
between ROCK and PTEN, as throughout these studies, one conclusion hinted by 
the data is that in epidermis, their roles in differentiation and barrier maintenance 
may similar. Given that actomyosin contraction by ROCK activation mediated 
changes in adherens junction (Sahai and Marshall, 2002) and previous data 
suggest that PTEN plays an important role in cell-cell adhesion (Subauste et al., 
2005) where both are linked to cell migration through focal adhesion kinase 
signalling. This idea is supported by bi-genic ROCK/Δ5PTENflx synergism that 
appeared to alter the keratinocyte differentiation instead of a commitment to 
papillomatogenesis. Thus, at 27 weeks, bi-genic ROCK/Δ5PTENflx hyperplasia 
showed a significant increase in mitotic index consistent with expansion of 
proliferative basal layers and delayed keratin K1 expression. However, at earlier 
times, this proliferation activity was possibly countered by an accelerated 
differentiation; mediated via ROCK2 and Δ5PTENflx interactions in differentiation 
that affected K1 and K6 expression in vivo and in vitro, and where p21-mediated 
down regulation of AKT at these early stages, might account for their lack of 
tumours. 
 
Nonetheless, despite their lack of tumours, these K14.cre/lsl.ROCKer/Δ5PTENflx 
mice proved to be very useful to investigate epidermal differentiation both in vivo 
and in vitro. Further, the in vitro data provided evidence that supports roles for 
both ROCK2 and PTEN that may be crucial in epidermal homeostasis. These 
roles that accelerate differentiation observed in K14.cre/lsl.ROCKer, 
K14.cre/lsl.ROCKer/fos and K14.cre/lsl.ROCKer/Δ5PTENflx keratinocytes may also 
account for the lack of overt tumours, and this role would certainly influence these 
early stages of carcinogenesis. For instance, premature keratin K1 expression 
suggests a commitment to differentiation, whilst the lack of keratin K6 (associated 
with stress/hyperproliferation) suggests the changes induced by ROCK2 activation 
could influence the differentiation mechanism. This change in keratin K6 was not 
as dramatic as compared to complete absence that observed in vivo following 
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PTEN mutation, which may be a response to anomalous AKT expression in basal 
keratinocytes; but, this again suggests links between ROCK and PTEN in the 
response to anomalous proliferation signals and reinforces links between their 
roles in epidermal physiology. With time, this increased proliferation overtakes this 
effect on differentiation in bi-genic ROCK/Δ5PTENflx model, as does expression of 
fos in the bi-genic ROCK/fos models. Here, data showed that fos activation 
restores both keratin K6 and K1 expression closer to a normal profile in bi-genic 
ROCK/fos keratinocytes in vitro and in vivo, giving highly keratotic papillomas that 
echo the differentiation aspects; again consistent with fos roles as a master 
regulator of epidermal homeostasis. Furthermore, the keratinocyte cell lines that 
have established from neonatal K14.cre/lsl.ROCKer, K14.cre/lsl.ROCKer/fos and 
K14.cre/lsl.ROCKer/Δ5PTENflx cohorts will be useful for further in-depth 
investigations in this differentiation/proliferation mechanism.  
 
Collectively, these bi-genic outcomes establish an early foundation status of 
ROCK2 activation in multi-stage carcinogenesis model compared to alternate 
systems; such as ROCK2 roles in malignant conversion (ROCK/ras1205) prior to 
the more accepted roles in malignant progression. In addition, phosphorylation of 
Mypt1 by ROCK activation which increase actomyosin contraction, may promote 
tenascin C expression as shown in bi-genic ROCK/ras1205 tumours. Whilst 
tenascin C shows high expression upon malignant progression (Dang et al., 2006) 
which is also consistent with ROCK activity in late cancer events (Croft et al., 
2004, Samuel et al., 2011) thus this may provide an idea that there is a possible 
connection between tenascin C and β-catenin in the progression mechanism 
mediated by ROCK2 activation-induced tissue stiffness. Yet this is still unclear and 
will be further investigated in future studies. Also for the first time, ROCK2 
activation acts early in formation of benign tumours and this mimics the initiation 
stage (ROCK/fos). Whilst the weak co-operation between ROCK and inducible 
PTEN loss in papillomatogenesis demonstrates the essential point that context is 
important to the eventual tumour outcome and requires multiple events. 
 
Remarkably, all tri-genic models: K14.cre/lsl.ROCKer/ras1276/fos, 
K14.cre/lsl.ROCKer/fos/Δ5PTENflx, and K14.cre/lsl.ROCKer/ras1276/Δ5PTENflx (and 
K14.ROCKer/ras1205/Δ5PTENhet) demonstrated direct co-operation of ROCK2 
activation and ras, fos, and /or Δ5PTENflx mutations in malignant conversion and 
/or malignant progression. Subsequently, analysis of the underlying mechanism in 
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this whole study shows the important relationship between p53 and p21 
expression in different epidermal layers to the outcome of each model: either to 
obstruct malignant conversion, induce malignant progression; or influence in 
keratinocyte differentiation in response to ROCK2 activation targeting 
ras/MAPK/fos and /or PTEN/PI3K/AKT pathways. For instance, aggressive SCCs 
and invasive pdSCCs histotypes were produced in tri-genic ROCK/fos/Δ5PTENflx 
and ROCK/ras1276/Δ5PTENflx (and ROCKer/ras1205/Δ5PTENhet) models given the 
early p53 loss in papillomas, followed by p21 expression that became supra-basal 
and /or disappeared which resulted in elevated expression of p-AKT in the 
proliferative tumour cells. Thus, this shows the crucial impact between p21 and 
AKT in the tumour outcome. Hence, in comparison to tri-genic ROCK/ras1276/fos 
model, little to no expression of p-AKT may be the reason of these tumours to 
remain as wdSCCs.  
 
Moreover, these data also showed that the tumour outcome become aggressive 
SCCs/invasive pdSCCs histotypes when the roles of ROCK2-mediated increase in 
tissue stiffness was overlaid with both MAPK and PTEN/AKT pathways. This idea 
is supported by a comparison to malignant progression in previous tri-genic 
ras1276/fos/Δ5PTENflx model which also had a dual target on both MAPK and 
PTEN/AKT, yet, tumours remained as wdSCCs due to the persistence of p21 
expression (Macdonald et al., 2014). However, in these current tri-genic models, 
with ROCK2 activation which hit on both MAPK and PTEN/AKT, data showed a 
remarkable malignant progression in both tri-genic ROCK/fos/Δ5PTENflx and 
ROCK/ras1276/Δ5PTENflx models. Furthermore, as shown in the latest tri-genic 
ROCK/ras1205/Δ5PTENhet model where rapid tumour progression occurred (at 5-6 
weeks) was due to an immediate loss of p53, followed by supra-basal expression 
of p21 even at pre-malignant stage which promotes p-AKT expression. This was 
also observed previously in bi-genic ras1276/Δ5PTENflx with induction of TPA 
promotion (Yao et al., 2006). Thus, again, this shows that targeting ROCK2 
signalling acts as a potential Achilles heel in ras cancer therapy in a dual hit target 
for both ras/MAPK/fos and PTEN/PI3K/AKT.  
 
Each bi-genic and tri-genic transgenic mouse model in this study has established 
a foundation to study ROCK-associated mechanism(s) that drives carcinogenesis 
through each specific stage. Thus, the mice and their tumours provide an archive 
useful for further analysis with variety of relevant targets that can widen the 
Chapter 5  280 
 
mechanism pathways. For example: β-catenin and GSK3β which may have a 
connection in a later progression stage between ROCK2-mediated elevation in 
tissue stiffness and the loss of compensatory p53/p21 profiles (Yao et al., 2008, 
Samuel et al., 2011), NFκβ transcription factor which can be activated by 
RhoA/ROCK signalling (Perona et al., 1997, Benitah et al., 2003) during disruption 
of cell-cell adhesion mediated by cadherins leading to cell proliferation, invasion 
and migration (Cowell et al., 2009); and also future studies on the relationship 
between ROCK2 and FAK together with cadherins that may be accountable for the 
rip/broken tissues and intercellular gaps in the late stage of cancer. In addition to 
the in vivo models and their use in new breeding to create new genotypes, since 
several cell lines were established, future in vitro study will further investigate cell 
motility and cell adhesion assays together with western analysis to analyse 
effected targets. 
Finally, these transgenic mouse models that provide a stable phenotype and have 
a connection with each stage-specific of cancer could be applicable to provide test 
animals to stringently assess new anti-cancer therapeutic agents in vivo prior to 
clinical trials which will contribute to the field of cancer research. 
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Appendix A 
  
Cell lines of primary keratinocytes  
Cell lines Genotypes Features 
ROCK1.0 K14.ROCK
er Fast-growing, not resistant to 
Ca2+ 
K.ROCK1.0 K14.cre/lsl.ROCK
er Fast-growing, not resistant to 
Ca2+ 
K.ROCK1.0C K14.cre/lsl.ROCK
er Slow-growing, not resistant to 
Ca2+ 
K.ROCK2.0 K14.cre/lsl.ROCK
er Fast-growing, not resistant to 
Ca2+ 
K.ROCK.FOS1.0 K14.cre/lsl.ROCK
er/HK1.fos Fast-growing, not resistant to 
Ca2+ 
Fos1.0C HK1.fos Slow-growing, not resistant to 
Ca2+ 
K.ROCK.P10F K14.cre/lsl.ROCK
er/Δ5PTENflx Fast-growing, not resistant to 
Ca2+ 
K.P10F K14.cre/Δ5PTENflx Fast-growing, not resistant to 
Ca2+ 
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Abstract/Publication 
1. 2013 International 
Investigative Dermatology 
Meeting. 
Inducible ROCK 2 activation increases primary 
keratinocyte differentiation but co-operates with 
rasHa activation in transgenic mouse skin 
carcinogenesis. 
Masre, S.F., Olson, M.F., and Greenhalgh, 
D.A. (2013) Inducible ROCK 2 activation increases 
primary keratinocyte differentiation but co-operates 
with rasHa activation in transgenic mouse skin 
carcinogenesis. Journal of Investigative 
Dermatology, 133(S1), S57-
S57.(doi:10.1038/jid.2013.96) 
2. XV World Congress on 
Cancers of The Skin, 2014. 
ROCK-2 activation alters keratinocyte differentiation 
and initiates malignant conversion in 
ras/fos/PTENnull transgenic mouse skin 
carcinogenesis  
Siti Masre1 , Nicola Rath2 , Michael Olson2 , David 
Greenhalgh1 , 1 Dept. Of Dermatology, School of 
Medicine, MVLS Glasgow University, Glasgow 
Scotland, UK, 2Tumour Microenvironment 
Laboratory Beatson Institute for Cancer Research, 
Glasgow Scotland, UK. 
3. American Association for 
Cancer Research, 2014. 
Inducible ROCK2/rasHa cooperation requires wound 
promotion to achieve malignancy in transgenic 
mouse skin carcinogenesis, whereas inducible 
ROCK 2/PTEN loss fails to achieve benign 
papilloma. Siti F. Masre, Michael S. Samuel, 
Michael F. Olson, David A. Greenhalgh. 
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